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Abstract 
 
Antibiotic resistance is an emerging global medical crisis. Resistant pathogens can evolve and 
spread rapidly in response to selection pressures exerted by antibiotics. A major concern in 
particular is the evolution of resistance to multiple drugs in many clinical pathogenic bacteria. 
Specifically, multidrug resistance (MDR) can appear either by de novo mutations or by acquiring 
resistance determinants from exogenous sources via recombination. However, the relative influence 
of mutation and recombination on bacterial adaptation to multiple drugs remains largely unknown. 
Therefore, I studied the evolution of de novo multidrug resistance in Acinetobacter baylyi, a Gram- 
negative environmental bacterium has also recently been found to be associated with clinical 
infection, by characterizing two-locus pharmacodynamic fitness landscapes, by assessing the role of 
recombination through natural transformation, and studying the spread of compensatory mutations. 
 In chapter 2, I characterized two-locus pharmacodynamics fitness landscapes (PDFLs) by 
constructing three sets of four different genotypes comprising streptomycin, rifampicin and 
kanamycin resistant mutants. I analysed the resulting PDFLs by characterising epistasis, collateral 
sensitivity or cross-resistance, drug interactions and mutation selection windows to understand the 
trajectories and rate of evolutionary adaptation of resistant pathogens at multiple loci under each of 
the corresponding antibiotic pairs with several hundreds of antibiotics concentrations. My results 
showed that fitness landscapes were largely non-epistatic between each pair of resistance conferring 
mutations in all three pairs of drug environments. However, a wider mutant selection window 
(MSW) was apparent for some drug pairs. I also found that a wider MSW can also occur in 
presence of cross-resistance (associated with a mutation conferring simultaneous resistance to 
several drugs belonging to the same class), which may have important implications in resistance 
evolution. In addition to this, I found a minor sign of an Eagle effect (non-monotonic effect of drug 
concentration on growth rate). Overall, the results we present here underline the importance of 
choosing the right drug for both combination and cyclic treatment to exclude the prolonged 
exposure of sub-MIC level of antibiotics.  
 
In chapter 3, I investigated the impact of recombination via natural transformation on the MDR 
evolution under static two-drug (rifampicin and streptomycin) antimicrobial combinations by 
employing an experimental evolution experiment. Here, I characterized the ancestor and the 
evolved populations with respect to de novo multidrug resistance by using different phenotypic 
assays and by next generation sequencing. Growth rate and competition assays demonstrated higher 
fitness of the populations propagated under drug pressures, but there was no difference in fitness 
gain between recombination-proficient and -deficient populations. Moreover, antibiotic 
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susceptibility assays showed that clones that evolved in presence of drugs had become strongly 
resistant to rifampicin but resistance to streptomycin was only weak. Additionally, de novo 
resistance to other antibiotic classes including ciprofloxacin was also observed in these populations. 
Consistent with these findings, whole genome sequencing revealed an abundance of drug specific 
resistance mutations, including rpoB mutation indicating target alteration for rifampicin as a 
resistance mechanism as well as mutations associated with multidrug efflux system encoding genes 
representing phenotypic resistance to multiple drugs. In conclusion, adaptive benefit of 
recombination via natural transformation under sub-lethal concentration of rifampicin and 
streptomycin is likely constrained by the low number of mutations that were spreading, which 
prevented clonal interference.  
 
In chapter 4, I investigated the adaptive role of compensatory mutations in a set of resistant 
populations comprising both single and multidrug resistant A. baylyi carrying both rifampicin and 
streptomycin resistance mutations by employing an evolution experiment in absence of drug 
pressure. I characterised the evolved endpoint and ancestral populations through phenotypic assays 
and by next generation sequencing to explore the adaptive mechanisms that have taken place during 
the course of evolution. My results revealed that the deleterious effects of resistance mutations are 
compensated for by varying degrees among different sets of resistant genotypes. Specifically, 
adaptation to the cost of resistance in a set of multidrug resistant and rifampicin resistant 
populations was higher compared to the subset of streptomycin resistant populations. This greater 
fitness improvement in multidrug resistant genotype was influenced by some of the fittest lineages 
following a bimodal fitness distribution without altering the MIC of the primary antibiotics. Whole 
genome sequencing data revealed that both costly rifampicin resistant and double resistant lineages 
adapted by compensatory mutations in the RNA polymerase core enzyme. However, only minor 
fitness compensation to the low cost streptomycin resistance mutation was observed, and without 
evolving any putative compensatory mutations. We observed a different parallel adaptive evolution 
in the double resistant genotype, which harboured an unexpected additional deleterious mutation. 
Surprisingly, half of the lineages originating from this double resistant genotype were better 
compensated for through reversion mutations, which were also accompanied by distinct 
compensatory mutations in RNA polymerase core enzyme, and those mutations were not shared by 
any rifampicin resistant genotypes. Finally our data suggest that adaptation to the cost of multidrug 
resistance is independent of the genetic background of mutations that appeared in single resistant 
genotypes.  
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Chapter 1: General introduction 
Drug resistance evolution: a global threat  
The introduction of antimicrobials to treat against infectious diseases was one of the greatest 
medical accomplishments in history. The objective was to save millions of lives facing severe 
infectious diseases. These antimicrobial drugs were used against a wide array of infectious 
diseases caused by bacteria, fungus, viruses and parasites [2]. However, the global emergence 
of resistance mechanisms among these pathogens has seriously undermined our current 
treatment options in many ways. Therefore, treatment failure due to the emergence of 
antimicrobial resistance has now become a global public health threat and a great economical 
problem [3]. Among these pathogens, bacteria are the most striking example – in terms of 
morbidity and mortality. Bacteria exploit many efficient strategies to deactivate the action of 
antibiotics, often leaving no effective antimicrobial compounds. Such resistant pathogens 
evolve very rapidly whenever antimicrobials are applied. Successful use of these therapeutic 
agents is mainly compromised due to the development of tolerance or resistance against them. 
Pathogens use diverse physiological and biochemical mechanisms in order to develop tolerance 
or resistance against antimicrobials. Studies concerning the population biology and 
evolutionary principle of such resistance are largely lacking, which is probably paving the way 
for these pathogens to develop resistance against diverse classes of antimicrobials. 
 
The first antibiotic to treat against infectious diseases – the sulphonamide – was in clinical 
practice in 1937, but the development of resistance against this compound was severely 
compromised by distinct mechanisms of resistance which are still found to operate in current 
ages. The first discovered naturally occurring antibiotic, namely penicillin was discovered by 
Alexander Fleming from Penicillium notatum in 1928 and introduced in the 1940s; however, 
the penicillin degrading enzyme penicillinase severely compromised the usefulness of this drug 
soon after its introduction [4]. The first antibiotic belonging to the aminoglycoside class called 
streptomycin was introduced in 1944 to treat against Mycobacterium tuberculosis – the 
causative agent of tuberculosis.  The usefulness of this antibiotic was also thwarted by as soon 
as resistance was evolved. In almost every cases, resistance mechanisms against antimicrobials 
were reported before their introduction, which raises important but yet unsolved questions 
regarding the origin of resistance and antibiotics [2]. Many studies have highlighted the source 
of these resistance genes, where most resistance genes were found in natural environments [5].  
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The bulk of the antibiotics that are used today were discovered and introduced into the market 
during the 1950s, sometimes referred to as the golden years in the history of the antibiotics era. 
Before the 1960s, resistance plasmids were found to be responsible for resistance against those 
antibiotics; therefore many pharmacological studies were carried out during 1960s and those 
studies mainly concentrated on the understanding of the mode of action of antibiotics as well as 
their administration. Later on, sixty-one different antibiotics were approved by the FDA (Food 
and Drug Administration, U.S.A.) between the year 1980 and 2009, but nearly half of them 
were withdrawn. Some drugs were removed for the safety and effectiveness issues while other 
were (apparently most of the drugs) removed owing to marketing policy related issues [6], such 
that it could be due to (1) infrequent prescription of those drugs, (2) the raw materials were 
very expensive, (3) the production process required multistep complicated process. Together 
these had made those drugs less profitable for the company; therefore those drugs were 
withdrawn from the market. 
However, the dearth of new antimicrobial classes was apparent between 1943 and 2000; during 
this period, only a few (~9 different classes) new antimicrobial classes were discovered and 
launched into the markets (Figure 1). Overall, in the last 50 years, only seven new classes of 
antibiotics, namely linezolid (2000), tigecycline (2005), daptomycin (2006), retaparmulin 
(2007), telavancin (2008), fidaxomicin (2011), and bedaquiline (2012) have come into clinical 
application with a single variant of each class [7, 8] . All these new classes of antibiotics were 
introduced after 2000, and resistance emergence against three of them, namely linezolid, 
daptomycin and tigecycline were also documented in clinical bacterial strains – for example 
drug resistance to more than one antibiotic was reported during this time in Escherichia coli, 
Salmonella, Shigella, MRSA (methicillin-resistant S. aureus), VRE (vancomycin-resistant 
enterococci), and others [9]. The rest of the four new classes, including retaparmulin, 
telavancin, fidaxomicin, and bedaquiline fall into narrow spectrum antibiotics targeting only a 
limited number of bacterial species belonging mostly to gram positive; no resistance 
emergence has been reported against them. This situation reflects the fact that the emergence 
and spread of resistant strains has been faster than antimicrobial drug development [10]. 
Further, this scenario suggests that antibiotics are gradually decreasing their efficacy against 
infections due to the evolution of extremely multi-resistant bacteria – mostly deadly Gram 
negative bacteria via enormous genetic flexibility. Most of these resistant bacteria are found in 
hospital settings where bacteria encounter high selective pressure exerted by antibiotics [11].  
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1943 • Penicillin 
1950 • Tetracycline 
1953% • Erythromycin 
1960% • Methicillin 
1967% • Gentamycin 
1972% • Vancomycin 
1985%
• Imipenem 
• Ceftazidine 
1996% • Levofloxacin 
2000% • Linezolid 
2003% • Daptomycin 
2005% • Tigecycline 
2007% • Retaparmulin 
2008% • Telavancin 
2010% • Ceftaroline 
2011% • Macrocyclic 
2012% • Diarylquinoline 
1940 • Penicillin R Staphylococcus 
1959 • Tetracycline R Shigella 
1962% • Methicillin R Staphylococcus 
1965% • Penicillin R Pneumococcus 
1968% • Erythromycin R Streptococcus 
1979% • Gentamycin R Enterococcus 
1987% • Imipenem & Ceftazidine R Enterobacteriaceae  
1988% • Vancomycin R Enterococcus 
1996% • Levofloxacin R Pneumococcus 
1998% • Imipenem & Ceftazidine R Enterobacteriaceae  
2000% • Linezolid R Tuberculosis 
2001% • Linezolid R Staphylococcus 
2002% • Linezolid R Enterococcus 
2004% • Daptomycin R Acinetobacter 
2005% • Daptomycin R Pseudomonas 
2007% • Tigecycline R Acinetobacter 
2009% • Ceftaroline R Neisseria%
2011% • Ceftaroline R Enterobacteriaceae & Staphylococcus%
Year of introduction Year resistance identified 
 
Figure 1 Sequential drug discovery and resistance evolution. Left panel shows year of drug 
discovery, and the right panel shows year of resistance emergence. No reported case of 
resistance evolution documented for Retaparmulin, Telavancin, Macrocyclic and 
Diarylquinolone. R – resistant   
Based on the extent of resistance to multiple drugs, bacteria have been classified into three 
groups. According to this definition, multi-drug resistant (MDR) bacteria are those that are 
resistant to one agent of three or more antimicrobial classes. Extensively drug-resistant (XDR) 
bacteria remain non-susceptible to at least one antimicrobial agent of 2 or fewer categories, 
whereas pandrug-resistant (PDR) bacteria are non-susceptible to all agents of all antimicrobial 
categories. This definition is applicable to both Gram positive and Gram negative bacteria such 
as S. aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), 
Pseudomonas aeruginosa and Acinetobacter spp. [12]. In this study, we defined multidrug 
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resistance bacteria are being resistant to at least two antimicrobial compounds belonging to 
either the same chemical class or two different classes. 
Antibiotics and their functional targets 
Antibiotics belong to different classes of chemicals, are of biological, synthetic or semi-
synthetic origin and have selective modes of actions. Based on their mechanism of actions, 
antimicrobial compounds are classified into two groups, namely bactericidal and bacteriostatic. 
Drugs are called bactericidal when exposure to this particular group of antibacterial compounds 
leads to the death of bacteria, whereas bacteriostatic drugs are only able to inhibit or hinder 
growth of bacteria but cannot kill bacteria. Both of these drug actions are principally targeted 
to the interference of bacterial cell-wall biosynthesis, DNA or RNA synthesis or repair [4]. 
Further, antibiotics have been classified based on the cellular component or system they affect 
[13]. Some of these antimicrobial agents target the synthesis of important cellular components, 
whereas some other classes target bacterial nucleic acid synthesis or repair [14, 15]. For 
example, fluoroquinolones target and inhibit important bacterial cellular system, such as 
topoisomerase II  (also known as DNA gyrase), and lead to the cellular death by formation of 
double-strand DNA breaks [16]. Another class of bactericidal antibiotics is the β-lactam 
antibiotics (i.e., penicillins, cephalosporins, capbapenems and monobactams), which act by 
binding to and inhibiting the penicillin binding proteins (PBP) leading to stop in cross-linking 
or transpeptidations within the bacterial cell wall, thus undergo cellular death [17]. 
Furthermore, some antimicrobial induced cell death is mediated by common detrimental 
response to drug-induced stresses. For example, bacteria response to most of the bactericidal 
antibiotics in a unfavourable way, such that bacterial important metabolic system, including 
central metabolic system called tricarboxilic acid (TCA) cycle as well as iron metabolism is 
inhibited by reactive oxygen radicals in response to lethal bactericidal antibiotics, resulting in 
cellular death [18, 19]. 
  
In what follows, I will briefly outline the mechanism of cellular killing by the bactericidal 
antibiotics namely rifampicin (belongs to ansamycin) as well as streptomycin and kanamycin 
(both belong to the aminoglycoside), since I have used these antibiotics in all three individual 
research projects of this PhD thesis. 
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Rifampicin is a semi-synthetic bactericidal antibiotic that can induce cell death by inhibiting 
bacterial RNA synthesis. Rifampicin triggers catastrophic effect on prokaryotic nucleic acid 
metabolism by interfering with β-subunit of RNA polymerase [20]. During execution of 
normal cellular function, β-subunit forms a stable channel between RNA–polymerase and 
DNA complex from which newly synthesized RNA strand arises [21-23]. Rifampicin binds 
stably and with high affinity to the β-subunit of DNA dependent RNA–polymerase (encoded 
by rpoB gene), thus inhibiting the high fidelity transcription and causing cellular death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aminoglycosides cause cellular death by interfering with cellular energetics, ribosome binding 
and protein synthesis [24]. Bacterial protein synthesis through translation of mRNA occurs in a 
sequential fashion involving the phases including initiation, elongation and termination. This 
process is operated in the cytoplasmic space involving ribosome as factory and many other 
Figure 2  Drugs, their cellular targets and the mechanisms cellular death. This figure shows 
different drugs and their different targets. Figure 2 reproduced from [1]. 
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important accessory translation factors available in the cytoplasm [25]. The ribosome is 
composed of two ribonucleoprotein subunits called 30S (encoded by rpsL gene) and 50S 
(Figure 2). Following formation of a complex between mRNA-transcript, N-
formylmethionine-charged aminoacyl tRNA, several initiation factors and a free 30S subunit 
(this process is called initiation step of translation), ribosome is assembled for the next 
translational step [25, 26]. Since this translation is a complex process requiring many cellular 
component parts and translation factors, drugs can interfere with protein synthesis in many 
different ways. Protein synthesis inhibitors are classified into 50S inhibitor and 30S inhibitor. 
50S inhibitors (i.e. erythromycin, clindamycin, streptogramin, chloramphenicol, and linezolid) 
interfere with protein synthesis by blocking initiation of protein translation (i.e., 
oxazolidinones), or translocation of peptidyl tRNAs [27, 28]. Inhibition of 30S ribosome 
involves blocking of the access of aminoacyl tRNAs to the ribosome. 30S ribosome inhibitor 
comprises tetracyclines and aminoclyclitols. Both spectinomycin and aminoglycosides, 
including streptomycin, kanamycin and gentamycin bind to the 16S rRNA component of the 
30S ribosomal subunit. Aminoglycosides binds to 16S rRNA which in turn alter the 
conformation of the complex formed by an mRNA codon and its cognate charged aminoacyl 
tRNA at the ribosome. This altered complex molecule results in defective protein [14, 29, 30].  
Types and mechanisms of antibiotic resistance 
Antibiotic resistance can be defined as the property inherent in bacteria by which successful 
uses of therapeutic agents are compromised by the evolution of tolerance or resistance against 
it [2, 31]. Generally, antibiotic resistance is associated with prolonged exposure to antibiotics. 
More specifically, bacterial population remains susceptible to antibiotics at the beginning of a 
treatment, but can sustain and evolve resistance against antibiotics gradually. Therefore, the 
continuous selective pressure exerted by antibiotics help bacteria evolve resistance to one or 
more drugs simultaneously [32]. Bacteria can subvert the action of antibiotics through many 
different ways, and this resistance fall into two major types, namely innate resistance and 
acquired resistance. In innate resistance, genes encoding resistance to antibiotics are inherently 
present in bacteria. On the other hand, bacteria can both survive and acquire resistance in 
presence of lethal effect exerted by antibiotics [33], and this phenomenon of resistance is called 
acquired or adaptive resistance. Now I will give a brief over view of these two mechanisms: 
Intrinsic resistance 
With intrinsic resistance, naturally occurring genes in the host cell chromosome impart 
resistance. All bacterial species exhibit intrinsic resistance to a certain array of antimicrobial 
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classes. The biology of these resistance mechanisms varies from bacteria to bacteria. Many 
bacteria carry genes or enzymes giving intrinsically resistance to particular antibiotics. For 
example, Streptomyces possesses some genes, which provide resistance to streptomycin 
antibiotic produced by itself. Enzymatic modifications of antibiotics have been well reported in 
many clinical bacterial populations. Such resistance mechanisms have commonly been 
documented for natural antibiotics, including aminoglycosides (i.e., kanamycin, amikacin and 
tobramycin) and b-lactam antibiotics. In each case, certain enzymes can modify the chemical 
component of the antibiotics, which in turn result in altered drug-target interactions [60]. 
Commonly observed aminoglycosides modifying enzymes are aminoglycoside 
acetyltransferase (AAC-3-II), aminoglycoside phosphorylase (APH-3’-I), and adenylate 
(nucleotidyltransferases). For example, AAC-3-II can modify a number of different 
aminoglycosides including amikacin, gentamycin and tobramycin. These enzymes are mostly 
carried by mobile genetic elements, and responsible for resistance to multiple antibiotics. It has 
been reported that multiple acetyltransferase encoding genes were carried on class-1 integron 
in clinical P. aeruginosa, and this bacterium was non-susceptible to many other classes of 
antibiotics including carbapenems and sulfonamides [61]. Aminoglycoside acetyltransferases 
also exhibits broad-spectrum activity. For example, in E. coli, a variant of aminoglycoside 
acetyltransferases (i.e. AAC(6’)-Ib) has been found to be associated with reduce susceptibility 
to ciprofloxacin – a synthetic antibiotic compound belongs to the fluoroquinolone class [170]. 
Enzymatic inactivation of b-lactam antibiotics is also common in many multidrug resistant 
clinical bacteria. Genes located on plasmids mostly encode these b-lactam degrading enzyme, 
but chromosomal genes can also encode this enzyme. Most clinical relevant b-lactam 
hydrolyzing enzymes are b-lactamase (first reported in S. aureus against penicillin), TEM b-
lactamase (gives resistance to multiple drugs and commonly found in gram negative bacteria 
containing also multidrug resistant R plasmids), CTX-M b-lactamase (this enzyme is encoded 
by chromosome of gram negative bacteria, subsequently transferred to the R plasmid). All 
these enzymes are belonging to ESBL (extended spectrum b-lactamase) enzyme [62, 63].  
 
Impermeability is another form of intrinsic resistance inherent in bacteria, where antimicrobial 
compounds cannot pass through the bacterial outer membrane. For example, glycopeptide 
antibiotics such as vancomycin can only target peptidoglycan cross-linking by binding to 
peptide chain of D-ala-D-ala of gram-positive bacteria, but it cannot pass through the outer 
membrane and reach to the peptides in the periplasm in Gram negative bacteria [35]. Another 
important resistance predominantly found in Gram negative bacilli is intrinsic mechanism of 
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resistance via efflux pump system. Efflux pumps are the major contributor of intrinsic 
resistance in Gram negative bacteria, which can actively transport multiple antibiotics out of 
the cell [59]. Even if an antibiotic can pass through to the periplasmic space by a membrane 
spanning porin protein (i.e. outer membrane porin (OMP)), it is removed or pumped out from 
the periplasm by active efflux system. Overexpression of efflux systems has been found to be 
associated with high-level resistance to many clinically important antibiotics. Efflux systems in 
bacteria are classified into two major groups based on their substrate specificity: substrate 
specific efflux pump can only transport a certain antibiotics (e.g., Tet efflux system which can 
only pump tetracycline out), whereas a broad-spectrum substrate specific efflux system can 
pump out many different antibiotics (MDR efflux pumps). Chromosomal genes encode these 
MDR efflux pumps, and sometimes these genes are transferred onto plasmids, which in turn 
disseminate to many other bacteria. There have been many of such MDR efflux systems 
reported in MDR bacterial populations [44]. Recently, it has been reported that genes encoding 
RND (resistance nodulation division) efflux pumps have been mobilized onto plasmid IncH1 
in Citrobacter freundii, which also carried an NDM-1 metallo-β-lactamase 1[76]. An example 
of intrinsic resistance mechanisms have been provided by Figure 3 which shows that  β-lactam 
antibiotic (A) targeting a penicillin-binding protein (PBP) first channel through the periplasm 
via membrane spanning porin protein and binds to the target site of penicillin binding protein 
(PBP), and thus interfere with bacterial cell wall synthesis – a natural mechanism of action of 
β-lactam antibiotic. However, antibiotic B can pass through the porin channel but is effectively 
pumped out from the periplasm via efflux pump, whereas antibiotic C cannot cross bacterial 
outer membrane. Therefore, such mechanism of resistance to both antibiotics (antibiotic B and 
C) called intrinsic resistance [36]. 
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Figure 3 Intrinsic mechanism of antibiotic resistance. Figure 3 reproduced from [36].  
Acquired resistance  
Acquired mechanisms are associated with mutations in different chromosomal genes targeted 
by antibiotics, or the acquisition of many different resistant genes from other bacterial species 
mediated by mobile genetic elements (MGEs) such as plasmids, transposons and integrons [11, 
34, 37, 38]. In the case of mutational resistance, bacteria often alter the binding site of the 
proteins targeted by antibiotics. Bacteria often alter the binding site of the proteins targeted by 
antibiotics. Mutation in the drug target also promotes over expression of targets during 
transcription step, these targets otherwise are naturally expressed at very low level. Or it could 
be another mechanism by which certain mutation can modify the drug target to withstand the 
lethal effect of an antibiotic. Consequently, the minimum inhibitory concentration (MIC) of a 
particular antibiotics rises beyond the therapeutic value which in turn preclude the clinical use 
of the drug [39]. Such mechanisms are not induced by antibiotic exposure, rather such 
resistance mutations appear during chromosomal replication. In Gram negative bacilli, such as 
in Enterobacter sp. and Pseudomonas aeruginosa, mutation in regulatory gene can give 
overexpression of the blaAmpC, together with AmpC cephalosporinases, this overexpressed gene 
undergoes imbalance between enzyme and substrate ratio, and both of them thus give 
resistance to both penicillin and extended-spectrum cephalosporin [40]. 
  
There have been plenty of such mutational resistances documented in bacterial populations; for 
example, mutational changes in the penicillin binding protein 2b can result in penicillin 
resistance in Pneumococci. Mutations in M. tuberculosis, S. aureus, E. coli, P. aeruginosa, and 
Acinetobacter baumannii give altered ribosomal binding sites and confer high-
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to aminoglycosides. Certain mutations can cause up-regulation of enzyme production or 
alteration of outer membrane porin (OMP), and this in turn impedes antibiotic penetration 
inside the bacterial cell, for example mutational change in the outer membrane porin (OMP) in 
E. coli and P. aeruginosa gives resistance to many antibiotics. Up-regulation of efflux pumps 
by mutation can also expel antibiotics out of the bacterial cells, and this phenomenon has been 
observed in fluoroquinolone resistant S. aureus and P. aeruginosa [34, 40-43]. These acquired 
mechanisms conferred by mutations in different chromosomal genes are collectively called 
vertical evolution. More example of mutational resistances such as clinically important 
fluoroquinolone resistance is conferred by mutations within the targets such as DNA gyrase 
(comprised of GyrA and GyrB protein) and topoisomerase IV (comprised of ParC/GrlA and 
ParE/GrlB protein) [64]. Most of these mutations conferring resistance to fluoroquinolone are 
located in a region called quinolone resistance determining region (QRDR) of GyrA and 
ParC/GrlA protein. Interestingly, mutations occured first in DNA gyrase in gram–negative 
bacteria, whereas mutations in topoisomerase IV first reported in gram-positive bacteria [53]. 
Another prominent example of resistance mediated by mutational target alteration is resistance 
to rifampicin antibiotic. Rifampicin in combination of another drug including isoniazid, 
pyrazinamide, ethambutol, or streptomycin remains the first-line therapy against tuberculosis 
infection [65]. However, mutation in rpoB gene causes conformational change in RNA 
polymerase β-subunit, thus inhibiting rifampicin from binding to its target site of the RNA-
polymerase. Mutation-conferring resistance to aminoglycosides are also common in many 
resistant bacterial populations including M. tuberculosis, whereas mutations in rrs gene 
conferring resistance to amikacin and kanamycin are also well documented in many other 
bacterial populations. Mutational alteration in small ribosomal protein (S12) encoded by rpsL 
gene, and also mutation in rrs gene conferring resistance to streptomycin or other 
aminoglycosides in M. tuberculosis are well documented [66]. Therefore, target alteration by 
mutation in many different genes can give rise to multiple drug resistance in clinically 
important pathogens including M. tuberculosis. From a population genetics perspective, these 
mutational alterations at multiple loci often produce extensive patterns of genetic interactions 
across the loci in antibiotic resistant bacteria, called epistasis [67-70]. This interaction also 
determines the evolutionary responses to a variety of environmental conditions, including in 
presence of multiple antibiotics [71-75]. Thus, even if the drug exposure is halted, resistant 
mutants may outcompete the susceptible counterparts and adapt in the drug free environment 
by this evolutionary responses through extensive multilocus genetic interactions, as has been 
reported in a multidrug resistant bacteria [69].  
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Certain mutations in bacterial cell wall components can cause altered membrane permeability. 
For example, in Gram negative bacteria, cells are covered by an additional layer, which 
restricts the entry of both hydrophobic and hydrophilic compounds into the cell. Under diverse 
physiological circumstances, bacteria transform this permeability barrier mediated by porin 
proteins, which helps bacteria transport different compounds in and out of the cell. These 
evolved porin proteins have been associated with multidrug resistance. For example, OmpF 
and OprD protein are commonly occurring porin proteins found in E. coli and P. aeruginosa, 
respectively. Both of them are involved in non-specific entry and exit points for different 
antibiotics and small chemical molecules. These porin proteins are involved in both acquired 
and adaptive resistance to multiple drugs. For example, imipenem and meropenem are passed 
through this entry, and mutations can cause reduced levels of OprD expression that confers 
resistance to these drugs. Moreover, mutations in genes involving an altered cell envelope can 
confer polymixin B resistance in P. aeruginosa. There have been numerous bacteria where 
multidrug resistance through altered membrane permeability have been reported [53]. 
 
In addition to the occurrence of mutational resistance, bacteria can acquire resistance elements 
from outside sources by a process called horizontal gene transfer (HGT). There are three main 
mechanisms of HGT by which bacteria acquire resistance genes or genetic elements from their 
exogenous sources (Figure 4). For example, a recipient cell can acquire a resistant gene from 
the donor either by transduction, transformation or conjugation [44]. During transduction 
process, gene transfer is mediated by bacteriophage where virus infects bacteria on a species-
specific mode. Although this process was thought to be relatively rare, bacteria acquire 
resistance genes via transduction whereby bacteriophages can infect and transfer resistance 
genes to a new bacterium. One such example is methicillin resistant Staphylococcus aureus 
(MRSA), which was thought to develop resistance through acquisition of mecA resistance gene 
from other bacteria by transduction [45]. Bacterial natural transformation is accomplished by 
taking up dead or degraded DNA (called donor DNA) by recipient bacterium from its 
exogenous sources and incorporates this DNA into the recipient’s genome by homologous 
recombination. Such transformation-mediated acquired resistance is thought to have occurred 
in Streptococcus pneumoniae, which acquired genes for altered penicillin binding proteins 
(PBP2Bs) from degraded Streptococcus mitis and conferred low affinity binding with penicillin 
antibiotics [46]. This mode of resistance acquisition has also been reported in the case of 
ceftriaxone resistance conferred by penA gene in Neisseria gonorrhoeae [47].  
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Figure 4 Acquired resistance mechanism in bacteria. Transmission of genetic material by 
horizontal genetic transfer, which is accomplished by three different mechanisms. Figure 4 
reproduced from [44]. 
Mobile genetic elements (MGEs) are defined as DNA molecules that facilitate both inter– and 
–intra cellular movement of DNA by encoding the necessary proteins and enzymes in their 
own DNA [77]. The widespread prevalence of MGEs in bacteria has facilitated the evolution 
of antibiotic resistance, multidrug resistance in particular. Examples of such MGEs include 
plasmids, insertion sequences, and integrons. [53]. The general mechanism of resistance 
transfer through MGEs is as follows:  multiple resistant determinants are borne on the MGEs 
and later mobilize or exchange their genetic elements conferring resistant to multiple 
antibiotics by the HGT. The majority of resistance genes harbouring plasmids are thought to 
disseminate to other bacteria by conjugation – the third mechanism of HGT. Some of the most 
notorious resistance enzymes, including carbapenemases were encoded by plasmids found in 
Gram negative Enterobacteriaceae [48]. Specifically, serine β-lactamases (KPC 
carbapenemase) and metallo-β-lactamases (e.g., NDM-1: New Delhi Metallo-β-lactamase) 
belong to carbapenemase enzyme, and both of them are capable of hydrolysing most of the β-
lactams currently available in the markets [49-51]. Another striking feature of conjugation is 
the dissemination of resistance genes between plasmid and bacterial chromosome via 
integrative chromosomal elements (ICEs) – these are also mobile genetic element (MGE). This 
type of resistance propagation has found to be prevalent in most of the gram negative bacteria 
and has been reported in streptococci [52].  
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It has also been reported that some bacteria can swap genes from evolutionarily distant bacteria 
via HGT (from Gram negative to Gram positive bacteria) [53, 78], this has probably enabled 
bacteria to evolve resistance to multiple drugs [79]. Therefore, the MGEs are regarded as an 
open source of bacterial multiple resistance evolution [80], as they can move from one cell to 
another or from one genetic location to another. To date, various plasmids (such as R factors/R 
plasmids with varying sizes ranging from 1 to 100 kb), transposons (i.e., Tn1, Tn4, Tn1545, 
Tn1691) and integrons (i.e., class 1 to 4) have been documented to capture and disseminate 
multidrug resistance [53]. Multidrug resistance can be transferred into susceptible bacteria by a 
single-event conjugation of a mobile R plasmid.  
 
Transposons are also mobile genetic elements and are found on the R plasmids, (Figure 5a). 
Transposons can integrate other transposons or can be integrated into host chromosome by 
transposase or recombinase encoded by its terminal region, thus mobilize resistance genes from 
plasmid to chromosome. Integron contains many different genes, called gene cassettes. A large 
integron contains more than one hundred gene cassettes. It has been reported that  ~3% of 
Vibrio cholerae genome comprised of these large integrons [81]. Integron with gene cassettes 
can also be transferred and integrated into new DNA through a single event mediated by 
integrase enzyme. Integrons can transfer and integrate multiple genes particularly resistance 
genes. More specifically, integron mediated resistance is accomplished by a site-specific 
recombination gene sequence called int. This gene encodes an integrase enzyme and integrates 
gene cassette (which may contain different resistance genes) to a specific site [82]. Mechanism 
of bacterial integron mediated resistance gene captures system is shown in Figure 5b. 
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Figure 5 Multidrug resistance via acquisition of mobile genetic element (MGE). Resistant 
plasmid harbouring many different transposons can confer multidrug resistance by a single 
conjugation event (a). Integron mediated resistance gene capture system is shown in Figure b. 
Integrase (transcribed under a downstream promoter (Pint) catalyse the insertion of an integron 
(blue). Resistance gene cassette 1 (red) is integrated into the attI site, which is under the 
influence of an upstream promoter (Pant). This way, many different resistance genes can be 
captured repeatedly, where all the resistance genes remain under the influence of the same 
promoter, thus become a resistance operon. Figure 5 reproduced from [60]. 
The MDR bacteria and their clinical impact  
Simultaneous resistance to several antimicrobial compounds in diverse pathogenic bacterial 
populations has become the major impediment in treating infectious diseases globally. Since 
bacteria develop such resistance very rapidly by newly arising resistance mechanisms, it is now 
very challenging to treat even common infectious diseases [53]. More specifically, our current 
standard treatment protocols fail to produce any significant therapeutic response against 
multidrug resistant pathogenic bacteria. Treatment failure due to the evolution of such 
pathogens also leads to the extended hospital stay with severe illness where patients are mostly 
exposed to higher risk of morbidity and mortality. The occurrence of such resistance 
mechanism has been reported in many clinical bacterial populations belonging to both Gram 
positive and Gram negative bacteria. These populations have been defined as multidrug 
resistant organisms (MDROs), and these MDROs show in vitro resistance to at least three or 
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more antimicrobial classes [12]. The most problematic MDR bacteria that clinicians frequently 
encounter are pan-resistant Gram negative bacteria, including P. aeruginosa, E. coli, A. 
baumannii, extended spectrum β-lactamases (ESBLs) and metallo-β-lactamases (MBLs, 
including KPC, VIM and NDM-1) producing K. pneumoniae, methicillin resistant S. aureus 
(MRSA), vancomycin resistant enterococci (VRE), and extensively drug resistant M. 
tuberculosis (XDR) [11, 15, 34, 49, 53-58].  
Antibiotics used in this study: action and resistance mechanisms 
Aminoglycosides 
Streptomycin and kanamycin, both are belonging to the aminoglycoside class, have been used 
in this PhD work as selective environments. Aminoglycosides are historically important for 
their role in the treatment of severe bacterial infections, especially infections caused by M. 
tuberculosis and S. aureus. Most antimicrobial drugs belonging to the aminoglycosides are 
bactericidal in nature, exhibit predictable pharmacokinetics, and often produce synergistic 
interactions when combined with other antibiotics [83-85]. These antibiotics mainly inhibit 
bacterial protein synthesis by interfering with small ribosomal subunit comprising 16S rRNA 
encoded by the rrs gene and many polypeptide units such as S12 encoded by the rpsL gene. 
16S rRNA plays a central role in protein synthesis, especially a highly evolutionarily 
conserved 530 loop region is part of the A site of the 30S ribosome (Figure 6). Aminoacyl-
tRNA partially binds to this A site and initiates the decoding process. Aminoglycoside 
molecules bind to the 16S rRNA and S12 protein in the 30S subunit of ribosome. Thus 
interfere with the decoding site in the vicinity of 16S rRNA and this disrupts the formation of 
the initiation complex, leading to mistranslation of mRNA and consequently cell death [24, 83, 
86-89]. Resistance to aminoglycosides is widespread in many bacterial pathogens, including 
M. tuberculosis, A. baumannii, E. coli, and P. aeruginosa; therefore, the usefulness of 
aminoglycosides has been greatly compromised. This resistance is mostly attributed to target 
alteration, enzymatic inactivation and reduced uptake or decreased cell permeability.  
First, alteration of the 30S subunit of the bacterial ribosome by commonly occurring single-
step chromosomal mutations confers high-level aminoglycoside resistance. This phenomenon 
has frequently been observed in both clinical and experimental bacterial populations when 
exposed to streptomycin. Mutations mainly occur in the rrs and rpsL genes which result in an 
altered ribosomal binding site for the antibiotics. Mutations in rpsL gene, specifically at 
residues 42 and 87, interact with 18, 27 and 44 helixes of 16S rRNA and prevent drug binding. 
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It has also been evident that fitness costs caused by rpsL mutations can be compensated for by 
mutations in the rRNA or other ribosomal proteins. A conformational change in 530 loop 
region of the 16S rRNA due to mutations in rrs gene also contributes to the high-level 
resistance to streptomycin, kanamycin and other aminoglycosides, and this mechanism has 
been observed both in gram-positive and gram-negative bacteria [89-93]. 
Significant resistance to streptomycin conferred by mutations in rrs and rpsL was reported in 
clinical isolates of M. tuberculosis. Most of these mutations were characterized by 
 transversion at position 513,  at position 516 in rrs gene; in rpsL gene, 
resistance to streptomycin was due to mutations at residues 42 and 87, and these are associated 
with  substitution respectively. Mutations at multiple sites of these 
genes conferring resistance to streptomycin and kanamycin have been reported in a wide range 
of other bacteria including E. coli, S. typhimurium, Pseudomonas putida and Borrelia 
burgdorferi [86, 87, 92, 94-98]. Therefore, it is anticipated that in my experimental system 
using Acinetobacter baylyi, similar resistance mutations to streptomycin will arise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Partial structure of 16S rRNA showing the 530 bps loop. Resistance to streptomycin 
is conferred by different point mutations in the 530 bps loop region shown by the solid arrows. 
This figure is based on E. coli 16S rRNA nucleotide numbering system. For M. tuberculosis, 
position of the mutations are estimated by subtracting 10 from the 530 bps loop region 
numbers, and 8 from the 915 region numbers.  Figure 6 reproduced from [99].  
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Second, enzymatic inactivation mediated by the aminoglycosides nucleotidyltransferases 
(ANTs), the aminoglycosides acetyltransferases (AACs) and the aminoglycosides 
phosphotransferases (APHs). These enzymes are by far the most commonly found enzymes 
conferring resistance to aminoglycosides and observed in clinically significant bacterial 
species. Structural modifications catalysed by these enzymes reduce the binding affinity by 
inducing unfavourable electrostatic or static interactions between aminoglycosides and the 
target rRNA. This phenomenon has been reported in P. aeruginosa, K. pneumoniae, E. coli and 
other bacteria. To date a vast array of these enzymes has been detected in both Gram positive 
and Gram negative bacteria of clinical origin, and most of these enzymes are harboured on 
plasmids and transposons [79, 83, 86, 87, 100]. In the first part of my project, I have used a 
strain carrying the nptII gene inserted in the chromosome. This gene encodes the neomycin 
phosphotransferase-II enzyme belonging to the aminoglycosides phosphotransferase (APH) 
family. Enzymes belonging to the APH family can inactivate a number other aminoglycoside 
antibiotics, including kanamycin. Therefore, strain harbouring nptII gene will enable me to 
ascertain to what extent collateral resistance to another antibiotic from the same class 
(streptomycin) occurs. 
 
Finally, mutations in the respiratory chain or ATP-synthatase and the regulatory genes 
encoding the efflux systems (acrB, mexZ, opmG, opmI) have also been reported to be 
associated with aminoglycoside resistance in a diverse bacterial species, especially in E. coli, 
A. baumannii, S. aureus and P. aeruginosa of clinical and laboratory origin.  Aminoglycoside 
resistance can also be conferred by mutation at the ksgA gene encoding S-adenosylmethionine 
(SAM)-dependent RNA methylase which interferes with post-transcriptional methylation of 
A1518 and A1519 of 16S rRNA nucleotides leading to inhibition of the initiation step of 
translation in E. coli and B. stearothermophilus. However, most clinically relevant 16S rRNA 
methyltransferase encoding genes are carried by plasmids, for example rmtA and armA were 
carried and disseminated by plasmid of P. aeruginosa and K. pneumoniae species, respectively 
[34, 57, 86, 101-105]. 
Ansamycins 
Rifampicin, a semisynthetic bactericidal antimicrobial drug. This antibiotic is derived from the 
ansamycin family, and has been used as a selective environment in this study. This antibiotic 
has a broad-spectrum antibacterial activity and is particularly effective at low concentration. 
Rifampicin has long been used as a first-line of drug against M. tuberculosis, the causative 
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agent of tuberculosis. Due to its broad-spectrum action, this antibiotic has also been used for 
the treatment of various other infections caused by Gram negative bacteria such as P. 
aeruginosa, E. coli, A. baumannii and many more. This antibiotic inhibits DNA-dependent 
RNA polymerase (RNAP), which has five subunits ( ). The RNAP is an important 
transcriptional component, which catalyses the transcription of DNA to RNA through 
polymerization of the ribonucleoside triphosphate on a DNA template. Rifampicin binds to and 
forms a stable complex with the β-subunit of the RNAP, thus suppress the initiation of protein 
synthesis in susceptible bacterial populations [106-109]. Bacteria acquire resistance to 
rifampicin at high rate. The most observed form of resistance to rifampicin is by spontaneous 
mutations in the rpoB gene. Specifically, a point mutation in the rpoB gene encoding the β-
subunit of RNAP is the main mechanism of acquired resistance. Mutation alters the binding 
site of the β-subunit structure of RNAP enzyme, as a consequent rifampicin loses its binding 
affinity and cannot produce any inhibitory effect on bacteria. This mechanism of resistance has 
frequently been observed in clinically significant bacteria, most notably in M. tuberculosis, P. 
aeruginosa, E. coli and many more. Commonly occurring rifampicin resistance mutations in E. 
coli are located in the central region of the polypeptide within cluster I, II and III. In M. 
tuberculosis, 40% of resistance is acquired by mutations at codon 432 to 458 within cluster I 
(Figure 7). In clinical A. baumannii strains, mutations are observed at multiple nucleotides 
located within a range of 500 to 580, whereas in laboratory strains mutations are located within 
a nucleotide region spanning from 1565 to 1741 nucleotide regions [106, 108, 109].  
 
 
Figure 7 Map of the RNAP β-subunit rifampicin resistance mutations in bacteria. Gray shaded 
zones correspond to highly conserved regions (labeled A to I) and red shaded zones correspond 
to rifampicin resistance region of the RNAP β-subunit (labelled I to III). Green, yellow and 
purple triangles correspond to resistance mutations in M. tuberculosis, E. coli, and B. subtilis 
respectively. Figure 7 reproduced from [106]. 
Additionally, many studies have attempted to investigate the potential impact of different 
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mutations in rpoB gene from other species by selecting spontaneous rifampicin mutants [70, 
110-113]. Therefore, we also expect to observe mutation in the rpoB gene conferring resistance 
to rifampicin antibiotic. Apart from this, other resistance mechanisms against rifampicin have 
been reported, including modification of cell permeability or membrane-associated efflux 
pumps, target duplication (presence of two different RNAP β-subunit genes gives high-level 
resistance to rifampicin), as well as resistance mediated by enzymatic modification. However, 
the occurrence of these resistance mechanisms has been reported only in a few instances [22, 
106, 113-115]. 
Evolutionary aspects of drug resistance 
Bacterial resistance to antibiotics is thought to be one of the best-known examples of biological 
evolution. The continued selection pressure exerted by different antimicrobial compounds is 
the main driving force contributing to this process. For example, an indiscriminate use of 
different types of antibiotics inhibiting the growth of bacteria in the host environment has 
resulted in the emergence and spread of resistant determinants in different bacterial 
populations, thus producing the resistant populations. There are two main processes involving 
bacterial evolution towards antimicrobial compounds. First, there are processes generating 
genetic variability, thus providing the raw material in this process of resistance evolution. This 
variability is attributed to a number of factors, including spontaneous resistance mutation, 
recombination and horizontal gene transfer. Second, natural selection acts on this genetic 
variation and thus driving the spread of resistant determinants in presence of a given drug. 
Antibiotics on the mutation frequency and mutation rate 
Exposure to antibiotics results in hyper mutator or mutator resistant genotypes in the 
populations. This means that antibiotics exert inhibitory effect on bacterial physiology, which 
in turn selects for the mutator or hypermutator genotypes. There are several types of antibiotics 
from different chemical classes can induce the mutagenesis effect in bacteria in many different 
ways, including ROS  (reactive oxygen species) oxidative damage induced by sub-inhibitory 
concentration of antibiotics in E. coli [18], SOS response [116], and general stress response 
[117]. Among these, SOS response is widespread in bacteria and is activated when DNA 
damage occurs. The SOS system promotes cell survival by repairing the damaged genome. 
This system has been extensively studied in E. coli involving more than 40 different genes, 
which are under the control of a repressor protein encoded by lexA gene. In response to DNA 
damage, multiple RecA protein binds at damaged DNA. Following binding to the damaged 
site, RecA induce proteolysis of the LexA, thereby de-represses the SOS regulon. An 
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intriguing feature of this system is inducible mutation at an elevated frequency. Many 
antibiotics activate SOS response in bacteria, including aminoglycosides (translational-stress 
induced mutagenesis), fluoroquinolone (DNA damaging antibiotics are clearly an SOS inducer 
since they can directly damage the DNA), and β-lactam classes of antibiotics [118].  The SOS 
response produces mutator phenotypes by inducing error prone DNA polymerase II, IV and 
polVI.  
The second way of generating mutator phenotype in response to stress (i.e., when nutrients 
become limited at stationary phase – this is called general stress) is down regulation of the 
enzymes involved in the correction of post-replicated DNA errors or mismatches. Enzymes and 
proteins involved in this process called mismatch repair system (MMR). Proteins involved in 
the MMR system play significant role in maintaining normal cellular function. Defective MMR 
system results in high mutation rate in the population. For example, in E. coli MutS and MutH 
are important MMR proteins, but both of them are down regulated by general stress (regulated 
by RpoS) due to the depletion of nutrients at the stationary phase, and thus increased mutation 
rates in this organism. Hypermutator P. aeruginosa have been reported in cystic fibrosis 
patients with altered MMR system with mutS is the most affected gene. These hypermutable 
genotypes are associated with antibiotic resistance in those patients [119-121]. In E. coli,  mutS 
gene acquired an increased frequency of A:T→G:C transversion mutation and thus affected the 
distribution of fitness effect when challenged with rifampicin antibiotic. More specifically, 
when mutS– and mutS+ populations of E. coli were exposed to rifampicin, greater part of the 
mutS– populations were fixed by one of the two-transversion mutations, but the mutS+ strain  
fixed a wide array of mutations [123]. 
ROS oxidative damage occurs when aerobic respiration system is distorted by the production 
of superoxide (O.-2), hydrogen peroxide (H2O2), and hydroxyl radical (OH.). Many bactericidal 
antibiotics and also immune responses produce these ROS species. ROS species have 
detrimental effect on normal cellular functions of bacteria, for example these molecules 
damage DNA and membrane proteins. In E. coli, drug-target interactions induce oxidation of 
NADH via respiratory electron transport chain (ETC) system. Hyper activation of the ETC 
results in ROS species. In experimental P. aeruginosa, H2O2 was reported to be associated with 
direct selection of elevated mutation rate. However, mechanism of antibiotic induced-ROS 
killing in bacteria and the increased mutation frequency has become an active debate since in 
many bacterial species, including L. monocytogenes, S. pneumoniae, bactericidal antibiotics 
were unable to produce ROS since those bacteria were devoid of cyclic TCA cycle and ETC 
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system, respectively.  
Therefore, it is apparent that resistance evolution is based on the generation of genetic variation 
(by mutation) in response to antibiotics followed by natural selection acting on this genetic 
variation [124, 125]. This mutation rate varies in bacterial species due to the MMR system 
[126].  
Role of HGT and recombination 
In addition to mutation, there are some other mechanisms in bacteria that produce genetic 
variability in response to antibiotics. For example, intragenomic reorganization of genomic 
sequences mediated by intra-chromosomal recombination can produce genetic variability in 
bacteria [124, 127]. Intragenomic recombination enables transfer of repeated homologous 
sequences, where a non-reciprocal transfer of information occurs between homologous 
sequences. Therefore, this process was thought to be less costly in the acquisition of a new 
mutation, it can maximize the benefits of having a weak mutation by increasing copy number 
[128]. Bacteria can take up foreign DNA from exogenous sources (i.e., from other organisms) 
by means of HGT. Both mechanisms play crucial role in bacterial evolution and adaptation to 
multiple antibiotics [129], as well as play role in immune evasion [130] and increased 
virulence through acquisition of new genes [131]. In particular, many different resistant 
determinants borne on MGEs (i.e., plasmids, transposons and integrons) are transferred and 
disseminated between different bacterial cells and species by means of HGT [125]. Gene 
recombination produces adaptive response through replacing the deleterious phenotype driven 
by mutation or by bringing beneficial mutation in diverse population [132]. It is thought that 
multidrug resistance through recombination; natural transformation in particular, brings more 
evolutionary benefits to the recombining bacterial population since natural transformation 
entirely takes place at the chromosomal level [133-135]. It has been reported that evolution of 
multidrug resistance in clinical strain of Acinetobacter baumannii was due to transformation, 
and later on it was suggested that more than 45 resistant genes had been acquired by this 
bacterium from other genera including E. coli, Pseudomonas and Salmonella by transformation 
[136]. 
Evolutionary dynamics of multidrug resistance 
Mutation supply rate determines the genetic variability in the infecting clonal populations 
under antibiotic selective pressure, as mentioned in preceding sections. Mutation supply rate is 
determined by population size and rates of mutation and HGT. However, adaptive evolution of 
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drug resistance, for example the rate at which antibiotic resistance will evolve and spread in the 
population is determined by several other factors, including relative fitness of the resistant 
genotypes as the function of drug concentration, strength of selection pressure, clonal 
interference, compensatory mutation, presence of epistasis, and drug-drug interaction [137]. 
 
Relative fitness in absence or presence of drug is a key component in determining how fast 
fixation and spread of a resistant population occurs at a given mutation supply rate [54]. When 
selective pressure is reduced, the frequency of resistant populations or reversibility is 
determined by the relative fitness cost. In many clinical conditions, fitness has been shown to 
be a key factor in shaping the evolutionary adaptation of pathogen populations of clinical and 
laboratory origin [138-140]. Both natural and clinical bacterial population confront a wide 
array of selective pressures in their surroundings. At high drug concentration, the rate of 
resistance emergence is determined by the pre-existing mutations in the population, whereas at 
low drug concentration populations are enriched with small-effect resistance mutations [141, 
142]. It has been shown in one recent study [143] that strong selection pressure favours high 
level of cross-resistance (negative collateral sensitivity) to many other antimicrobial classes, 
whereas under low selection pressure populations enrich with weaker cross-resistance 
Together, this suggests that the emergence and spread of resistant population is attributed to the 
strength of selection pressure, which further complicates the resistance evolution. 
  
Number of mutants and their rates of emergence are two important factors, which help predict 
the simultaneous presence of different resistant mutants in a given population. For example, 
diverse mutants can appear and simultaneously present in the same population of bacteria, as 
has been reported in clonal M. tuberculosis population during long-term antibiotic treatment. 
Specifically, this bacterium experienced gradual increase in resistance mutations with apparent 
clonal sweeps and co-existence of different resistance mutations [144, 145, 171]. Therefore, in 
this particular situation, clonal interference is thought to influence the evolutionary dynamics 
[172]. More specifically, when different beneficial mutations (i.e., beneficial in the context of 
resistance evolution such that a particular resistance mutation appears in response to an 
antibiotic) arise independently in different lineages, they compete against each other, leading to 
the loss of most clones from the population and the appearance of dominant clones [146]. This 
phenomenon has been termed as clonal interference which has been demonstrated in the cost of 
resistance when experimental resistant bacterial population evolved in absence of particular 
antibiotic induced selective pressure [147, 148]. Thus, clonal interference is likely potentiated 
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by the large population size with increased mutation frequency. This phenomenon has already 
been confirmed experimentally during adaptation of resistance plasmids to their bacterial hosts 
and adaptation to the fitness cost conferred by resistance mutations [172]. Similarly, multidrug 
resistance can be the result of concomitant presence of multiple resistance conferring mutations 
in individual clonal lineage. 
 
Epistatic interactions – where the fitness effects of mutations depends on the genetic 
background – plays an important role in the evolution of multidrug resistance [75]. Epistasis 
can occur between genes [149], within a single gene encoding a single resistance protein [68, 
150], or between a chromosomal gene and a gene encoded on a plasmid [151]. A large body of 
studies has identified pervasive epistasis in bacterial adaptive evolution under a variety of 
conditions. For example, in two studies, positive epistasis (when a double mutant has a higher 
fitness than expected from the sum of the costs of individual mutations) was reported to be 
associated with the evolution of multidrug resistance in the cost of resistance [69, 152]. 
Although reduced use or withdrawing of antibiotic use has been suggested to reverse antibiotic 
resistance [54], epistasis plays a major role in determining the adaptive potential of resistant 
populations. For example, in some form of epistasis, called reciprocal sign epistasis, the fitness 
of multidrug resistant genotypes in the absence of drugs is greater than either of the singly 
resistant genotypes. This means that acquisition of additional new resistance determinants  
(new resistance mutation or new resistance plasmid) can further accelerate fitness of the initial 
resistant genotype. Therapeutic options become limited when this particular form of epistasis 
arises in clinical pathogens. 
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Figure 8: The relationship between relative fitness, resistance and rate of formation is shown 
by considering hypothetical sets of all possible drug-resistant mutant variants shown by panel 
a. Each circle represents one specific resistant mutant, and the size of each circle corresponds 
its rate of formation. The probability of fixation of a resistant mutant is determined by the rate 
of formation or mutation rate, extent and level of drug selection and relative fitness. Interaction 
between two resistant genotypes and the resultant epistasis are shown by panel b. Different 
mechanisms such as the efficacy and potential failure of cycling collaterally sensitive 
antibiotics shown by panel c-e. Fitness landscapes with collaterally sensitive antibiotics are 
shown by panel c and d, which show that genotypes that are resistant to drug A or drug B 
appear as fitness peaks when the environment contains the drug to which they are resistant but 
as fitness valleys in alternative drug treatment. Such rotation of the drugs can lead to a cycle of 
evolution switching between these genotypes (solid arrows). However, doubly resistant 
mutants can evade this trap (dashed arrows). Panel e shows two possible evolutionary routes in 
the MICs of component drugs during antibiotic cycling. During cycling treatment bacteria gain 
resistance to multiple drugs when resistance swaps between two states (shown by solid arrows) 
even in the case where each individual mutation induces collateral sensitivity (dashed arrow). 
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In this figure, panel a and b are reproduced from [137], while panel c and d are reproduced 
from) [153].  
  
Compensatory evolution is another important means of adaptive evolution of antibiotic 
resistance , which also involves epistasis. Antibiotic resistance is deleterious (on bacterial 
fitness) in absence of drug pressure. In absence of drug pressure, resistance determinants often 
impose fitness costs in the form of reduced growth, reduced transmission or reduced virulence 
[154]. However, secondary mutations may arise in the resistant population that compensate for 
these costs of resistance. This phenomenon of adaptive evolution has been reported both in 
vivo and in vitro studies [155, 156]. Compensatory mutations can also be resistance mutations 
themselves, which can both compensate and confer resistance to other antibiotics. Here, the 
initial resistance mutation (conferring resistance to drug A) in absence of drug pressure is 
deleterious, but is compensated by another mutation conferring resistance to drug B. This 
phenomenon has recently been observed between a streptomycin resistance mutation and a 
rifampicin resistance mutation in E. coli [152].  
 
Drug interaction is an important factor in determining bacterial evolutionary adaptation to 
multiple drugs. Drug interactions are classified into two types: physiological interactions and 
evolutionary interactions. During physiological interaction, two antibiotics are used in 
combination and they can produce synergistic interaction, antagonistic interaction, or they can 
suppress each other’s effect – called suppressive drug interaction.[157]. Such drug interactions 
arise when the combined inhibitory effect of two drugs is larger (called synergistic interaction 
which is more inhibitory) or smaller (called antagonistic interaction, where higher MIC is 
needed to obtain the same level of inhibition of synergistic drug pair) than expected based on 
an additive model. During suppressive drug interaction, two drugs in combination produce 
weaker effect than the null additive expectation and also weaker than the effect of each of the 
drugs alone. It has been reported that synergistic drug pairs, at a certain concentration 
threshold, potentiate the evolution of resistance by extending the traditional mutant selection 
window towards the sub-inhibitory concentration [158, 159]. These studies have shown that 
certain drug specific resistance mutation arise first (resistance mutation to drug A) in a 
combination of two drug (drug A + drug B), which diminish the synergistic action of that pair 
owing to that drug specific resistance mutation. Subsequently, this mutation confers enhanced 
growth advantage against that drug pair and drives the acquisition of resistance mutation for 
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another drug (drug B). Thus multiple resistance mutation appears in presence of combination 
of a synergistic drug pair. Therefore synergistic drug pairs used at concentrations below the 
minimal inhibitory concentration (MIC) accelerate the resistance emergence. On the contrary, 
with drugs that interact antagonistically certain mutation or mutation to drug A breaks and 
convert antagonistic interactions into synergistic. Thus antagonistic drug pairs decelerate the 
resistance evolution to the second drug. On the other hand, evolutionary interactions are 
classified into two types: cross-resistance and collateral sensitivity. Resistance mutations or 
genes – arising through either spontaneous mutation or horizontal gene transfer (HGT) – can 
simultaneously confer resistance to another drug (called cross-resistance) or become more 
sensitive to another drug (called collaterally sensitive) [160, 161]. Cross-resistance is the 
function of the evolutionary response to a single antibiotic; therefore cross-resistance is 
different to the physiological interactions, which require drugs to be administered in 
combination. 
Study organism 
Throughout my PhD work I used the gram-negative bacterium Acinetobacter baylyi as my 
experimental system. This bacterium possesses a highly efficient DNA-uptake system, which 
makes it an ideal model organism for studying natural transformation [162]. Originally isolated 
from the environment, in a few instances this bacterium has also been found to be associated 
with hospital-acquired infections with multiple MBL (metallo-beta-lactamase) carbapenemase 
enzymes, including blaSIM-1 and blaOXA-23 [163, 164]. This bacterium is also important in terms 
of drug discovery since systematic chemical-genetic screens have been performed in this 
bacterium [165] along with other important bacterial pathogens including M. tuberculosis 
[166], P. aeruginosa [167] by using a transposon insertion library. This screening has revealed 
that a large numbers of genes influence drug susceptibility; hence they are regarded as 
candidate antibiotic potentiation targets. However, the fold-MIC changes in antibiotic 
concentration ranged from a two-fold to eight-fold between wild type and mutant strains, and 
this observed hypersensitivity was thought to be typically rather modest. Another important 
feature is that the whole-genome sequence is available for this bacterium [168, 169], which has 
made it easier to monitor any genetic changes in the evolved population that has occurred 
during the course of evolution experiment or in strains associated with chapter 2.  
Scope and significance of this thesis 
Multidrug resistance (MDR) remains one of the major reasons for therapeutic failure in treating 
infectious diseases in recent days. The MDR pathogen population can emerge and spread in the 
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face of selective pressure exerted by drugs or they revert to the original susceptible state when 
the selective forces are discontinued. This means that evolutionary adaptation to multiple drugs 
follows a complex evolutionary path determined by many factors. Previously, many studies 
have made different conclusions on factors contributing to the rate of this resistance evolution 
under variety of contexts, including the occurrence and molecular characteristics of the 
resistance mutations, the fitness effects of drug resistance mutations in the presence and 
absence of drug induced selective pressure and how these factors impact the evolutionary 
trajectories of the resistant population. Nevertheless, evolution of multidrug resistance is a 
multifaceted phenomenon involving more factors, which were less studied in earlier studies. 
For example, among many others, it is yet unclear how a completely susceptible bacterium 
evolves de novo multidrug resistance in an environment enriched with a combination of drugs. 
Factors important in this context include pharmacodynamics (bacterial fitness as a function of 
drug concentrations, including drug-drug interactions), epistasis, and compensatory mutations. 
A complete understanding of these features will be important in predicting and preventing 
future multidrug resistance evolution in pathogen populations. Therefore, this PhD thesis 
attempts to expand our understanding further by investigating more factors that influence the 
development of de novo multidrug resistance under laboratory conditions. 
  
From a public health perspective, this study is of importance since antibiotic resistance has 
become a serious public health problem due to high level of resistance against the treatment of 
infectious diseases globally. To combat this resistance problem, combination therapy has 
become an effective therapeutic choice. However, even in combination therapy, we need to 
better understand to what extent resistance can be selected for and what type of two-drug 
concentrations affect the potential for this resistance evolution, as resistance to multiple drugs 
have already threatened our antibiotic arsenal. Therefore, understanding the population genetic 
processes involving multidrug resistance is essential for proposing different but prudent 
treatment strategies, including combination therapy or drug-cycling, and this may ultimately 
help reduce the emergence of multidrug resistance pathogen. 
Thesis outline  
The first part of this thesis (Chapter 1, literature review) provides a general background on the 
history, importance, and molecular and evolutionary aspects of antimicrobial resistance, in 
particular multidrug resistance in bacterial pathogens. In Chapter 2 I report characterisations of 
pharmacodynamics fitness landscapes, seeking to better understand how antibiotic 
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concentrations and fitness interactions contribute to the evolution of drug resistance. From an 
evolutionary perspective, this study will increase our understanding of how populations may 
adapt to complex environment containing multiple antibiotics. In Chapter 3 I investigate the 
impact of recombination via natural transformation on the de novo multidrug resistance 
evolution in two-drug environments in experimental bacterial populations. This perhaps 
reflects on the actual situation when pathogen population are confronted with different 
selective pressures posed by antibiotics inside the host body compartments. Chapter 4 
investigates the mechanisms of compensation to the cost of multiple drug resistance mutations 
harboured by bacteria in the absence of selection pressure. This chapter is of particular 
importance since we do not know how multiple drug resistance bacteria adapt to their fitness 
costs. Then in Chapter 5 (general discussion) in which I reflect on the main results, their 
implications, limitations of the research, and future avenues of investigation.  
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Chapter 2: Experimental estimation of pharmacodynamics fitness 
landscapes in the evolution of multidrug resistance 
Summary 
Combination of multiple drugs has been an effective therapeutic treatment protocol over 
monotherapy since the success of a single drug therapy is increasingly being threatened by the 
evolution and spread of antibiotic resistance mutations. The sustained effectiveness of 
combination treatments depends crucially on the speed at which these resistance mutations 
arise, spread and are combined to form multidrug resistance. Until now we only know a little 
about how cross-resistance and collateral sensitivity, interactions between drugs and epistasis 
determine the evolution of multiple drug resistance. By constructing three pairs of resistance 
mutations, we studied the resulting fitness landscapes where we measured growth rates as a 
proxy for fitness in concentration gradients of the corresponding drugs. This was done using 
Acinetobacter baylyi, which has recently been found to be associated with multiple drug 
resistance, including carbapenem resistance in hospitalised patients.  
Overall, the data we obtained here show that fitness landscapes were largely non-epistatic 
between each pair of resistance conferring mutations under all three pairs of drug 
environments. A wider mutant selection window was apparent for two antibiotics pairs where 
the sub-MIC concentration space was many fold lower than the MIC of the susceptible 
genotype. Thus, these results suggest that the sub-MIC antibiotic concentration is also 
generated in certain body compartment during combination therapy which may potentiate the 
evolution of de novo multidrug resistance. Our results also point to cross-resistance – a 
phenomenon where a mutation confers simultaneous resistance to several drugs belonging to 
the same class. We find that a wider mutation-selection window can also occur in presence of 
cross-resistance, which may have important implications in resistance evolution. We also 
observes a minor sign of Eagle effect for a singly resistant genotype treated with an antibiotic, 
which was non-specific to that particular drug. Overall, our results underlie the importance of 
selecting the right drug during cyclic treatment and also motivate using optimal treatment 
dosing regimes during combination therapy that exclude the prolonged exposure of sub-MIC 
level of antibiotics. More extended analyses of such fitness landscapes considering more drug 
pairs that target different bacterial physiological pathways is essential to obtain a solid 
understanding of de novo multidrug resistance evolution. 
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Introduction 
The broad occurrence of antibiotic resistance has become a major cause of concern in treating 
infectious diseases. Specifically, the emergence of resistant bacteria to several antimicrobial 
compounds – of both synthetic and semi-synthetic origins – over the last decades poses serious 
threats, which eventually portrays greater lack of understanding of the factors contributing to 
the evolution of multidrug resistance [1-4]. Despite substantial knowledge of the molecular 
basis of resistance, the population biological principles determining the evolutionary routes 
towards drug resistance is largely lacking – for example, complete understanding of selection 
pressures, environmental variations and evolutionary constraints are important for predicting 
evolutionary paths towards resistance [5-8]. 
 
The fitness landscape [9] – a fundamental concept in evolutionary biology – captures the 
relationship between genotype and evolutionary fitness. This widespread metaphor portrays the 
possible evolutionary trajectories of adaptations of a set of genotypes where the genotypes are 
mapped onto phenotypes (i.e. finesses determined by the growth rate of genotypes) by 
mutational network, which in turn determine the trajectories [10-15], mode and tempo of an 
adaptive process, or adaptive protein evolution, including evolutionary adaptation of bacterial 
pathogen to multiple antibiotics [16] and affinity maturation [17, 18]. Fitness landscapes also 
play important role in many theories, including theories concerning the evolution of sex, 
speciation, genetic robustness and evolvability [19-22]. 
 
An important feature of fitness landscapes is epistasis (Figure 1), where fitness effects of 
alleles at different loci deviate from their individual allelic fitness effects. Positive epistasis 
predominates when two beneficial mutations (beneficial in the context of a given environment) 
in a genotype jointly increase the net fitness more than the sum of their individual fitness 
effects. On the contrary, negative epistasis implies that combined fitness effect of the two 
beneficial mutations is less than the sum of their individual fitness effect [23, 24]. Furthermore, 
other patterns of epistasis can also be observed, for example sign or reciprocal sign epistasis. In 
the case of sign epistasis, the selective effect brought by mutation to a locus depends on the 
selective effect incurred by mutation to other locus, whereas in reciprocal sign epistasis, 
selective effect depends on both loci [25-27]. 
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Multidrug resistance usually evolves through adaptation at multiple loci in a genome of a 
pathogen. Each of these loci harbouring drug specific resistance mutation can also confer 
resistance to several other drugs. This phenomenon of resistance to multiple drugs is 
widespread in many clinical bacteria; most notable of such multidrug resistant bacteria, in 
terms of global morbidity and mortality, are clinical Mycobacterium tuberculosis, Klebsiella 
pneumoniae, Pseudomonas aeruginosa and Klebsiella pneumoniae [28-30]. In such cases, 
where drug specific resistance mutations carried by different genotypes, including single drug 
resistant and double resistant mutant, the rate at which these genotypes will spread in the 
population is determined by relative fitness. Therefore, the concept of fitness landscape is 
important for studying the evolutionary dynamics of multidrug resistance driven by mutations 
at several loci. More specifically, when resistance to several drugs are present in the 
populations – considering resistance to several drugs conferred by mutations at several drug 
specific loci – fitness landscape can assign fitness values of all genotypes and determine the 
rate of adaptation or long-term success in the population under antibiotics environment. Thus, 
defining different features of this fitness landscape is crucial and could explore new avenue on 
understanding the protein evolution of multidrug drug resistance.  
 
Epistasis plays an important role in the spread of resistance mutations in the population. 
Epistasis is measured by determining relative fitness among genotypes comprising both 
susceptible and resistant genotypes. Therefore, epistasis in presence or absence of drug 
pressure takes different forms. Theoretical and empirical observations have characterized the 
fitness landscape by determining epistasis for antibiotic resistance conferred by mutations at 
several loci under different selective environment [31-34]. From those studies, it is apparent 
that in presence of drug-selection pressure, fitness of a resistant genotype depends on and 
further increased by additional mutation, as genotype carrying the first resistance mutation may 
not be the fittest in the population. Therefore, additional mutation in an additive way forms the 
fittest genotype sustaining drug-selection pressure and spread in the population. However, in 
case of epistatic interactions, fitness may increases or decreases when both mutations interact 
positively or negatively (Figure 1, right panel). In absence of antibiotics selection pressure, 
synergistic cost/substantial decrease in fitness can be observed in singly resistant genotypes or 
increased in fitness incurred in a double resistant genotype when two costly mutations 
positively interact each other and increased fitness more than any of the single resistant 
genotypes (illustrated in Figure 1, left panel), a form of epistasis called sign epistasis (SE) [8]. 
Therefore, it is possible to observe many different types and degree of interactions between 
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resistance genes or mutations in absence or presence of drug pressure. In addition to this, more 
different forms of epistasis are presented in Figure 1.  
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Figure 1 Illustration of the simplest two-locus fitness landscape.  Considering a two-locus 
fitness landscape in presence and absence of drugs, several types of epistasis are possible. ‘S 
and R’ denote susceptible and resistant alleles respectively. ‘SS’ shows fitness for the wild type 
genotype with green column. Two different single resistant genotypes denoted by ‘SR’ and 
‘RS’ with their corresponding fitness are shown by blue and red columns, whereas purple 
colour with ‘RR’ represents fitness for the genotype carrying both resistant mutations. Here, 
epistasis is defined as a deviation from the additive effect (shown by brown columns; here, 
fitness for the double mutant can be predicted from the fitness of the two single resistant 
genotypes). Different purple columns show different types of epistasis. In absence of drug 
selection pressure (left panel), different types of epistasis can be observed. In addition to 
positive and negative epistasis, sign epistasis (SE) can be observed when two resistance 
mutations interact positively and increase fitness at least more than one of the single resistant 
genotype. An extreme form of sign epistasis called ‘reciprocal sign epistasis (RSE) occurs 
when two resistance mutations interact in a way that gives rise to a higher fitness than both of 
the single resistant genotypes. A special type of sign epistasis (denoted by SE*) can be seen 
when one resistance mutation compensates for fitness costs imposed by the other. This type of 
sign epistasis is particularly relevant in the evolution of multidrug resistance. In presence of 
drugs, both positive and negative epistasis can be observed between resistance mutations (right 
hand panel). 
In experimental population, epistasis between different mutations has been reported. In the 
case of TEM β-lactam resistance, five point mutations gave strong resistance where extensive 
reciprocal sign epistasis documented in presence of cefotaxime [11]. However, this type of 
epistasis was absent in mutations conferring resistance to rifampicin in P. aeruginosa but 
wide spectrum of negative epistasis was prevalent [35]. In absence of drug pressure, studies 
revealed an abundance of epistatic interactions between mutations conferring drug resistance, 
where positive epistasis was found to be predominant in the population [16, 36]. Another 
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study reported a multitude of sign epistasis between chromosomal resistance mutations and 
resistance mutations harboured by plasmid [27]. In the above-mentioned studies, an important 
factor was not considered while characterizing fitness landscape of drug resistance: different 
antibiotic concentrations and their impact on the bacterial growth or death rate. In case of 
multidrug resistance evolution, evolving bacterial population confront differential drug 
pressures throughout the environment, and the fitness landscapes underlying drug resistance 
will vary along with these different concentrations and combinations of drugs. More 
specifically, the effectiveness of an antibiotic depends on its absorptions, distribution, and 
decay (which we call pharmacokinetics or PK) as well as the specific functional relationship 
between the concentration of drugs and the growth or kill rate induced by that drug (which we 
call pharmacodynamics or PD) [37-41]. The PD functions vary when mutations are acquired 
across loci; therefore, it is particularly important to investigate how pharmacodynamics and 
the multilocus population genetics together impact the evolutionary adaptation to multiple 
drugs. The PD approach has widely been employed for a single drug and for a single 
(susceptible) genotype. Here, the net growth rate (positive or negative) of a bacterial 
population is measured in presence of different concentrations of a single drug. 
Mathematically, this net growth rate as a function of antibiotic concentration is often 
described by Hill-function [37, 42]. Two previous studies described the pharmacodynamics or 
growth/death rates of a susceptible genotype at different concentrations of two drugs by 
employing a two-drug PD approach; these studies revealed that Hill functions give a good fit 
when considering drug-drug interaction parameter as well as drug concentrations [43, 44]. 
However, these studies were limited by factors such as drug specific resistant mutants 
including single and double resistant genotypes were not considered. Therefore, the 
evolutionary interactions between resistance mutations as well as drug interactions were 
largely ignorant in those studies.    
 
Drug interactions are an important factor inherent in two-drug pharmacodynamics. Analogous 
to genetic interactions, drug-drug interactions are classified into three main types namely 
additive, synergistic and antagonistic, where antagonistic and synergistic interactions are 
defined on the basis of deviation from an additive effect of a pair of drugs. Additivity can be 
defined by two main methods namely, Bliss independence and Loewe additivity. According to 
Bliss independence, the relative effect of a drug at a particular concentration is independent of 
the presence of the other drug. By contrast, Loewe’s definition is premised on the idea that a 
drug is non-interacting with itself – if two drugs are in fact the same or similar – then their 
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combined effect would be identical to the effect of one of those drugs used alone in double 
dose [45-48]. In synergistic drugs pairs, maximum therapeutic outcomes are expected, whereas 
antagonistic drug pairs debilitate therapeutic success and negatively correlate with bactericidal 
activity [43]. Studies suggest that antagonistic interactions narrow the drug concentrations and 
slow down and/or reverse the rate of resistance evolution [48-50]. However, these studies were 
limited in that either fitness was measured for all genotypes but only in absence vs. presence of 
drug pressure, or that fitness was measured over a wide range of drug concentrations but only 
susceptible bacteria were considered. 
 
One recent theoretical study has characterized pharmacodynamics fitness landscapes for 
multidrug resistance based on Hill pharmacodynamic functions that describe fitness of all 
genotypes with continuously varying concentrations of two drugs. This theoretical 
investigation suggested that pharmacodynamic fitness landscapes would be characterised by 
pervasive epistasis. This epistasis can result from 1) fitness costs of resistance (epistasis is 
expected to arise at drug concentrations around the MIC of the wild type and resistant 
genotypes even if the costs are additive; 2) cross-resistance or non-specificity of resistance 
mutations (such that one particular resistance mutation can also confer resistance  to the other 
drug); and 3) drug interactions (synergistic drug interactions should lead to negative epistasis 
and antagonistic interactions should lead to positive epistasis). In this chapter I will test this 
hypothesis experimentally. Specifically, I will characterise two-locus pharmacodynamic fitness 
landscapes comprising both susceptible and resistant genotypes (both single and double 
resistant) in absence and presence of the two corresponding drugs at varying concentrations. I 
then analysed the key properties of these pharmacodynamics fitness landscapes such as 
epistasis, collateral sensitivity or cross-resistance, and drug-interactions in order to better 
understand the role of these factors in multidrug resistance evolution. 
 
In the present study all genotypes were constructed by a combination of traditional mutation 
selection assays (i.e. single resistant genotypes were constructed in presence of rifampicin and 
streptomycin antibiotics; only kanamycin resistant genotypes were created by insertion of nptII 
gene) and natural transformation assay (all three double resistant genotypes). For further 
confirmation for additional mutation, we screened for additional mutation by whole genome 
sequencing. Three different antibiotics we have used belong to two different chemical classes; 
two of these antibiotics belong to the same chemical classes (i.e. kanamycin and streptomycin 
belongs to aminoglycoside, both of them typically interfere with important bacterial cellular 
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processes, including protein synthesis inhibition), and rifampicin belonging to rifamycin class 
interfere with RNA-polymerase-β-subunit (RNAP). Growth rates - proxy for fitness - were 
measured for all different representative genotypes (a susceptible, two singly resistant and a 
double resistant genotype) under all possible antibiotic environments - for example - fitness is 
measured for each of the four different genotypes in absence of drug pressure, in presence of a 
single drug and in presence of a combination of both drugs covering a wide range of antibiotic 
concentrations. 
Materials and methods 
Bacterial strains, media and growth conditions used in this study 
We used Gram negative Acinetobacter baylyi derived from ADP1 strain (NC_005966) [53]. 
These strains were devoid of plasmids as well as bacteriophages, and were recombination 
efficient with fully functional DNA-uptake machinery for natural transformation assay. One 
strain we used for rifampicin and streptomycin mutant screening was a tryptophan auxotroph, 
and also had a insert of cyan fluorescence marker (ecfp) (trpE27 ACIAD0921::ecfp).  The third 
one called kanamycin resistant strain was also a tryptophan auxotroph harboured an nptII 
(neomycin-phosphotransferase-II) gene conferring resistance to kanamycin and a yellow 
fluorescence marker (trpE27 ACIAD0921::eyfp ACIAD3309::nptII). 
 
We used LB medium for all experiments and for most assays (i.e. for bacterial culture 
preparation, growth rate assays, broth MIC-assay, and for the amplicon and whole genome 
sequencing). The list of different antibiotics that we used is given in table 1. According to the 
manufacturer recommendation, liquid LB (lysogeny broth) was prepared at a concentration of 
25 g/L, whereas, LB agar was prepared at 32 g/L final concentration. Cultures were grown at 
30°C with shaking at 180 r.p.m. Rifampicin and streptomycin antibiotics were purchased from 
Sigma-Aldrich, and kanamycin was purchased from A.G. Scientific, Inc. Kanamycin and 
streptomycin solutions were prepared from powder stocks dissolved in sterilized H2O and 
rifampicin was prepared from liquid stocks into CH3OH. Drug gradients were prepared in LB 
medium by serial dilution method. 
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Table 1 List of different antibiotics and their targets  
Antibiotic name Drug class Target 
Streptomycin* Aminoglycoside 30S ribosome 
Kanamycin* Aminoglycoside 30S ribosome 
Gentamycin Aminoglycoside 30S ribosome 
Rifampicin* Rifamycin DNA dependent RNA polymerase (RNAP-β-subunit)  
Ciprofloxacin Fluoroquinolone DNA topoisomerase II (DNA gyrase), IV 
Nalidixic acid Fluoroquinolone DNA topoisomerase II (DNA gyrase), IV 
Trimethoprim FSI1 DFHR 
Penicillin Penicillin Cell wall synthesis 
* Antibiotics used for single drug resistant genotypes and subsequent double resistant 
genotypes construction for the PDFLs; 1Folate synthesis inhibitor. DHFR: Dihydro folate 
reductase 
Mutants screening from ancestral sensitive strain and Sanger sequencing  
To construct rifampicin and streptomycin mutant, ancestral sensitive strain was streaked on LB 
agar plate from -80° freezer and incubated overnight at 30°C. From this plate, overnight culture 
was setup from a single clone in fresh 20mL LB broth in a 50mL falcon tube at 30° C with 
shaking (180 r.p.m). Mutant screening for a single drug was carried out by plating 100uL of 
overnight culture on LB agar plates supplemented with either 10mg/mL of rifampicin or 
10mg/mL of streptomycin and incubated at 30°C for maximum of 48 hours. The 
concentrations we used were 10-fold and 5-fold higher than the MIC of rifampicin [~1ug/mL] 
and streptomycin [~2 ug/mL], respectively. After a maximum of 48 hours of incubation, 
individual mutants were isolated from both the rifampicin and streptomycin supplemented 
plates and overnight culture with these individual clones were set up in LB broth supplemented 
with the respective antibiotics and concentrations. Individual mutants were then frozen in 15% 
(v/v) glycerol at -80°C for further assays.  
Sanger sequencing was performed to sequence targeted genomic locations of the individual 
mutant. We sequenced two regions of rpoB gene (rpoBI primer pairs which covered 
nucleotides ranging from 1–1342, including resistance cluster I, and rpoBII which covered the 
second spanning nucleotides 1240–2226 nucleotides, including resistance cluster II) by using 
two pairs of primers to detect the mutation responsible for rifampicin resistance (Rifr). These 
primer pairs were designed based on a literature search to detect the common regions covering 
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the occurrence of common rifampicin resistance pathway conferred by mutation in the rpoB 
gene [54]. Similarly, to detect the streptomycin resistance (Stpr) mutation, two pairs of primers 
were constructed targeting rrs and a single pair of primers for the rpsL gene, because most of 
the mutations conferring resistance to streptomycin appear in these two genetic loci [55, 56]. 
Detailed primer information, PCR master mix preparation and the PCR program are provided 
in supplementary Table S1-S3. DNA extraction was carried out from these individual resistant 
clones by using Promega genomic DNA extraction kits (Promega, California), followed by 
PCR amplification of rpoB, and rrs gene fragments. Sanger sequencing was carried out on 
these amplified PCR gene products, and mutations were determined by DNA Sangers sequence 
analysis on Geneious version 9.1.4 (BioMatters Inc.). 
Construction of double resistant strain and Sanger sequencing 
In the following step, we constructed three different double resistant genotypes by a natural 
transformation assay by following a protocol developed by de Vries and Wackernagel [57] 
with slight modification. In short, individual competent cells of rifampicin and streptomycin 
resistant mutant strains obtained earlier were prepared by adding 1mL overnight culture into 
100 mL of LB broth in Erlenmeyer flask for a period of 6-8 hours growth at 30°C with 
constant shaking at 180 r.p.m., followed by centrifugation at 8500 rpm for 2 minutes and 
collection of pellets. In the next step, approximately 300uL LB broth supplemented with 
glycerol (20% v/v) was used to re-suspend the pellets by pipette tips very gently. This 
suspension of pellet contained competent cells and was stored in a -80°C freezer. The 
following day, transformation of competent cells with DNA (obtained from rifampicin and 
streptomycin mutants as donor strain in either way) was carried out by taking 20mL of LB 
broth supplemented with MgCI2 (0.25mM) and CaCI2 (0.25mM) in 300mL Erlenmeyer flasks. 
After adding DNA, the flask containing both competent cells and DNA was placed on the 
shaker (at 30°C with 170 rpm as shaker conditions) for aeration for a period of 90 minutes. 
This allowed competent cells to take up DNA from its surrounding. After appropriate aeration, 
the cultures were centrifuged at 6000xg for 5 minutes and re-suspended the pellet by adding 
300uL fresh LB into to tube and mix the pellet by pipette tips very gently. From this tube, 
appropriate volume of this LB broth containing competent cells were streaked on LB agar plate 
supplemented with both antibiotics, for example, plates were supplemented with 4 ug/uL 
rifampicin and 20 ug/uL streptomycin in combination. The cultures were then diluted and 100 
L of these cultures were plated and left for adequate dry up for a maximum of 5 minutes. 
After this, all plates were incubated for a maximum of 40 hours at 30°C and visible individual 
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colonies were picked up and overnight cultures were setup in LB broth supplemented with 4 
ug/uL rifampicin and 20 ug/uL streptomycin in combination. Individual culture of these double 
resistant mutants (StpRRifR) were frozen in 15% (v/v) glycerol at -80°C freezer. Sanger 
sequencing was carried out on this StpRRifR to confirm the location of the mutations in rpoB 
and genetic loci.  
Structure of two-locus fitness landscape 
According to the scheme, this study first aims at determining fitness of all genotypes by 
constructing different genotypes either by a combination of traditional mutation selection 
assays (single resistant genotypes) and natural transformation (double resistant genotypes) 
assay. Background and construction scheme of different genotypes for characterizing the 
PDFLs is outlined in Figure 2 used three different types of antibiotics belonging to two 
different classes in my experiments. These antibiotics are typically targeted to perturb bacterial 
important cellular processes, including inhibition of nucleic acid synthesis as well as protein 
synthesis inhibition (Table 1). 
SSR 
SRR RSR 
SSS 
SRS RSS 
RRS 
PDFL 1 
PDFL 2 
PDFL 3 
Kanamycin Streptomycin Rifampicin 
 
Figure 2 Three resulting pharmacodynamic fitness landscapes (PDFL) characterized in this 
study. The above figure shows our empirical fitness landscapes comprising three loci and 
seven different genotypes. Starting from a completely susceptible genotype SSS (with colors 
indicating the three drugs and corresponding loci), we constructed three single resistant (R) and 
three doubly resistant genotypes. Each node connected by the line indicating the evolutionary 
accessibility towards the multiple drug resistant genotypes. The three resulting 
pharmacodynamic fitness landscapes were studied. 
Growth rate assays 
Growth rates for seven different genotypes comprising three fitness landscapes were measured 
by spectrometry (SynergyTM HT microplate reader, Biotech, USA). In doing so, individual 
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resistant genotypes (i.e., susceptible, single resistant and double resistant genotypes) were first 
streaked on fresh LB agar plate from the -80°C freezer, and then a single colony from each 
plate was further grown overnight in LB medium on an orbital shaker (180 rpm) at 30°C. From 
this overnight culture, the growth rates of each clone were measured by obtaining the growth 
curve (OD600) in LB broth with or without antibiotics (we used kanamycin, streptomycin and 
rifampicin in different combinations). Statistical software R was used for finding the best curve 
fitting a line for data obtained from spectrometer. In short, raw OD values were normalized to a 
blank OD and log-transformed before analysis. The slope for the exponential growth was 
determined over a 32 data points correspond to growth over 160 minutes. 
Determination of Minimal Inhibitory Concentration (MIC) 
We determined the MIC of each of the constructed genotypes to check the level of resistance 
conferred by the evolved spontaneous drug specific resistant mutations.. Exponential cultures 
in LB broth were prepared, and samples containing around 5 × 105 colony forming units were 
transferred to polypropylene microtiter plates containing 180uL LB supplemented with known 
amounts of antibiotic. After 12 hours of incubation at 37 °C, growth was visually monitored. 
We carried out this to determine the evolutionary interactions of cross-resistance and negative 
cross-resistance to other drugs. 
Statistical analysis 
Various statistical methods were employed at the population level for data analysis. We first 
employed an analysis of variance (ANOVA) model to compare growth rate of the ancestral 
genotype with all the mutant genotypes in absence of drug environment to measure the fitness 
cost of antibiotic resistance. Similar analysis was employed for broth MIC and e-Test assay for 
the ancestral and mutant genotypes. All statistical analysis was carried out using JMP version 
12. 
Results 
Determination of resistance mutations involved in the two-locus empirical fitness 
landscapes 
In this study, we constructed our three two-locus empirical fitness landscapes from three 
individual mutations conferring resistance to kanamycin, rifampicin and streptomycin 
antibiotics respectively. At first we constructed single resistant genotypes from a completely 
susceptible strain either by mutant screening (i.e. we selected rifampicin and streptomycin 
resistant genotype) or by site directed mutagenesis (kanamycin resistant genotype was 
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constructed by insertion of nptIII gene through Tn5 transposon insertion). It is worth 
mentioning here that the frequency of rifampicin resistant mutation was much higher than the 
frequency of streptomycin resistant mutation (based on the appearance of the number of visible 
colonies on LB plate supplemented with many fold higher than the MIC of respective 
antibiotic; data not shown here). This result led us to carry out a targeted amplicon sequencing 
in the targeted genes (we designed primer by targeting specific allelic position to cover the 
commonly found mutation in both rpoB locus (mutation in this locus confer resistance to 
rifampicin) and the rpsL locus (mutations at this locus cause streptomycin resistance). Our 
targeted sequencing revealed that indeed the streptomycin resistant genotype carried a point 
mutation (K43T) in rpsL (encoding 30S ribosomal subunit) and rifampicin resistant genotype 
harboured a point mutation (P571L) at the rpoB locus (encoding RNAP, RNA polymerase β-
subunit). We then constructed our three double resistant genotypes by introducing two of these 
unique resistance mutations conferring resistance to two distinct antibiotics respectively by 
natural transformation assay. To know the level of resistance, all single and double resistant 
genotypes were tested for the MIC (tested by E-test and broth micro-dilution in LB medium in 
presence of respective antimicrobial compounds). This antimicrobial susceptibility testing 
revealed high level of resistance in all different genotypes when we compared them with the 
susceptible genotype. For example, the MIC for the rifampicin resistant genotype was >32 
mg/L (indicated as the highest concentration in the gradient strip) and for the streptomycin 
resistant genotype the MIC was >1024 mg/L (indicated as the highest concentration in the 
gradient strip). For the kanamycin resistant genotype the MIC tested with broth micro-dilution 
method was >1024 mg/L. Similar resistance profile was observed for all the double resistant 
genotypes. 
Table 2 List of genotypes of A. baylyi used in this study.  
Letter ID Genotype AA change Gene affected Fold-MIC change 
SSS WT NA NA 1 
RSS Kan nptIII* nptIII* >1032 
SRS Stp K43T rpsL >1032 
SSR Rif P571L rpoB >32 
RSR KanRif P571L nptIII*; rpoB >1032 
RRS KanStp K43T nptIII*; rpsL >1032 
SRR RifStp P571L; K43T; S325P rpsL; rpoB; cyoA >1032 
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Seven genotypes of A. baylyi along with their genetic background and resistance profile used in this 
study comprising three two-locus fitness landscapes. Experimental ID indicated by three capital letters 
indicating different genotypes with corresponding resistant loci. Genetic characteristics such as amino 
acid changes are also provided. Information for an additional mutation in one double resistant 
genotype indicated by SRR*. The susceptible genotype (trpE27 ACIAD0921::ecfp) indicated by SSS 
where each of these three letters stands for a specific locus giving resistance to three antimicrobial 
compounds: the first ‘S’ for kanamycin resistant gene; the second ‘S’ is for streptomycin resistant 
gene ; the third ‘S’ for rifampicin resistant gene rpoB. The nptIII gene was inserted by Tn5-
mutagenesis (ACIAD3309::nptIII). 
To quantify each of these fitness landscapes, we further examined mutational background for 
each of the genotypes by carrying out whole genome sequencing to confirm that these 
mutations were the same and no other additional mutations were present in any of the seven 
different genotypes. Whole genome sequencing revealed exactly the same resistance mutation 
in all three double resistant genotypes, and these double resistant strains were constructed 
through natural transformation assay. However, one additional mutation in the cyoA locus was 
also detected in one double resistant genotype harbouring the K43R rpsL and P571L rpoB 
mutations (table 2; see Discussion). We assigned these three fitness landscapes as Kan-Rif, 
Kan-Stp and Rif-Stp. 
Costs associated with single and double resistance genotypes 
Antibiotic resistance is often associated with fitness cost under non-selective conditions [58]. 
We aimed to characterize our two-locus PDFLs in the evolution of multidrug resistance both in 
presence and absence of drug pressure. Therefore, we first determined the cost of resistance by 
measuring growth rates in LB medium without antibiotics for each of the six constructed 
resistant strains and compared them with the ancestral susceptible genotype. Our growth data 
revealed a significant fitness costs for all the resistant genotypes except for the kanamycin 
resistance genotype (Figure 3(a): ANOVA, pairwise-comparison given by connecting letters 
using TK-HSD test). The rifampicin resistant genotype suffered a higher fitness cost compared 
to the streptomycin resistant genotype. Pairwise comparisons also revealed that all three double 
resistant genotypes were significantly different from each other. Among them, strikingly, the 
SRR genotype (dually resistance to rifampicin and streptomycin) experienced the highest 
fitness cost. Sign epistasis, especially reciprocal sign epistasis through mutually exclusive 
mutations can make evolutionary trajectories inaccessible and is associated with multi-peak 
fitness landscapes [59, 60]. We, therefore, further compared fitness between single vs. double 
resistant genotypes to discern any potential epistatic effects in the cost of resistance. The 
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fitness of the RRS genotype (resistant to both kanamycin and streptomycin) was greater than 
that of both corresponding single resistant genotypes, but the difference to SRS was not 
significant. Similarly, we observed no significant differences in fitness costs between the RSR 
and SSR genotypes, so that there was also no evidence of sign epistasis in this comparison. 
With the fitness landscape between rifampicin and streptomycin resistance mutations, we 
observed an additive fitness cost for the double resistant genotype (SRR) such that the 
combined costs of the two single resistant genotypes (SRS and SSR) equals the cost of the 
double resistant genotype (SRR). 
 
Following I analysed the three-factor ANOVA distinguishing between individual mutations 
and interactions between mutations. This result suggests that both rifampicin and streptomycin 
resistance mutations incurred significant fitness cost but the kanamycin resistant genotype 
incurred marginally significant fitness cost. However, we did not observe any significant 
interactions between any of the resistance pairs suggesting no epistasis in the cost of resistance 
among them. Parameter estimates for the three-factor ANOVA is given by Table 3. 
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Figure 3 Fitness of different genotypes in absence of drug pressure and the corresponding 
two-locus fitness landscapes. Panel a shows boxplots of growth rates in absence of 
antibiotics for the susceptible and the six resistant genotypes, indicating fitness costs of 
resistance. Relative fitness costs are also given under each box. Thick white horizontal 
lines indicate the median, the box represents the upper and lower quartiles, vertical lines 
represent the range between minimum and maximum of growth measurements, and the 
black circles represent outliers.   Growth rates of genotypes connected by the same letter 
shown on top of the plot are not significantly different (ANOVA: pairwise comparison 
using TK-HSD test). Panel b illustrates which genotype belongs to which of the three 
two-locus fitness landscapes (Kan-Rif, Kan-Stp, Rif-Stp). Here, black dots represent the 
susceptible allele and coloured dots the resistant allele (blue=Kan, red=Rif, green=Stp). 
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Table 3: Parameter estimates for the three-way ANOVA with different resistance mutation 
Source Nparm DF SS F Ratio Prob>F 
KanR 1 1 0.00000091 0.6361 0.0426 
StpR 1 1 0.00008643 60.2113 <0.0001* 
RifR 1 1 0.00024705 172.1098 <0.0001* 
KanR*StpR 1 1 0.00000108 0.7533 0.3873 
KanR*RifR 1 1 0.00000012 0.0833 0.7734 
StpR*RifR 1 1 0.00000048 0.3323 0.5654 
 
Growth rates for the two-locus pharmacodynamics fitness landscapes 
We next measured the growth rates for all seven genotypes comprising our three fitness 
landscapes in presence of combinations of two antibiotics. Thus we obtained growth rate 
estimates for our three resultant pharmacodynamics fitness landscapes. First, let us consider the 
Kan-Rif fitness landscape. In the Kan-Rif fitness landscape, the data we obtained here are in 
accord with general expectations. For example, in presence of antibiotics, an elevated MIC 
level was observed in genotypes carrying drug specific resistance mutations (Figure 4). 
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Figure 4 Pharmacodynamic fitness landscape of Kan-Rif. Plots show maximum growth rates 
[min-1] of four different genotypes in presence of combinations of kanamycin and rifampicin: a 
fully susceptible genotype (SSS), a genotype resistant to Kan (kanamycin) only (RSS), a 
genotype resistant to Rif (rifampicin) only (SSR), and a genotype resistant to both antibiotics 
(RSR). Growth rate is given by gradient scale. Grey dot indicates no growth. 
The fully susceptible genotype suffered an abrupt decline in fitness in presence of kanamycin 
antibiotic but a gradual decrease in fitness was observed for rifampicin antibiotic (Figure 4a). 
A similar pattern of growth reduction was observed for the kanamycin resistant genotype under 
rifampicin antibiotic, but the growth rate was higher in response to high levels of kanamycin 
(Figure 4b) owing to the nptIII gene, which conferred high-level resistance to kanamycin. For 
the rifampicin resistant genotype, reduction in growth was influenced by kanamycin as has 
been observed for the susceptible genotype, but no apparent change in reduced growth was 
observed against rifampicin because the mutation P571L in rpoB gene was responsible to 
withstand high level of rifampicin. In contrast, we observed that the double resistant genotype 
can grow better by sustaining the high level of inhibitory effects exerted by both drugs, shown 
by Figure 4d.  
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For the Kan-Stp fitness landscape (Figure S1), the susceptible genotype experienced a rapid 
decline in fitness for kanamycin (as described above) but a steady drop of fitness was observed 
against streptomycin antibiotic. Maximum reduction in growth rate against streptomycin was 
observed for the kanamycin resistant genotype, but drug also belongs to the same chemical 
class, and this phenotypic plasticity towards improved growth advantage has been defined as 
collateral resistance [61]. Thus, we assume that this improved growth rate would be due to a 
phenotypic resistance inherent in streptomycin resistant genotype. Subsequently, we observed 
remarkably a greater growth advantage for the double resistant genotype when streptomycin 
was used alone suggesting that this higher fitness advantage was due to the high fitness cost 
associated with K43R mutation at the rpsL locus, which helped bacteria grow better in parallel 
environment (Figure S1). 
 
In Rif-Stp fitness landscape, a gradual drop in fitness for both drugs was observed for the 
susceptible genotype when both rifampicin and streptomycin drugs were used alone or in 
combination (Figure S2 panel a). Between the two single resistant genotypes, a strong growth 
advantage was provided by the streptomycin resistance mutation in presence of streptomycin, 
but we observed a gradual growth decline for the streptomycin resistant genotype when tested 
in presence of rifampicin (which is non-specific to the resistance mutation). However, we 
observed that this genotype grew slowly at very high concentration of rifampicin, suggesting 
that a partial cross-resistance was conferred by the streptomycin resistance mutation. On the 
other hand, a gradual decline in growth was observed for the rifampicin resistant genotype 
when tested in both specific and non-specific drug environments (Figure S2 panel c). By non-
specific we mean that when a single resistant genotype, here rifampicin resistant genotype is 
tested against a new antibiotic, here we tested growth rate of the rifampicin resistant genotype 
in presence of streptomycin antibiotic to which this rifampicin resistant genotype is expected to 
be susceptible against streptomycin and the MIC is expected to be similar to the wild-type 
MIC. This non-specific slow growth rate of a rifampicin resistant genotype in presence of non-
specific drug environment suggests the presence of a possible Eagle effect – a phenomenon 
where an increased antibiotic concentration promotes bacterial survival such that the dose 
response curve or kill-curve of an antibiotic is not always monotonic and this effect was 
previously proposed based on a single antibiotic [62]. This Eagle effect was previously 
reported in response to antibiotics inhibiting bacterial DNA-synthesis, most strikingly 
ciprofloxacin antibiotic [Lewin, C. S. et al. 1991 EJCMID]. The role of the Eagle effect in the 
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evolution of multidrug resistance has not been investigated; therefore it is also important to 
explore more on how the Eagle effect operates in combination therapy and potentiate the 
evolution of multidrug resistance such as whether any drug combination against a resistant 
pathogen provide any selective advantage to the new drug of that combination of drug pair. In 
this study, we observed a slower growth rate for the double resistant genotype, which grew 
across the entire concentration gradient of rifampicin and streptomycin antibiotics used in 
combination (Figure S2 panel d).  
Drug interactions potentiate the evolution of multidrug resistance 
Pairwise drug prescription has been an effective therapeutic option, and being applied in many 
clinical conditions and infectious diseases, of most notable example is in tuberculosis treatment 
[48, 63]. However, bacteria show a diverse response to antibiotic combination, for example it 
has been shown that synergistic drug interaction accelerates the evolutionary adaptations to 
multiple drugs [49].  
In our study, drug interaction was defined as a deviation from a form Bliss independence [60], 
which assumes that fitness reductions caused by two drugs are additive. Thus, deviation from 
Bliss independence results in either positive or negative drug interactions arising from a 
particular drug pair. We used the following formula [51] to calculate the degree of drug 
interactions from the maximum growth rate and the corresponding reduction in growth caused 
by two drugs when used in combination: 
I(A1,A2) = w(0,0) + w(A1,A2) – w(A1,0) - w(0,A2) 
 
Here, I(A1,A2) stands for drug interaction which is the function of two drugs (A1 and A2) when 
administered in combination,,w(0,0) is for growth rate of a genotype when the concentration of 
each drug is zero. On the contrary, w(A1,A2) stands for growth rate which is caused by the 
presence of  any given concentration of both drugs.,  w(A1,0) and  w(0,A2) represent growth 
rates in presence of a single drug only, for example in presence of either drug A1 or A2 with a 
given concentration. 
 
For the kanamycin-rifampicin drug pair (Figure 5), a varying degree of drug interactions was 
apparent. We observed a similar pattern of interactions between susceptible and kanamycin 
resistant genotypes, especially in concentration gradients where the concentration of 
kanamycin was higher. In both cases, negative drug interaction was predominant. However, 
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there were apparently no interactions when the concentration of rifampicin was higher when it 
combines with low kanamycin drug concentrations. It is worth mentioning here that the fitness 
between susceptible and kanamycin resistance genotype was indistinguishable. 
 
For the rifampicin resistant mutant, synergistic drug interaction was apparent in presence of 
this drug pair where the concentration of rifampicin antibiotic was higher. It should be noted 
here that the fitness cost was significantly higher in rifampicin resistant genotype. For the 
double resistant genotype, synergistic interaction was predominant in all concentrations 
ranging from sub-MIC to supra-MIC level. However, one previous study under two-drug 
treatment environment found a robust negative interaction at sub-MIC drug concentration, but 
no apparent interactions were identified at supra-MIC of this drug pair [44]. Interestingly, with 
this drug pair, we observed synergistic drug interaction across the entire range of antibiotic 
concentrations space predominated by kanamycin tested for the double resistant genotype 
harbouring drug specific resistance mutations.  
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Figure 5 Drug interactions between kanamycin and rifampicin antibiotic. Drug interaction is a 
function of two antibiotics in combination given by a gradient scale from negative to positive 
interactions across all genotypes. Concentration of rifampicin is given on the x axis, 
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concentration of kanamycin is given on the y axis. Grey dots represent concentration where no 
growth was detected, and black dots represent no interaction rifampicin and kanamycin 
antibiotics. Red dots are for negative drug interactions. An earlier study reported that 
synergistic drug interaction between erythromycin and doxycycline for a wide range of 
concentrations was associated with the emergence of increased frequency of resistance 
population of S. aureus [48]. So, the result we show here supports the fact that synergistic drug 
combination enables bacteria to evolve with multiple drug resistance with low fitness cost 
(Figure 4) associated with the resistance mutations.  
For the kanamycin and streptomycin, no clear pattern of interactions were observed for the 
susceptible and two of the drug specific single resistant genotypes, but a wide range of 
negative drug interaction was pervasive in the double resistant genotype harbouring two drug-
specific resistance mutations (Figure S3). It is also worth mentioning that these two antibiotics 
belong to the same chemical class and perturb the same cellular process. The resulting fitness 
(shown by Figure S1) of this genotype for each concentration of this drug pair was lower 
compared to the kanamycin-rifampicin genotype (Figure 4). 
 
We also determined the interaction between rifampicin and streptomycin (Figure S4). We 
observed apparently no drug interaction between these two drugs across entire drug-drug 
concentration space (compared to other two drug pairs). One previous study on susceptible M. 
marinum predominantly found negative drug interactions at sub-MIC concentration for all 
different combinations of drugs including rifampicin and streptomycin – this interaction was 
defined as ‘pharmacodynamic antagonism’ [44]. In our case, we observed this antagonism for a 
limited number of sub-MIC concentration in susceptible genotypes, but for the two single 
resistant genotypes we did not observe any interaction. For the double resistant genotype, we 
observed both synergistic and antagonistic interactions on a limited number of drug 
concentrations. 
Mutation-selection window (MSW) 
We further examined the MSW in presence or absence of a single drug and a combination of 
drugs. Specifically, we identified which genotype has the highest fitness in absence, presence 
of a single drug and a combination of both drugs (Figure 6). Understanding the MSW is 
particularly important since resistance evolution takes place in a drug space spanning from the 
MIC (the concentration at which the frequency of resistant genotype arise at a low number 
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which means that wild type sensitive genotype is selected for at low frequency at the MIC 
concentration of administered antibiotics) to the MPC (the concentration at which the 
frequency of resistant genotype decline to undetectable value). This is a traditional 
consequence of the MSW [64]. Since the drug concentrations are not static, but always 
fluctuate in time and space, thus the MSW is also affected, especially concentrations around 
the MIC. This means that differential drug concentrations around the MIC potentiate the 
evolution of resistance [65, 66]. The traditional MSW is affected by the sub-MIC drug 
concentration because selection of resistance has been documented for a single drug at very 
low concentration (i.e., this concentration is many folds below the MIC) [67], but – though in a 
limited occasions – this concept of MSW was extended for a multidrug environment by 
employing a combination of theoretical and experimental approach. Those studies suggested 
that a narrower MSW can be achieved when two drugs interact antagonistically and also there 
is a small cross-resistance [48]. It is worth mentioning that this previous study was conducted 
in presence of combination of two drugs by employing completely a susceptible genotype. In 
our study we determined the size of the MSW to understand the impact of three different drug 
combinations and the interactions among them, for example we determined the fittest genotype 
out of the four belonging to a particular fitness landscape (Figure 6).  
At first, let us consider kanamycin-rifampicin drug pair (Figure 6a). In the absence of 
antibiotics, susceptible bacteria were predicted to outcompete all three resistant genotypes 
owing to the fact that the resistance mutations imposed fitness costs in absence of selection 
pressure. As expected, we found that susceptible bacteria outcompeted all other three resistant 
genotypes in absence of antibiotics (shown by green stripe). However, both drug specific 
resistant bacteria outcompeted the susceptible bacteria when the concentration of both drugs 
extended beyond the MIC point. This point also suggesting that concentration above the MIC 
is optimal for spontaneous resistance selection, and this also supports the view of a traditional 
MSW. However, we also observed that both kanamycin and rifampicin resistant genotypes 
experienced superior growth advantages at the sub-MIC concentrations (which is even below 
the MIC) of the susceptible strain.  In addition to this, we also observe that the kanamycin 
resistant genotype outcompeted the susceptible genotype at very low concentrations of 
kanamycin; this could be due to the fact that the kanamycin resistant genotype we used here 
incurred very low fitness cost. 
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Figure 6 Drug interactions and drug concentrations affect the mutant selection window (MSW) 
of different genotypes. The MSW indicates at which antibiotic concentration a particular 
genotype can grow and outcompete other genotypes.  The MSWs of each concentration of 
drugs and drug pairs are plotted (plot a-c for three different drug combinations), with the three 
double resistant genotypes indicated by purple circles in all there cases, the susceptible 
genotype indicated by green circle in all there cases, and three single resistant genotypes 
indicated by red for kanamycin and blue for rifampicin in kanamycin-rifampicin combination; 
red for kanamycin and blue for streptomycin for kanamycin-streptomycin combination; and red 
for rifampicin and blue for streptomycin for rifampicin-kanamycin combinations. 
But, considering a concentration of a drug pair of kanamycin and rifampicin, ,we observed that 
sub-MIC concentrations space for susceptible bacteria was narrowed down mostly by the 
kanamycin resistant genotype, and also by the multidrug resistant genotype. One plausible 
explanation is that kanamycin resistant genotype perhaps acquired selective advantage which 
disrupted the synergistic interactions between these two drugs (Figure 6a). Secondly, we did 
not observe any superiority of the rifampicin resistant genotype at any particular concentrations 
below the MIC of this drug pair, but we observed this trend sporadically above the MIC 
concentrations; this could be due to the fact that the rifampicin resistant genotype incurred 
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highest fitness cost and also required relatively a high concentration of selective environment 
to regain its optimal growth ability. We also found that rifampicin resistance genotype was 
fitter in some combination of drug where the concentration of kanamycin was below the MIC. 
Finally, as expected, the double resistant genotype occupied the entire window ranging from 
sub-MIC to the MPC (though we did not determine the fitness under such high concentration, 
but we considered it with respect to the MIC of susceptible genotype as well as the 
concentration of drug that we used for the mutant screening) as a result of the selective 
advantage provided by both resistance genes that help occupy the highest drug-drug 
concentration space.  
A similar trend was observed for the kanamycin-streptomycin drug pair, where the only 
exception was for the double resistant genotype. In a single drug environment of streptomycin, 
almost the entire single drug space was occupied by the double resistant genotype. This is 
probably due to the fact that the cost associated with streptomycin resistance was higher than 
the kanamycin resistance in absence of drug pressure. Therefore, the double resistant genotype 
grew better in presence of streptomycin to compensate for the costly streptomycin resistance 
mutation (Figure 6b).  
With rifampicin-streptomycin combination, we observed a traditional MSW, where the two 
single resistant genotypes and a double resistant genotype captured their local concentrations 
space through drug specific resistant mutations. However, we also observed that the 
streptomycin resistant genotype had a higher growth rate than the rifampicin and the double 
resistant genotype (Figure 6c) suggesting that there are some regions below the MIC in a two 
drug space of the MSW where a less costly resistance mutant can grow better presumably to 
capture future resistance potential against incoming drug perturbation.  
Epistasis between resistance mutations 
Finally, we measured epistasis from growth rates for each of the double resistant genotypes 
belonging to three different fitness landscapes (Figure 7). Specifically, we calculated epistasis 
as deviation from independent effects of alleles at the two loci in presence of two antibiotics 
with varying concentrations [51]. The formula is given below: 
 
E(A1,A2) = wSS(A1,A2) + wRR(A1,A2) – wRS(A1,A2) - wSR(A1,A2) 
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Here, E stands for epistasis in presence of combination of two antibiotics with varying 
concentrations,  is for fitness of the susceptible genotype in presence of the same drug 
environment,  is the fitness for the double resistant genotype in presence of the same drug 
environment,  and  represent fitness for the two single resistant genotypes. 
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Figure 7 Pairwise epistasis between resistance genes of the three different fitness landscapes. 
Plots show epistasis in absence and presence of three different drug pairs. Epistasis is given by 
a gradient scale spanning from negative to positive epistasis. Blue and red dots represent 
positive and negative epistasis respectively. Grey dots represent no epistasis was detected in 
particular drug concentrations. Panel (a) shows epistasis between kanamycin and rifampicin 
resistance mutation, panel (b) shows epistasis between kanamycin and streptomycin resistance 
mutation, and panel (c) shows epistasis between rifampicin and streptomycin resistance 
mutation. 
Overall, we generally observed that our fitness landscapes are non-epistatic, both in presence 
of a single drug or both drugs (Figure 7). In few instances we observed minor positive 
epistasis in presence of high concentrations of kanamycin and rifampicin drug pair, which 
means that the double resistant genotype experiences higher replication rates than expected 
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based on the growth rate of the susceptible and the single resistant genotypes. On the other 
hand, in presence of only a single antibiotic, weak negative epistasis was pervasive between 
kanamycin and rifampicin resistant mutations. We also observed a strong negative epistasis in 
presence of rifampicin at supra-MIC of the susceptible genotype. This result in presence of 
rifampicin suggests that negative epistasis beyond the MIC was attributed to the high cost 
rifampicin resistance mutation which was unable to improve its fitness burden even when it 
combines with a genetic background having a very low cost kanamycin resistance mutation. 
Rarely, we also observed positive epistasis at high concentrations of rifampicin and 
streptomycin antibiotics combination, especially at supra-MIC of kanamycin but around the 
MIC of rifampicin. 
 
Between kanamycin and streptomycin resistance mutation, we observed a strong positive 
epistasis at the MIC of kanamycin antibiotic (here, MIC of kanamycin is meaning the MIC of 
the wild type). But very weak negative epistasis was apparent below the MIC, whereas 
epistasis progressed towards zero or no epistasis was discernible above the MIC. In presence of 
only streptomycin, we observed seemingly no epistasis or very weak positive epistasis in 
presence sub-MIC concentration of streptomycin. Further, this positive and negative epistasis 
in presence of only a single antibiotic could be explained by the fact that the kanamycin 
resistance gene imposed less fitness cost compared to the streptomycin resistance mutation. On 
the contrary, the streptomycin resistance mutation itself was costly at concentrations above the 
MIC of the susceptible counterparts; therefore growth rate was lower than expected. In line 
with this, in presence of both drugs, epistasis takes alternative form, for example no epistasis in 
presence of high streptomycin antibiotic space but negative epistasis was observed in presence 
of kanamycin antibiotic with concentrations ranging from sub-MIC to the MIC. In general, 
there was apparently no epistasis observed in presence of both drugs (this drug pair belongs to 
the same chemical class and acts upon the same target i.e. 30S ribosome) suggesting that 
evolutionary adaptation to multiple drugs from the same chemical class is independent of 
epistatic interactions in presence of both drugs which antagonistically inhibit each other 
(Figure S3). 
 
In the third fitness landscape comprising rifampicin and streptomycin resistance mutations, we 
observed a varying degree of negative epistasis between rifampicin and streptomycin resistance 
mutations. In combination of rifampicin and streptomycin antibiotics, strong negative epistasis 
was prevalent when the concentration of rifampicin was higher in that drug pair. This could be 
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explained by the fact that the high cost of the rifampicin resistance mutation requires higher 
concentration of rifampicin antibiotic in order to release its high fitness burden. It should be 
noted here that this double mutant genotype experienced highest fitness cost also carried an 
additional deleterious mutation at cyoA locus (Figure 3a; indicated by RSR). We confirmed 
this by measuring growth rate of this genotype and then compared it with a double resistant 
genotype that only harboured rifampicin and streptomycin mutations but not the additional 
cyoA mutation. This result revealed that the double mutant genotype harbouring the additional 
point mutation in cyoA locus was less fit than the double mutant genotype without the cyoA 
mutation. Therefore, we consider that the fitness landscape comprising this genotype would 
presumably be enriched with positive epistatic without this additional mutation at cyoA gene. 
However, in presence of only a single antibiotic, most notably when rifampicin antibiotic was 
used alone, a steady increase in negative epistasis was observable. In this case, strong negative 
epistasis was apparent around the MIC of rifampicin (here we are referring to the MIC of the 
wild type susceptible genotype). A similar observation was also made for the fitness landscape 
consisting of kanamycin and rifampicin resistance mutations. Whereas, in presence of 
streptomycin antibiotic alone we observed mostly weak negative epistasis at sub-MIC 
concentration of streptomycin but strong negative epistasis at the MIC concentrations. 
Therefore, observed epistasis between streptomycin and rifampicin resistance mutations we 
observed here was different than the epistasis between streptomycin and kanamycin resistance 
mutations antibiotics in presence of a single streptomycin antibiotic.  
Discussion 
Evolution of pronounced resistance to a single drug is mediated by a sequential accumulation 
of multiple resistance conferring mutations in the same genetic locus. For example, empirical 
data suggest that a single mutation is not adequate to cause clinically important levels of 
resistance against antibiotics of the fluoroquinolone class [68-70]. This evolutionary process of 
the acquisition of multiple resistance mutations has been extensively studied for a single drug 
[11, 33, 71-73]. Resistance to multiple drugs also involves mutations at multiple loci, where 
each mutation can give resistance to a specific drug or may confer resistance to other drugs 
belonging to the same class or a new class by a mechanism called cross-resistance or negative 
collateral sensitivity.[74-76]. Despite the rapid emergence of multidrug resistance in recent 
days in many clinical bacterial populations [2, 29, 30, 77-80], only a handful of studies have 
been attempted to explore the precise evolutionary mechanisms underlying multidrug 
resistance in bacteria [16, 81]. Such studies characterised fitness landscapes of multidrug 
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resistance by determining epistasis in the cost of resistance, where positive epistasis was 
predominant. However, epistasis not only depends on the genetic background at which they 
arise [82], but the pharmacodynamics of drugs (i.e. fitness in presence of drugs and the 
interactions between drugs) may also influence the epistasis between multiple resistance 
conferring genes, as has recently been investigated at theoretical level [51]. 
 
Here, we characterised fitness landscapes comprising different resistant genotypes including 
the susceptible and resistant genotypes under a variety of environmental conditions such as 
drug free environment, in presence of a single drug and combination of drugs to understand the 
evolutionary dynamics of mutations at multiple loci conferring resistance to multiple drugs.  
Although the pattern of epistasis varied in all three different fitness landscapes, our results 
indicate that all three fitness landscapes produce weakly negative epistasis or no epistasis. This 
non-epistatic fitness landscapes are attributed to the types (i.e. antibiotic of specific class and 
its cellular target), and the concentrations of drugs (i.e. fitness varies with in absence or 
presence of a single drug or in a combination of both drugs, as well as the types of drugs that 
have been used). This means that epistasis, though it was weak but on limited occasions, was 
apparent for a given set of genotypes, which were influenced by the drug specific resistance 
mutation as well as pharmacodynamics (i.e. relationship between the concentration of drug and 
fitness) of the administered drugs. In all cases, diminished fitness advantage for all single 
resistant genotype was apparent in absence of drug pressure. This slower growth rates in 
absence of drug pressure were mostly due to the fitness cost incurred by drug specific resistant 
mutations, which may have given rise to non-epistatic fitness landscapes. It is worth 
mentioning that in two cases, one mutation (i.e. kanamycin resistance genotype) doesn’t entail 
a fitness cost, and in the third case, in addition to the rifampicin and streptomycin resistance 
mutation, Although the genetic context is different, such non-epistatic fitness landscapes was 
previously reported in E. coli [26], but at the same time our result in absence of drug pressure 
differed by earlier studies where positive epistasis was predominant [16, 86]. 
 
Importantly, whole genome sequencing detected the presence of an additional mutation in the 
cyoA gene in the streptomycin-rifampicin double resistant genotype. In E. coli, this gene 
encodes subunit II of the cytochrome bo3 terminal oxidase complex. Gene expression analysis 
of cyoA revealed an inter-population variability under tetracycline induced stressful 
environment, which is associated with adaptive resistance to tetracycline [83-85, 101]. A 
system level investigation has confirmed that mutations in other components of the cytochrome 
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oxidase transfer system, such as mutations in cyoB, conferred reduced susceptibility to 
antibiotics belonging to the aminoglycoside class [102]. In our case, we speculate that this 
cyoA mutation arose during strain construction through natural transformation assay, perhaps 
when the competent cells were treated with salt. Although we did not measure the MIC of this 
genotype for tetracycline or any other drugs, this mutation might have conferred heterogeneous 
resistance to other drugs. Our growth rate estimates suggest that this mutation incurred 
significant fitness cost (Figure S5). Therefore, this additional mutation might have affected 
epistasis of this double resistant genotype.   
 
We also show that our fitness landscapes were influenced by fitness cost such that presence of 
only a single drug would yet be a non-specific environment for other resistance conferring 
mutation commonly harboured by a single resistant and a double resistant genotype. In this 
particular case, for example, a mutation conferring resistance to drug A will affect the growth 
in presence of drug B to which the MIC is unaffected. This means that growth is further 
exacerbated by the presence of drug B plus the cost of resistance incurred by the original 
mutation. Such situation has not been previously investigated experimentally, but here we 
observed a pervasive negative epistasis (i.e., both weak and strong negative epistasis).  
 
In one case (i.e. between kanamycin and rifampicin resistance mutation) both weak and strong 
negative epistasis arose in presence of a single drug at concentration spanning from very low to 
the concentration around the MIC. Most notably, weak negative epistasis was apparent in 
presence of varying concentration of kanamycin, whereas strong negative epistasis was 
observed only in presence of the MIC concentration of the rifampicin antibiotic (Figure 7). 
This particular negative epistasis was observed in the case of costly resistant mutants. For 
example, in presence of kanamycin antibiotic only, the double resistant genotype (harbouring 
no-cost kanamycin resistance mutation and high-cost rifampicin resistance mutation) can grow 
slower. Weak epistasis means that decreased fitness advantage of this double mutant genotype 
is achieved by the integration of a costly rifampicin resistant genotype on a genetic background 
harbouring less costly resistant mutation. In other word, multidrug resistance evolution 
presumably takes place when less costly resistant genotype release the fitness burden by 
integrating a costly resistance mutation. 
 
We also show strong negative epistasis between kanamycin (no-cost resistant genotype) and 
streptomycin resistance genotype (costly resistant genotype compared to the kanamycin 
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resistant genotype) in presence of only kanamycin antibiotic at concentration around the MIC. 
This observation also suggests that strong negative epistasis may decrease the adaptive 
potential for multidrug resistance evolution given that a low cost resistance mutation acquires a 
costly resistant mutation.  
 
We then measured epistasis between rifampicin and streptomycin resistance mutation. Earlier 
studies documented positive epistasis between these two drug resistance mutations in absence 
of drug pressure [16, 81]. However, we observed a pervasive negative epistasis or no epistasis 
between rifampicin and streptomycin resistance mutation both in presence of single drug and 
multidrug environment (Figure 7). A strong negative epistasis was present when the 
concentration of rifampicin was higher or when this drug was combined with streptomycin 
antibiotics. This could be explained by the fact that the high cost rifampicin resistance mutation 
requires higher concentration of rifampicin antibiotic in order to release its high fitness cost. 
However, an additional point mutation (i.e. mutation in cyoA gene we identified by whole 
genome sequencing) was present in this genotype,. This additional mutation further increased 
the fitness cost in this genotypes (Figure 7). We suggest that without this additional mutation, 
the fitness landscape would presumably be less or non-epistatic. Therefore, we suspect that this 
type of deleterious mutation may have occurred and confounded previous studies [81, 86, 87], 
where epistasis was measured without sequencing of bacterial whole genome. 
 
We investigated epistasis on fitness landscapes when there was a cross-resistance or negative 
collateral sensitivity. Cross-resistance has been defined as a function of the evolutionary 
response to a single antibiotic. So, unlike physiological interaction, cross-resistance does not 
require which drugs to be applied in combination [52]. Cross-resistance occurs in situation 
when evolution of resistance to a drug can simultaneously select for resistance or decreased 
sensitivity to multiple drugs. This phenomenon of resistance evolution has been reported in 
many clinical situations, especially in the case of treatment failure due to multidrug resistant 
bacteria harbouring a single point mutation or a resistant enzyme capable of neutralizing many 
different antibiotics, including NDM-1-metallo-β-lactamase (New-Delhi metallo-β-lactamase 
carried by the plasmid) producing K. pneumoniae is capable of hydrolysing many other 
different antibiotics [88], or altered efflux–pump mediated cross-resistance has also been found 
to be associated with resistance to multiple drugs in many bacterial species, including P. 
aeruginosa and many other gram negative bacilli [89, 90]. Theoretical observation suggests 
that epistasis can emerge in presence of cross-resistance. For example, in a situation when two 
72 
 
resistance mutations slightly increase the MIC for both drugs individually, but more increase in 
MIC to both drugs occurs when two mutations act in combination as a result of positive 
epistasis, or negative epistasis arise in presence or absence of even low level of cross-resistance 
[51]. Therefore, we considered analysing the concept of cross-resistance to understand the 
evolutionary dynamics of multiple resistance conferring genes giving rise to epistasis on the 
pharmacodynamics fitness landscapes. In our study, we observed such cross-resistance 
conferred by streptomycin resistant genotype, which underwent improved growth advantage in 
presence of kanamycin and rifampicin antibiotics by increasing its MIC to both drugs. Similar 
cross-resistance was observed in an earlier systematic study between kanamycin and 
streptomycin. For example, cross-resistance that we observed here – between rifampicin and 
streptomycin – was found to be collaterally sensitive to each other in previous study [74]. This 
difference could be due to the fact that the genetic background and the fitness cost incurred by 
streptomycin resistance could be different than what was found in previous study. This means 
that our low-cost streptomycin resistance mutation could be a hyper-accurate phenotype, which 
is streptomycin dependent [56, 91]. Our growth rate data also support the notion that 
streptomycin resistance mutation that we observed here resulted in higher fitness compared to 
the growth rate in absence of drug pressure (Figure S2).  Therefore, we assume that this hyper-
accurate phenotype gives higher growth advantage in presence of streptomycin and, at the 
same time, it gives improved growth advantage when it is exposed to rifampicin antibiotic 
whose target also belongs to the same flow of a fundamental cellular process (i.e., 
transcription!translation).  Such prediction was made by an earlier study where positive 
epistasis was pervasive [16]. Another distinct case of cross-resistance we observed in this study 
was kanamycin resistant genotype gave decreased susceptibility to rifampicin. This result also 
contradicts the result observed in an earlier study [74].The result we obtained here would be 
due to the fact that both kanamycin and rifampicin belong to two distinct classes of antibiotics 
with two different cellular targets, for example rifampicin targets RNA-polymerase and  
streptomycin targets 30S ribosome. The gene nptII we used here encoded neomycin 
phosphotransferase II enzyme not only conferred high level of kanamycin resistance, it also 
probably affected the binding affinity of rifampicin antibiotic to the RNA-polymerase core 
enzyme, which in turn resulted in decreased susceptibility to rifampicin. Therefore, our study 
highlights the need for more detailed studies for further understanding of cross-
resistance,which might be helpful in designing effective treatment strategies in many clinical 
situations, especially in the case of drug cycling.  
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We also considered factor such as contribution of drug-drug interactions on bacterial fitness 
associated with resistance evolutions on the pharmacodynamic fitness landscapes. Antibiotics 
when used in combination can have synergistic, antagonistic or suppressive effect [46, 95]. In 
synergistic drug combination, reduction in fitness is more than the expected from the sum of 
the two individual single drugs, while antagonistic drug interaction is associated with less 
reduction in fitness. For the suppressive drug interaction (a special form of antagonistic 
interaction), combined effect of two drugs is weaker than the effect of the individual drugs 
[45]. Several previous studies examined the effect of drug combinations with varying degree of 
drug interactions to explore the potential spontaneous resistance evolution against those drugs 
combinations. For example, both theoretical and empirical studies suggest that synergistic and 
antagonistic drug interaction leading to negative and positive epistasis respectively can also 
slow down or accelerate the evolution of multidrug resistance, respectively [50, 51]. Therefore, 
we attempted to characterise our fitness landscapes when there is drug interaction (deviation 
from Bliss independence) and drug specific resistance mutations are in actions. We observed a 
varying degree of synergistic drug interaction between kanamycin and rifampicin, for which 
we also identified negative epistasis. Our result indicates a good concordance with previous 
studies [16, 50-51], but differs from the expected positive epistasis in the absence of fitness 
costs [51]. In absence of fitness cost, we also observed a varying degree of antagonistic 
interactions between kanamycin and streptomycin. In presence of this drug pair, there was no 
detectable epistasis observed between those drug specific resistant mutations. This could be 
explained by the fact that both antibiotics belong to the same chemical class, target the same 
cellular function, and also undergo a negative collateral sensitivity to each other. In the case of 
rifampicin and streptomycin drug pair, no apparent interaction were observed nor any epistasis 
between these two-specific resistant mutations. However, in the cost of resistance, positive 
epistasis was reported between these two drug specific resistance mutations [16].  
 
The mutant selection window (MSW) is defined as the concentration space between the MIC 
for the susceptible bacteria and the MPC for the resistant bacteria [96]. We characterise MSWs 
in presence of multidrug environment. Previous studies have reported that the MSW can vary 
(i.e. narrower or wider MSW) or remain static under two-drug antimicrobial environment [48, 
97] . Therefore, to understand the impact of drug combinations and the interaction between 
drugs on the size of the MSW, we aimed at determining selective advantage of each genotype 
under each concentrations of drug that we used for the fitness measurement. Our results 
indicate that the concentration space for drug pairs that we used (i.e., kanamycin-rifampicin, 
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kanamycin-streptomycin, and rifampicin-streptomycin) were not confined to the traditional 
MSWs, rather extended further below the MIC – called the minimal selective concentration 
(MSC) [98]. This means that selection of resistance occurs at concentration ranging from very 
low to very high drug concentrations. This wider space for these MSWs was attributed to a 
number of factors and also implicated with resistance emergence: 1) some drug concentrations 
allowed wild-type susceptible bacteria to grow at very low concentrations of kanamycin and 
rifampicin combination. This clearly suggests that selection of resistance, multidrug resistance 
in particular, may occurs at the sub-MIC concentration of this drug pair. Analogous to this 
finding, such observation was made by an earlier study in experimental bacterial population in 
presence of a single drug [99]. We observed similar result for other drug pair for both single 
and double resistant genotypes, for example in presence of kanamycin and rifampicin 
antibiotics (when used alone or in combination), we observed a wider MSW for the kanamycin 
resistant genotype as well as for the double resistant genotype harbouring both kanamycin and 
rifampicin resistant mutations at sub-MIC combination of this drug pairs 2) similarly, a wider 
MSW was also observed between kanamycin and streptomycin antibiotic, 3) but a narrower 
MSW was observed for the rifampicin and streptomycin drug pair which follows a traditional 
MSW. Overall, our results suggest that selection of resistance against multiple drugs may also 
occur at sub-MIC combination of two-drugs and/or in a situation when there is a cross-
resistance imparted by a singly resistant genotype. The result we presented here also supports 
the concept of minimal selective concentration (MSC) – biologically relevant sub-MIC 
selective concentration where antibiotic concentration is several hundred below the MIC of 
susceptible genotype – which was suggested by an earlier study where selection of resistance at 
very low antibiotic concentrations was reported [99]. Thus, the results we have presented here 
may enhance our understanding of the multidrug resistance evolution under variety of drug 
environments. Our results together with others may implicate the need for the revision of the 
traditional concept of mutant selection window [96], especially in the case of evolution of 
multidrug resistance.  
 
In this present study, we characterised our pharmacodynamics fitness landscape by measuring 
growth rates as a proxy for fitness. The results we have presented here warrant the need of 
integration of kill rates (negative growth rates) for fitting the Hill-pharmacodynamics function 
as well as determining the epistasis at concentration beyond the MIC. For further exploration 
of the consequences of multidrug resistance evolution on the pharmacodynamics fitness 
landscapes, we should determine other fitness components such as the carrying capacity and 
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the duration of the lag phase, since a varying competitive ability in both cases was reported 
earlier [81]. These differential trait effects has been revealed by a recent study with both in 
single and double resistant genotypes, for example some of the rifampicin resistance mutations 
were shown to be beneficial in growth rate but all were found to be deleterious on their 
carrying capacity, despite their competitive superiority [100]. Therefore, both growth rate and 
carrying capacity are important determinants of the maintenance of resistance. We also found 
that a double resistant genotype in addition to drugs specific resistant mutations (i.e. resistance 
mutations in rpoB and rpsL loci) harboured an additional deleterious mutation in cyoA locus, 
which was detected by sequencing of the whole genome. This additional mutation in cyoA 
locus possibly affected the epistatic interactions between two drug specific resistant mutations 
in our study. We also suspect that unexpected additional mutations like the one in cyoA locus 
we detected perhaps occurred but not been detected in earlier studies due to the lack of whole 
genome information. Fitness estimates may therefore was misleading in those studies. 
Additionally, we only studied two-locus fitness landscape by constructing two specific 
mutations conferring resistance to two antibiotics. Despite many known resistance mutations in 
those drug specific resistance loci, several combinations of those drug specific resistant 
mutations may cause problem in determining the trait effects (i.e. growth rate, kill rate, fitness 
in carrying capacity). We also determine fitness under static drug environment, but the 
dynamics nature of multidrug resistance evolution remains to be explored. We have measured 
the growth rates at constant drug conditions from a master antibiotic solution on everyday basis 
where possible drug decay may have occurred, which might have affected the constant drug 
conditions during the growth assay. 
 
In conclusion, epistasis play important role in the adaptive evolution; of special relevance is the 
recent observations that pharmacodynamics fitness landscapes are characterised under wide 
range of drug concentrations, including single drug and combination of drugs. Our results 
indicate non-epistatic fitness landscapes between resistance conferring mutations in absence or 
presence of drugs, but resistance mutations were previously shown to produce epistasis in 
presence of fitness cost [103]. However, we observed a wider mutant selection window for two 
antibiotics pair where the sub-MIC concentration space is many fold lower than the MIC of the 
susceptible genotype. Thus, these results suggest that the sub-MIC antibiotic concentrations, 
can also be generated in certain body compartment during combination therapy, may potentiate 
the evolution of de novo multidrug resistance, as has previously been reported by an empirical 
study for a single drug [99]. Another important aspect of this study was cross-resistance –  a 
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phenomenon where a mutation conferring simultaneous resistance to many other drugs 
belonging to the same class. We also show that a wider MSW also occurred in presence of 
cross-resistance, which may be an important implication in resistance evolution. Overall, the 
results we have presented here underlie the importance of choosing the right drug during cyclic 
treatment as well as using optimal treatment dosing regimes during combination therapy that 
exclude the prolonged exposure of sub-MIC level of antibiotics. Therefore, more extended 
analysis of such fitness landscape is required in determining epistasis in the evolution of 
multidrug resistance evolution.  
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Figure S1 Pharmacodynamic fitness landscape for the Kan-Stp. Plots show fitness of different 
genotypes in presence of two antibiotics kanamycin and streptomycin combination. Growth 
rate as a function of two antibiotics is given in gradient scale from 0.0 to 0.03. 
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Figure S2 Pharmacodynamic fitness landscape for the Stp-Rif. Plots show fitness of different 
genotypes in presence of two antibiotics streptomycin and rifampicin combination. Growth rate 
as a function of two antibiotics is given in gradient scale from 0.0 to 0.03. Gray stripe 
represents no growth was determined for certain drug concentrations.  
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Figure S3 Drug interactions between kanamycin and streptomycin antibiotic. Drug interaction 
is a function of two antibiotics in combination given by a gradient scale from negative to 
positive interactions across all genotypes. Grey dots represent concentration where no growth 
was detected. WT indicates the wild type, Kan indicates kanamycin resistant genotype, Stp 
indicates streptomycin resistant genotype, and KanRif indicates double mutant genotype 
harbouring both resistance mutations. 
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Figure S4 Drug interactions between rifampicin and streptomycin antibiotic. Drug interaction 
is a function of two antibiotics in combination given by a gradient scale from negative to 
positive interactions across all genotypes. Grey dots represent concentration where no growth 
was detected. WT indicates the wild type, Rif indicates rifampicin resistant genotype, Stp 
indicates streptomycin resistant genotype, and KanRif indicates double mutant genotype 
harbouring both resistance mutations. 
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Figure S5 Mean growth rates for three different genotypes. Each error bar was constructed 
using 1 standard error from the mean of 5 independent population replicates measurements. All 
genotypes are significantly different from each other, except SRR1 and SRR2 (ANOVA: 
pairwise comparisons wising TUKEY-HSD post-hoc test: p-value = 0.8051). SRR1 and SRR2 
were the same strain only differed by construction through natural transformation method such 
that SRR1 was constructed using StpR as a donor, while SRR2 was constructed using RifR as a 
donor. SSS = Susceptible/wild-type genotype; both SRR1 and SRR2 are double mutant 
harbouring both rpsL and rpoB mutations; SRR* is also a double mutant genotype carrying 
both rpoB and rpsL mutation plus an additional mutation at cyoA locus, and this genotype was 
used for characterizing pharmacodynamic fitness landscape. 
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Table S1 List of primers used in amplifying targeted allele sequences. 
 
 
 
Table S2 PCR master mix preparation per reaction 
Reagents Amount [uL/reaction tube] 
PCR buffer 10x 2.5 
MgCl2 25 mM 2.5 
dNTP 10mM 0.5 
TaqGold 5U /µL 0.1 
Primer mix (conc. 0.5µM) (F+R)                1.5 
Sigma H2O 17.9 
Template DNA 5 
Tolal volume  30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene name Primer sequence 
rpoB 1 (forward) TTCGATTCAGGTCGACTCGT 
rpoB 1 (reverse) CAGGCGTTCTGGAACAAGAT 
rpoB 2 (forward) TGGATCAAAACAACCCATTG 
rpoB 2 (reverse) ATCGCCACGACCCACTTTAT 
rrs 1 (forward) GGCAGGCTTAACACATGCAA 
rrs 1 (reverse) CTACGCATTTCACCGCTACA 
rrs 2 (forward) CTGGAGGAATACCGATGGCG 
rrs 2 (reverse) TAACCGCCCTCTTTGCAGTT 
rpsL (forward) ATGGCAACAACAAATCAGTT 
rpsL (reverse) TTATTTCTTAGGACGTTTAG 
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Table S3 PCR program used to amplify the targeted allele sequences 
PCR program:      
Step Temperature Time 
1 (hold) 95°C 6 minutes 
2 (denaturation) 94°C 45 seconds 
3 (annealing) 58°C 45 seconds 
4 (elongation) 72°C 2 minutes 
5 (repetition) Step 2 to 4 for 35 cycles   
6 (final elongation) 72°C 10 minutes 
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Chapter 3: Emergence of de novo multidrug resistance in 
experimental bacteria populations evolving under sub-lethal drug 
combination: the role of natural transformation 
Summary 
The emergence of multidrug resistant bacteria has become a major cause of therapeutic failure 
in treating infectious diseases. Multidrug resistance is frequently acquired by horizontal gene 
transfers, but can also arise de novo through mutations. In the latter case, recombination may 
still be important in reducing clonal interference between selected resistance mutations that 
spread simultaneously within the population. Many bacteria, including important pathogens, 
regularly undergo recombination via natural transformation (uptake of free DNA from the 
environment), but the role of natural transformation in the evolution of de novo multidrug 
resistance evolution is unclear. Our study aims at characterizing the evolutionary dynamics of 
de novo multidrug resistance through evolution experiments in which the emergence and 
spread of resistance mutations is monitored and the impact of recombination is assessed. We 
initiated our evolution experiment with populations comprising either naturally competent or 
non-competent genotypes of the Gram-negative bacterium Acinetobacter baylyi. These 
populations were then propagated by serial transfer for ~650 generations under sub-lethal doses 
of rifampicin and streptomycin antibiotics used in combinations. We then characterized our 
evolved populations by employing different phenotypic assays and by whole genome 
sequencing. Both growth rate and competition assays demonstrated that the populations 
propagated under drug pressure had evolved higher fitness when tested in same environment, 
but there was no difference in fitness gain between competent and recombination-deficient 
populations. Moreover, our antibiotic susceptibility assays showed that all clones that evolved 
in presence of drugs had become strongly resistant to rifampicin, whereas resistance to 
streptomycin was much weaker or absent. Consistent with these findings, whole genome 
sequencing revealed an abundance of different rpoB mutations (indicating target alteration as a 
resistance mechanism). We have also identified a number of other mutations that have been 
reported to be associated with resistance to other antibiotics. In conclusion, we saw no 
evidence that recombination by transformation facilitates adaptation to antibiotics, possibly 
because the limited number of mutations that were spreading simultaneously prevented clonal 
interference. 
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Introduction 
Recombination is a complex evolutionary process. This process is ubiquitously present in the 
nature, including both in prokaryotic and eukaryotic populations. Nevertheless, the benefit and 
the cost of recombination yet remain a paradoxical question in evolutionary biology [1-3]. It is 
assumed that allelic associations – called linkage disequilibria (LD) – between different loci 
that are broken up by recombination determine the adaptive benefit of recombination. For 
example, recombination can help purge deleterious mutations harboured by particular 
population lineage [4-6], or accelerate adaptation in situations where beneficial mutations arise 
at different loci of diverse population lineages and compete against each other – a phenomenon 
called clonal interference [7, 8].  
 
In many bacterial species, recombination plays a key role in the adaptive process by generating 
genetic variations by acquisition of genes and genetic elements from their surrounding sources 
via horizontal gene transfer (HGT) [9-11]. For example, recipient bacteria incorporate DNA 
from dead cells or other inter bacterial genes and genetic elements such as different gene 
clusters, plasmids, transposons, prophages [12]. Subsequently these genes or extra 
chromosomal genetic determinants are integrated into bacterial genomes by single HGT event 
via recombination. 
 
Recombination helps bacteria to adapt to many environments by evolving new functions 
necessary for their existence, including adaptation to antibiotics, colonization of new habitats 
or hosts by increasing virulence or pathogenicity, or metabolization or synthesis of new energy 
sources [13-16]. This process is accomplished by three main mechanisms: conjugation 
(mediated by extra chromosomal DNA, such as plasmid), transduction (DNA transfer mediated 
by phages), and natural transformations (where free DNA from the environment is integrated 
into the bacterial chromosome) [17].  
 
During transformation process, DNA molecules are released in the environment from degraded 
bacteria and taken up by recipient bacteria through homologous recombination, which results 
in transformant bacteria [18]. For example, recipient bacteria capture antibiotic resistance 
genes from the biosphere by natural transformation [18, 19].  The source of DNA for 
transformation includes the genomes and extra chromosomal elements of dead cells of the 
same species or of unrelated organisms, and living cells that actively release DNA [20]. A 
number of different bacterial species have been reported to be competent for natural 
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transformation, including Bacillus subtilis, Neisseria gonorrhoeae, and Helicobacter pylori 
[21-23].  
 
Genetic exchange via natural transformation in bacteria is different from eukaryotic sex. 
Therefore, a varying degree of benefits and costs is associated with bacterial recombination via 
this mechanism [24]. For example, apart from bringing beneficial mutations in the same 
genome, transformation is thought to be an active means of nutrient provider through DNA 
uptake from surrounding environments to help repair the replicative DNA lesions or to reduce 
mutational load in the population [25, 26]. However, with regard to reducing the mutational 
load of a population theoretical studies suggest that transformation decreases fitness when the 
source of DNA is from closely related dead cells which are originated from low-fitness 
mutants compared to their living counterparts, or benefit of recombination achieved via natural 
transformation which can reduce the mutational load in a non-competent genetic background 
[27, 28]. Furthermore, transformation is regarded as a complex and costly process because it 
requires many metabolic proteins for the uptake of DNA molecules from the surroundings 
[25].  
 
Two previous experimental studies provided contrasting views on the benefit and cost of 
recombination via natural transformation. For example, one study in support of the benefit of 
natural transformation reported the accelerated adaptation by recombination via natural 
transformation in Helicobacter pylori [29]. Conversely, another study documented conditions 
where recombination via natural transformation did not play a role in the adaptive process [25]. 
However, one recent study [30] reported growth phase specific benefit of recombination via 
natural transformation in A. baylyi, while, benefit of recombination via natural transformation 
was found to be absent in the same species by another recent study [31]. 
 
Multidrug resistance is a global medical problem, and it is thought that resistance to multiple 
antibiotics is an evolutionary process and operated by de novo mutations (i.e. point mutation, 
insertion, deletion or duplication) or by recombination (transfer of resistant genes or genetic 
determinant from other bacteria) [32-35]. In presence of antibiotics selection pressure, bacteria 
can adapt and evolve by forming resistance mutations. Adaptation to multiple drugs has been 
observed in many bacterial pathogens such as M. tuberculosis [36], A. baumannii [37], and 
many more.  
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Analogous to clonal interference, when multiple resistance mutations spread simultaneously in 
a population, they may compete against each other. In this particular situation, beneficial 
mutations can be integrated into the same genome by recombination which breaks down this 
clonal interference [16]. Therefore, we assume that recombination could be an adaptive process 
in presence of multiple antibiotics. To date, only a single experimental study [13] has 
investigated the impact of recombination via natural transformation on bacterial adaptation 
under multiple antibiotics. This study revealed that recombination via natural transformation 
can accelerate adaption by bringing resistance genes together [13]. More specifically, this study 
showed that in the absence of recombination, initial single resistant strains inhibited the 
evolution of multidrug resistance, but adaptation was accelerated by recombination when two 
resistance genes were incorporated into the same genome via natural transformation. However, 
this study has some potential shortcomings in terms of de novo multidrug resistance via natural 
transformation. More specifically, this study was carried out starting with two strains already 
harboured resistance mutations. This means that bacteria acquired multidrug resistance via new 
mutations were not considered in this study. Additionally, all the evolved bacteria were 
exposed to a single drug concentration, but many de novo resistance mutations in presence of 
that particular drug pressure could also be selected for. This study also did not characterize the 
evolved strains at genomic level, so the genetic changes that occurred in the population 
remained unexplored. Typically, this approach only can detect a single adaptive step but does 
not decipher how multiple resistances are acquired sequentially, or the recA-deletion strain 
used in that study probably encountered a number of pleiotropic effects that were not 
investigated. 
 
Here, we investigate the impact of recombination via natural transformation in the evolution of 
de novo multidrug resistance in clonal susceptible bacterial populations under sub-lethal (sub-
MIC) concentrations of two-drug antimicrobial combinations by employing an experimental 
evolution approach. We assume that under two-drug antimicrobial treatment, initial clonal 
susceptible bacterial populations will diversify by acquiring drug specific resistance mutations 
and compete against each other over the course of evolution. Consequently, de novo multidrug 
resistance evolution will take place where recombination via natural transformation will reduce 
competition between drug-specific multiple beneficial mutations that arise within separate 
lineages during the course of evolution.  
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We used A. baylyi as our experimental system, which is a soil dwelling gram-negative 
bacterium possessing an extensive metabolic versatility, and is highly competent for natural 
transformation [38, 39]. Moreover, this bacterium has recently been found to be associated 
with hospital-acquired infections and is related to A. baumannii, an important nosocomial 
pathogen [39]. Additionally, whole-genome sequence of this bacterium is available [40]. 
Together, these features have made A. baylyi an attractive model organism in microbiology and 
evolutionary biology. We used different genetic constructs of competent (Rec+) and non-
competent (Rec-) strains to investigate the effect of genetic exchange on laboratory evolution 
of bacterial de novo multidrug resistance by integrating experimental evolution with whole 
genome sequencing of the evolved populations to monitor the actual evolutionary steps that 
have taken place. 
Materials and methods 
Strains, media and growth conditions used in this study 
We used A. baylyi derived from ADP1 strain (NC_005966) [40] - details are listed in Table 1. 
All strains used were devoid of plasmids as well as bacteriophages. Therefore, natural 
transformation is the only means of recombination among recombination-efficient (Rec+) 
populations in this study. We used two different Rec+ strains that were fully susceptible to 
antibiotics and employed in the evolution experiment to investigate how a fully susceptible 
bacterium adapts to a multidrug environment. The genetic architecture of these two Rec+ 
strains was identical with the only exception of a fluorescent marker. These fluorescent 
markers were used to detect possible cross contamination events during the course of 
experiments. These two strains also possessed fully functional DNA uptake systems making .. 
Table 1 Description of different populations of A. baylyi used in this study. 
Strain Genotype Description Reference 
ADP1Rec+3 trpE27 
ACIAD0921::ecfp  
Transformation-efficient ancestor strain; tryptophan 
auxotroph; cyan fluorescence marker (ecfp) 
Genome 
sequenced in 
this study 
ADP1Rec+4 trpE27 
ACIAD0921::eyfp  
Transformation-efficient ancestor strain; tryptophan 
auxotroph; yellow fluorescence marker (eyfp) 
Genome 
sequenced in 
this study 
ADP1Rec-
13 
trpE27 
ΔcomFEBC::dhfr1  
Transformation-deficient control strain; tryptophan 
auxotroph; trimethoprim resistance marker (dfhr1) 
Genome 
sequenced in 
this study 
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these bacterial strains capable of transformation with high efficiency. A Rec- strain was used as 
a negative control, and this strain was devoid of a functional DNA-uptake system due to the 
disruption of comFEBC gene cluster. All strains were provided by Nils Huelter and Pal 
Johnsen from the Arctic University of Norway. 
 
We used lysogeny broth (LB) for all experiments and most assays (i.e. for the growth rate, 
serial passage, competition assays, and bacterial culture preparation for the whole genome 
sequencing); for antibiotic susceptibility assays, we used Muller Hinton-II (MH-II) medium 
supplemented with 0.05 tryptophan because all the strains we used in our experiment were 
tryptophan auxotroph (information provided in table 1). 
Experimental evolution experiment 
A single colony of each strain of A. baylyi (Rec+3, Rec+4, 2xRec-) was grown overnight in LB 
media. Thirty six population in total founded from each of these four progenitor strains by 
adding 10uL of overnight culture in 990uL LB medium. The experiment was carried out for 
three different antibiotic treatments (see below) and three replicate lineages per treatment. 
Populations were grown in 24-well plates on an orbital shaker (280 rpm) at 30°C, and these 
growth conditions were maintained throughout the experiment. After 24 hours, 10uL of each 
population was serially passaged to 990uL of fresh LD medium and propagated for another 24 
hours. In this way, one hundred serial transfers were made which resulted in approximately 
650 generations of bacterial growth. Samples were stored and frozen at 15 different time points 
at -80°C in 15% (v/v) glycerol.  
Three different selection environments were used in this study: no-drug treatment (ND: LB 
medium without supplements), low-drug (LD: LB medium supplemented with 0.125 mg/mL of 
rifampicin and 0.25 mg/mL of streptomycin), and high-drug (HD: LB medium supplemented 
with 0.25 mg/mL of rifampicin and 0.50 mg/mL of streptomycin). We used these 
concentrations of two-drug antimicrobial combinations because these combinations were 
strong enough to exert a significant level of selective pressure on the bacteria whilst still 
permitting sufficient growth (as ascertained in pilot experiments, see Figure S1).  
Growth rate assays 
Growth rates for the evolved populations at different time points were measured by 
spectrometry (SynergyTM HT microplate reader, Biotech, USA). In doing so, individual 
clones from different time points (transfer 0, 10, 20, 48, 100) were first streaked on fresh LB 
agar plates from the -80°C freezer, and then a single colony from each plate was further grown 
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overnight in LB medium on an orbital shaker (180 rpm) at 30°C. From this overnight culture, 
the growth rate of each clone was measured by obtaining the growth curve (OD600) in LB 
broth with or without antibiotics in different combinations, including those that were used in 
the initial evolution experiments. We measured growth rates in 96-well plate (i.e., we used 5uL 
of culture into 175uL of LB) by spectrometry (SynergyTM HT microplate reader, BioTek, 
USA). The reader was set at 30°C with continuous shaking for 12 hours. Read (based on 
absorbance) was collected every 5 minutes interval at wavelengths of 600nm. The individual 
clones were also stored in -80°C freezer in 15% glycerol (v/v) for further analysis. Statistical 
software R was used for finding the best curve fitting a line for data obtained from the 
spectrometer. In short, raw OD values were normalized to a blank OD and Ln (natural log) 
transformed before analysis. Then the steepest slope over a 32 data points correspond to 
growth over 155 minutes (data obtained through every 5 minutes reading interval, including 
the initial read obtained at the beginning of the assay) period was determined. 
Antibiotic susceptibility assay by disk diffusion  
Antibiotic susceptibility testing was carried out for the same clones for which growth rates 
were measured. We employed disk diffusion testing as a proxy for determining antimicrobial 
resistance profiles among clones at different time points of the evolved populations. Individual 
clones were streaked on LB agar plates followed by overnight growth (18 hours) of a single 
colony in 15mL fresh LB medium. This overnight culture was diluted to 1:10 and inoculated 
on fresh LB agar with a sterile cotton swab. Prior to applying the antimicrobial disks, plates 
were left ajar for five minutes to absorb any excessive moisture on the agar surface. Two types 
of antimicrobial disks were used for the susceptibility testing which were obtained from Oxoid 
(Basingstoke, UK). These disks possessed the following concentrations: rifampicin 30ug and 
streptomycin 25ug representing approximately 10-fold and 5-fold higher MIC than the ancestor 
strain for the respective antimicrobial compounds (based on earlier growth rate and MIC assays 
in presence various concentrations of individual drug). Three disks per antibiotic were 
dispensed to the agar surface using sterile forceps and left for five minutes to make sure that 
the disk has made thorough contact on the surface of the agar. The disks were placed by 
maintaining a maximal distance between two antibiotics in order to avoid any potential 
interactions that may give rise to distortion of inhibition zones. All plates were then inverted 
and placed inside a plastic bag and incubated at 30°C for 18 hours followed by measurement of 
diameter of inhibition zones (mm) to determine growth around the disk.  Since there is no 
specific susceptibility breakpoints set by the EUCAST (European Committee for Antimicrobial 
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Susceptibility Test) nor the CLSI (Clinical and Laboratory Standards Institute, USA) for the 
tested antimicrobial disks for the strains (A. baylyi) used in this study, the antimicrobial 
susceptibility profile of our evolved strains were interpreted based on earlier growth rate assay. 
Antibiotic susceptibility assay by E-test  
 Additionally, we characterized the MIC profile of our evolved endpoint populations and 
ancestral populations with E-test assays. Individual clones were streaked on Mueller-Hinton 
(MH-II; Becton, Dickinson, and company, N.J, U.S.A) plates from frozen stock, and incubated 
for 18 hours. Suspensions of the organisms were prepared by picking appropriate number of 
colonies and suspending in 1.5 ml of saline under aseptic condition, and the turbidity was 
adjusted by measuring the optical density (OD600) of this bacterial saline suspension by 
spectrometry (SynergyTM HT microplate reader, BioTek, USA). Turbidity of this bacterial 
saline suspension was adjusted to that of a McFarland 0.06 to 1.0 standard. A total of 
approximately 0.1 ml of the 1.0 McFarland suspension was plated on a MH-II agar plate by 
using a sterile cotton swab. In doing this, sterile cotton swab was dipped into the adjusted 
suspension, and rotated several times and pressed firmly on the inside wall of the tube above 
the fluid level to remove the excessive inoculum from the swab. Then MH-II agar plate was 
inoculated by streaking the cotton swab over the whole sterile agar surface.  This procedure 
was repeated at least two more times by rotating the plate approximately 60° each time to 
ensure an appropriate distribution of inoculum on the whole surface of the plate. In the final 
step, the rim of the MH-II plate was swabbed at least twice. Then the lid of the plate was kept 
open for approximately 5 minutes to allow for any excess surface moisture to be absorbed 
before applying the E-test strip. After adequate drying, a maximum of three E-strips 
(rifampicin, streptomycin and ciprofloxacin) were placed in one plate. The antibiotic strips 
were placed by maintaining a maximal distance between two antibiotics in order to avoid any 
potential interactions (i.e. antagonism, synergism, inhibition or induction) that may give rise to 
distortion of inhibition zones. All plates were inverted with the lid side up and placed inside a 
plastic bag and incubated at 30°C for 18 hours. MICs were read from the test strip where the 
elliptical zone of inhibition intersected with the MIC scale on the strip. Although there is no 
specific susceptibility breakpoints set by the EUCAST nor the CLSI for the tested 
antimicrobial stripes for the strain (A. baylyi) used in this study, we also carried out E-test on 
E. coli ATCC 25552 strain as a control strain to interpret the MIC of the experimental strains 
by comparing with this control strain. 
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Competitive fitness assay 
Competition experiments for each of the evolved clones from the end point population (~650 
generations) were carried out in the same culture conditions used to propagate the evolving 
populations. In this assay, we used a reference tryptophan auxotroph strain harboring nptII 
(neomycin-phosphotransferase-II) (trpE27 ACIAD0921::eyfp ACIAD3309::nptII), gene 
conferring resistance to kanamycin antibiotic. Each of the evolved clones and marker strains 
were taken from the freezer, acclimatized by plating on LB agar, and incubated overnight at 
30°C. Afterwards, a single colony from individual plate was transferred into 1 mL of LB broth 
contained in individual wells of 24-well plates. These cultures were then incubated for 24 
hours on an orbital shaker (250 rpm) at 30°C, which represent one complete growth cycle. 
Then, to start with the actual competition assay, each acclimated culture (5uL from each of the 
well representing each of the evolved clones) and reference strain culture (5uL) was inoculated 
into 9.9mL of LB with or without antibiotics contained in individual wells of 24-well plates, 
and mixed together. Individual samples (10uL) were taken immediately after mixing followed 
by serial dilution in PBS saline solution and plated on LB agar plates (at least 3 replicates of 
100uL) supplemented with or without kanamycin (50mg/mL). Similarly, samples were taken 
after 24 hours, and serially diluted and plated on LB supplemented with or without kanamycin 
(50 mg/mL). LB plates were incubated for ~16 to 18 hours at 30°C, and subsequently colony 
forming units (CFUs) were counted visually. 
 
Finally, relative fitness (w) was calculated as the ratio of the realized Malthusian parameters of 
the two competitors over the course of the 24-hours of competition as follows: 
w = ln(Ef/Ei)/ln(Mf/Mi) 
where E and M correspond to densities of the evolved population and reference competitor, 
and subscripts i and f designate initial and final densities, respectively. However, this 
calculation is highly sensitive to sampling error when the difference between two Malthusian 
parameters of the two competitor strains arise in different nutrients medium (as in our case is 
the medium was supplemented with two different antibiotics in combination); therefore, we 
also calculated the selection rate constant as a measure of relative performance in relative 
fitness as has previously been done by Travisano and Lenski, 1996 [41]. 
Bacterial whole genome sequencing and library preparation 
Initially, individual clones (the same ones as for the previous fitness assays) were inoculated on 
LB agar plates from the cryotube followed by overnight incubation at 30°C. A single colony 
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was then inoculated in 10mL LB broth and incubated overnight at 30°C on orbital shaker (180 
rpm). Then DNA extraction from pure culture of individual clone was performed using 
PureLink® Genomic DNA Kits (Invitrogen). After extraction, DNA quantification was carried 
out using spectrometer based microplate reader on Take-3 plate  (SynergyTM HT, Bio Tek, 
USA). Then samples were diluted in TRIS buffer to 8-10 ng/uL and stored in -20°C. 
 
Library was prepared using a Nextera XT kit (Illumina, San Diego, CA, USA) according to 
manufacturer’s instructions but with slight modifications. Overall, library preparation was 
carried out in 5 steps. In step 1, gDNA concentrations were standardized across samples (for 
example, 8 ng/mL for each strain). Step 2 involved tagmentation of input DNA by the Nextera 
XT transposome. The Nextera XT transposome simultaneously fragments the input DNA and 
adds adapter sequences to the ends, allowing amplification by PCR in subsequent steps. In step 
3, tagmented DNA was amplified for a short cycle with the PCR. In step 4, PCR amplified 
fragments or library DNA were purified using AMPure XP beads (Agentcourt Ampure XP: 
Beckman Coulter AMPURE XP, U.S.A), which removed short library fragments from the 
samples. In the final step, each library was normalized which ensures that equal library 
representation has been achieved in pooled sample. In doing so, we run our purified samples 
further on the Shimadzu bioanlyzer for the selection of expected fragment lengths between 300 
and 800. Then we pooled the library, and further purified with AMPure XP beads followed by 
Pippenprip size selection. Finally, the pooled library was sequenced on the Illumina MiSeq 
platform (300bp paired-end). 
Analysis of genome data 
The reads (forward and reverse) generated from the Illumina MiSeq run were first quality 
trimmed with 0.05% error probability, paired and then mapped to our ancestral genomes of A. 
baylyi. Ancestral strains were assembled by mapping their reads against the reference genome 
of A. baylyi, which is available on the NCBI GenBank (NC_005966). All steps were carried 
out using Geneious version 9.1.4 (BioMatters Inc.). In short, we used ‘Find variations/SNPs’ 
tool implemented in Geneious to identify SNPs and indels with minimum reads coverage of 5 
and a variant frequency of at least 95%. A subset of SNPs identified in the rpoB gene was 
further verified by Sanger’s sequencing of polymerase chain reaction (PCR) amplicons 
(detailed primer information and PCR program are provided in supplementary table S3-S5). 
For each SNP in this rpoB gene, a subset of clones harbouring this mutations (9 out of 18 
mutations identified in the 36 evolved strains) were selected, and were amplified a 500–700 bp 
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PCR product covering the SNP initially identified during initial SNPs analysis, and directly 
sequenced the PCR products. All 9 mutations that we cross-examined were successfully 
confirmed. 
Statistical analysis  
For data analysis, various statistical methods were employed at the population level. We first 
used an analysis of variance (ANOVA) model to compare growth rates between ancestral 
genotypes and evolved endpoint populations with genetic background (i.e. Rec+ and Rec-) and 
testing environments (ND, LD, and HD) as fixed effects, and replicate evolved populations as 
random effect. We also employed a fully factorial combined ANOVA model for the relative 
comparison of competitive fitnesses of the evolved populations from transfer 100 (T100) 
which represents about ~650 generations of growth (both Rec+ and Rec-) and transfer 0 (T0) 
which represents ancestral populations (both Rec+ and Rec-). We considered replicate 
populations as random effect, and treatment and genetic background (Rec+ and Rec-) as fixed 
factors implemented within the model. We used LS means contrasts in the factorial ANOVA 
model to compare the Rec+ and Rec- populations at transfer 0 and 100 days. Similar analysis 
was employed for both disk diffusion and E-test MIC assay for the ancestral and evolved 
populations. All statistical analyses were carried out using JMP version 12 and R version 3.1.2. 
Results 
Phenotypic investigation on the evolutionary benefit of natural transformation in de novo 
multidrug resistance 
To investigate the contribution of recombination in the de novo multidrug resistance, we 
evolved replicate populations of competent (Rec+) and non-competent (Rec-) A. baylyi under 
three different treatment environments for ~650 generations. We introduced static antibiotic 
concentrations comprising no drug (ND), low drug (LD) and high drug (HD) treatment. We 
confirmed that these concentrations of drugs exerted sufficient growth inhibitions (LD:  ~15% 
growth reduction, HD: ~20% growth reduction, see Figure S3). Therefore, we expected that 
the selection pressures we used were sufficient to produce genetic variability among 
populations over time, and we assumed that natural transformation would play an important 
role in adaptation to these environments. 
 
We investigated the level of adaptation by measuring growth rates of the evolved populations 
from T100 (endpoint population) and T0  (initial population) by exposing them to the same 
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media and selective pressure that we used earlier in the evolution experiment. In addition to 
this, we also quantified growth rates for the initial and the endpoint evolved populations in all 
other treatment environments. This investigation allowed us to directly observe to what extent 
adaptation had taken place in Rec+ and Rec- evolved populations after ~650 generations. 
 
EvolEnv
HD LD ND
M
ea
n 
gr
ow
th
 [m
in-
1] 0.000
0.005
0.010
0.015
0.020
0.000
0.005
0.010
0.015
0.020
0.000
0.005
0.010
0.015
0.020
HD
LD
ND
TestEnv
0 100 0 100 0 100
Transfer
Rec- Rec+Genotype 
 
Figure 1 Growth rate for the ancestral and endpoint population. Growth rates were measured 
for ancestral (T0) and evolved endpoint (T100) populations. Plot shows mean growth rates for 
the ancestral (T0) and evolved endpoint (T100) populations. Error bar = SEM (±1). 
Following ~650 generations, growth rate assays indicate that populations propagated under 
selective environments had evolved higher growth rates (F1, 226 = 198.96, p-value = <0.0001, 
see Figure 1). This was apparent for all the populations when tested in the same selective 
environments. For example, populations with higher growth rates were observed when evolved 
and tested under LD and HD environments. Another important observation was that 
populations evolved under the LD and HD treatments showed lower growth rates when tested 
in ND treatment environment. This indicates possible fitness cost incurred by resistance 
mutations in the evolved populations when tested in absence of drug pressure, as has been 
suggested by previous studies [19, 42]. Therefore, our results support the fact that populations 
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evolved in the presence of combination treatments adapted better than those evolved under no 
antibiotics. However, no differences in growth rates were observed between Rec+ and Rec- 
populations indicating a uniform adaptive response across Rec+ and Rec- populations (Figure 
1). We further investigated the statistical basis of fitness improvement in the endpoint 
populations. More specifically, we were interested to see to what extent populations acquired 
higher growth advantage when tested in the same selective environments. Therefore, we 
investigated growth rates of the evolved endpoint populations by employing a linear mixed 
effect model. In this model, growth rates were explained with the main effects of genotype 
(Rec+ and Rec-), evolved environment, and testing environment, and all their two-way and 
three-way interactions. Plates and strains in which genotypes were nested were used as a 
random factor as one replicate of each treatment was found on each of three plates. 
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Figure 2 Mean growth rates for the endpoint populations. This plot is based on evolved 
environment vs. testing environment as a measure of adaptation. Each experimental replicate 
was measured at least five times. These are repeated measurements of the final outcome so 
they have been averaged. Error bar = SEM (±1). 
Our results indicate that populations evolved better when they were tested under the same 
environment (Figure 2). We observed a significant association between evolved and testing 
environment (p-value = <.0001*). However, this analysis did not reveal any significant 
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association between genotypes and evolved environments (p-value = 0.9966), nor any 
association between genotypes and testing environments (p-value = 0.3413). All the parameter 
estimates are given in the following Table 2.  
 
Table 2 Growth rates of the endpoint populations. Growth rates explained with evolved 
environments (EvolEnv) and testing environments (TestEnv). Genotype has two biological 
replicates (Rec+ and Rec-) for each level and three technical replicates (i.e., three plates) for 
each of the two levels. Testing environment (TestEnv) has three levels (i.e., ND, LD and HD), 
and it is replicated across the two Rec+ and two Rec- strains for three times (i.e., three plates). 
Source Nparm DF DFDen F-ratio Prob > F 
Genotype 1 1 86 2.3227 0.1312 
Strain [Genotype] 2 2 86 1.0899 0.3409 
EvolEnv 2 2 86 8.8130 0.0003* 
EvolEnv*Genotype 2 2 86 0.0034 0.9966 
TestEnv 2 2 86 10.6571 <0.0001* 
TestEnv*Genotype 2 2 86 1.0885 0.3413 
TestEnv*Genotype*EvoEnv 4 4 86 0.0678 0.9914 
TestEnv*EvolEnv 4 4 86 13.3149 <0.0001* 
 
The above results indicate an elevated growth rates for the populations evolved and tested 
under antibiotics supplemented selective environment. However, based on these results we 
cannot infer any potential contribution of recombination in the elevated growth rates among 
these populations. Therefore, we then tested the adaptive potential of recombination via natural 
transformation (the main hypothesis of this chapter) by employing a mixed effect model using 
Rec and adaptation: growth rate ~ genotype * evolved environments + plate + strain 
[genotype], where plate and strain [genotype] are random effects. This analysis revealed that 
populations evolved in the face of selective environments adapted better but no significant 
differences were observed in growth rates between Rec+ and Rec- genotypes evolved under 
three different treatment environments. 
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Figure 3 Mean growth rates for the evolved endpoint populations as a measure of 
adaptation. This plot is based on genotype vs. testing environment as a measure of adaptation. 
Each experimental replicate was measured at least five times. These are repeated 
measurements of the final outcome so they have been averaged. Standard error = SEM (±1). 
 
Table 3 Parameter estimates for the fixed effect test for the growth rates of the endpoint 
populations. Growth rates explained with evolved environments (EvolEnv) and genotypes with 
two biological replicates (Rec+ and Rec-) for each level and three technical replicates (i.e., 
three plates) for each of the two levels. Evolved environment (EvolEnv) has three levels (i.e., 
ND, LD and HD), and each time it is replicated across the two Rec+ and the two REC- strains 
three times in three plates. 
Source Nparm DF DFDen F-ratio Prob > F 
Genotype 1 1 98 1.3963 0.2402 
Strain [Genotype] 2 2 98 0.6552 0.5216 
EvolEnv 2 2 98 5.2979 0.0065* 
EvolEnv*Genotype 2 2 98 0.0020 0.9980 
To summarize the above findings, I presented the following Figure (Figure 4) for the evolved 
endpoint populations. From this figure, it is clear that population grew better in their respective 
environments; however a substantial fitness cost was also incurred when the evolved 
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populations were tested in alternative environments meaning that drug specific resistance 
mutations incurred fitness cost in the absence of selective environments. 
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Figure 4 Mean growth rates for the evolved endpoint populations after ~650 generations. In 
this Figure, X-axis represents genotype by evolved environment by testing environments. Error 
bar = SEM (±1). 
Growth rate measurement was not sufficient to determine the observed fitness differences 
between Rec+ and Rec- populations as one recent study reported differences in fitness trade-off 
between adaptation to active growth phase and survival in stationary/death phase caused by 
pleiotropic antagonism [30]. This finding may mirror the similar pattern of growth phase 
specific fitness differences between Rec+ and Rec-, which means that that both Rec+ and Rec- 
populations may experience fitness differences in active growth phase and stationary phase. 
We did not determine death rate or growth rate during active growth phase in our evolved 
strains, however we further explored these differential adaptive traits by measuring competitive 
fitness. To this end, we competed terminal and ancestral populations (i.e. Rec+ and Rec-) 
against a reference strain by employing pair-wise competition assays Then we compared the 
level of adaptation relative to the ancestral strains. We then estimated relative changes in 
competitive fitness by measuring the selection rate constant (Ds) by calculating the natural log 
difference in population in CFU/mL after 24 hours of competitions for each experimental and 
ancestral lines [41]. We observed that the relative fitness of competent and non-competent 
populations evolved in the presence of static stress induced by rifampicin and streptomycin 
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was significantly distinguishable from no drug treatment environment indicating that stressful 
conditions significantly favoured adaptations compared to benign environment (F-test = 
115.58, DF = 2, 175, p-value = <0.0001) (Figure 5).  
 
Figure 5 Competitive fitness for the evolved endpoint populations. The plot shows relative 
change in competitive fitness (Δs) for the evolved thirty-six endpoint populations. Rec+ and 
Rec- populations are indicated by coloured dots representing the mean of at least five 
independent competitive fitness measurements for a single population from each of the Rec- 
and Rec+ population that tested under different environments. Each black bar overlaid 
represents the mean of the six representative strains. Error bar = SEM (±1) 
However, we observed that the level of adaptation is independent of the strength of selection 
indicating that there were no differences in fitnesses observed between low drug and high drug 
treatment across all populations (Figure 5). Contrary to the expectation that competence 
(Rec+) accelerates adaptation, we found instead that there were no fitness differences between 
Rec+ and Rec- evolved terminal populations (F-test = 0.0762, DF = 1, 175, p-value = 0.7829) 
(Figure 5).  
 
This indistinguishable competitive fitness between Rec+ and Rec- led us into further 
investigation to know whether fitness among genotypes derived from the endpoint populations 
also varied across three different replicate plates. For example, evolved environment we used 
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has three levels (ND, LD, HD) and it is replicated across two Rec+ and two Rec- genotypes 
three times in three plates (i.e., P1, P2, P3). To investigate this we performed a linear mixed 
effect model using evolved environment and genotype as fixed effects, and plate and strain 
[genotype] as random effects. Our analysis did not reveal significant effect of recombination 
on the competitive fitness nor any interaction between evolved environment and genotype. For 
the random effect tests, the test results revealed no significant effect of recombination for each 
the plates (Figure 6). We only observed a significant effect of the evolved environment on 
competitive fitness. Detailed parameter estimates for this test is given in Table 4.  
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Figure 6 Mean competitive fitness vs. evolved environment across replicate plates. Each of the 
plates represented by coloured bar with the mean of two distinct genotypes. Each bar 
represents each plate with two genotypes. Error bar = SEM (±1). 
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Table 4 Parameter estimates for the fixed effect test for the mean relative competitive fitness of 
the endpoint populations. 
Source Nparm DF DFDen F-ratio Prob > F 
Genotype 1 1 26 0.0198 0.8891 
Strain [Genotype] 2 2 26 0.0337 0.9669 
EvolEnv 2 2 26 48.8780 <0.0001* 
EvolEnv*Genotype 2 2 26 1.0483 0.3649 
 
We further investigated the diversity of susceptibility profile across population where we tested 
both ancestral and evolved endpoint populations. We explored this by carrying out an 
antimicrobial susceptibility test by using rifampicin and streptomycin antibiotic disks. We used 
these disks since our evolved environments (i.e., LD and HD) were supplemented with these 
two antimicrobial compounds in combination (i.e. LD and HD treatment) throughout our 
evolution experiment. We interpreted the zone of inhibition as measure for the adaptive 
response to the stress.  We observed a significant effect on the observed inhibition zone (F-test 
= 4.7596; DF= 2; p-value = 0.01145). This observation indicates that zone of inhibition was 
significantly affected by the evolved environments. But, no significant differences were 
observed between Rec+ and Rec- population (F-test = 0.5808; DF = 2; p-value = 0.56203). 
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Figure 7 Disk diffusion test as a measure of resistance evolution. Each number represents the 
zone of inhibition [mm] and is the mean of three independent measurements. In this 
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experiment, the concentration of the disk for streptomycin was 25 µg/mL, and 30 µg/mL for 
rifampicin. Com+ and Com- indicates recombination proficient and deficient populations 
respectively. Genotypes indicated with P1 to P6 representing the total replicate populations in 
three different plates where each plate has two Rec+ and Rec- for each of the three different 
evolved environments. WT represents the original wild-type susceptible genotypes. The 
gradient colour corresponds to zone of inhibition, and represents the extent of resistance, for 
example inhibition zone of 0 [mm] represents highly resistance (indicated by red colour, and 
blue indicates low level of resistance. We observed a significant interaction between evolved 
environments and tested drugs (F-test = 2.9908; DF = 2; p-value = 0.05653); this result also 
supports that resistance was more pronounced to rifampicin antibiotic (Figure 7), which 
inhibits bacterial transcription by binding to the β-subunit of RNA-polymerase encoded by 
rpoB gene. However, very low or no resistance was observed to streptomycin, which inhibit 
protein synthesis by interfering with 30S ribosomal subunit; this might reflect the fact that 
translation machinery are evolutionarily conserved (relatively low mutation rate) and costly 
(relatively high fitness cost) [43, 44]. 
 
However, the disk diffusion test that we performed was not sufficient enough to determine the 
level of resistance against the selective environments after ~650 generations. Therefore, we 
performed E-test assay on the endpoint population to determine the effect of these drug 
specific resistance mutations. This approach allowed us to further determine change in the MIC 
profile by using not only the antibiotics we used in our evolution experiment, but we also 
tested the MIC for an additional class of antibiotic (ciprofloxacin) as a proxy to determine 
whether the evolution of multidrug resistance was taken place under sub-lethal selective 
environments. We further investigated into the statistical basis of the elevated level of MIC (we 
consider this as an adaptive response and we used fold MIC change), and this high MIC is also 
the result of recombination. Therefore, we employed a mixed effect model such that: MIC ~ 
Rec * antibiotic + Plate + Strain [Rec], where plate and strain [Rec] are used random effects. 
The test result revealed no significant effect of recombination on the MIC or any interaction 
between antibiotic and Rec. Rather we observed that antibiotic had significant effect on the 
level of the MIC irrespective of Rec type (Rec is referring to the recombination proficient 
(Rec+) and deficient (Rec-) genotype). Parameter estimates for this model is given in Table 4. 
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Table 5 Parameter estimates for the fixed effect test for the mean fold-MIC change of the 
endpoint populations. 
Source NParm DF DFDen F-ratio Prob > F 
Genotype 1 1 26 0.2498 0.6214 
Antibiotic 2 2 26 19.7554 <0.0001* 
Genotype*Antibiotic 2 2 26 0.1666 0.8475 
Strain [Genotype] 2 2 26 0.5744 0.5700 
 
Therefore, the E-test results revealed a significant increase in fold-MIC change to both 
rifampicin and ciprofloxacin but very low to the streptomycin, which is indistinguishable 
between Rec+ and Rec- (Figure 8).  Similar results also observed for the disk diffusion test 
suggesting drug specific resistant mutations occurred during the course of evolution. 
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Figure 8 MIC distribution for three different antibiotics. The MIC was determined by using E-
test assays. De novo resistance to ciprofloxacin (Cip) was observed in all populations 
(irrespective of Rec+ and Rec-) evolved under LD and HD environments suggesting an 
adaptive resistance through mutational alteration in the efflux pump system. 
Our results are also in line with the observation that the frequency of streptomycin resistance 
mutations was very low as seen in the previous mutant screening where we selected for 
spontaneous streptomycin resistant mutants on plates with even only 5-fold higher 
concentration than the wild type MIC (data not shown here). Based on this data, we speculated 
that other phenotypic changes might contribute to the mild but indistinguishable adaptive 
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response to streptomycin across Rec+ and Rec- population. Taken together, these results 
suggest two important conclusions about different genotypes and their adaptation to LD and 
HD environment: (1) adaptation does occur, and it is driven primarily by selection of resistance 
to streptomycin and rifampicin antibiotics; and (2) disk diffusion test revealed no significant 
difference in zone of inhibition between Rec+ and Rec- (Figure S1). This could be explained 
by the underlying genetic architecture of the endpoint populations; for example, drug specific 
evolved environments helped both Rec+ and Rec- to acquire resistance against those drugs. 
Genomic investigation of natural transformation in the evolution of multidrug resistance 
We anticipated that Rec+ populations could potentially alter the evolutionary dynamics by 
bringing beneficial mutations (resistant mutations) from separate cells into a single genetic 
background, and would thereby increase the fixation rate of beneficial mutations (Fisher-
Muller effect). Therefore, we expected an increased frequency of multidrug resistant 
genotypes. As noted earlier that we did not find any fitness differences between Rec+ and Rec- 
lines under sub-inhibitory stressful conditions. However, there is a possibility that this 
selection pressure in combination might have mutagenic effects on bacterial competence. This 
is because stress induced by antibiotics greatly increases the competence in many bacterial 
species which are lacking of SOS-system [45, 46], thus SOS-induced mutagenesis could also 
result in elevated drug specific resistance mutations conferring higher fitness in Rec- 
populations. 
 
Therefore, we investigated the influence of competence (Rec+) and non-competence (Rec-) by 
sequencing the genomes of the evolved clones that were also assayed phenotypically. More 
precisely, we further wanted to investigate into the indistinguishable benefit of recombination 
by looking at the genomic level to know whether this indistinct phenotypic property between 
Rec- and Rec+ population is also mirrored by the low number of overall mutation in the 
evolved endpoint population. Therefore, we sampled one genotype from each of the 36 evolved 
endpoint populations along with their ancestral genotypes. We obtained a median coverage of 
~38-fold per genotype (mean = 49.5; range 25–50) on the Illumina MiSeq platform, using 
300bp paired-end reads. One previous study suggested that 15/20-fold coverage is adequate for 
identifying a modest number of mutations in laboratory selected microbial strains [47]. In our 
study, the depth of coverage we achieved should, therefore, allow us to detect all SNPs and 
small indels throughout the genome that have occurred during the course of evolution over a 
hundred day of transfer. In addition, the sequenced genomes were surveyed for the large 
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insertion/deletion events, such as mobile genetic elements insertions or excisions were 
manually investigated by looking at the specific deleted regions identified initially. We were 
unable to inspect some portion of the genome for some strains due to low coverage (<5). We 
selected this coverage threshold arbitrarily with a notion to detect all the nucleotide changes in 
the entire populations and then to further validate them by traditional amplicons sequencing of 
a subset of SNPs that were identified with higher frequency in the populations. 
 
Across all evolved lines, we identified 168 mutations comprising 129 nucleotide changes (22 
of which were intergenic), and 25 large deletions. Overall, these mutations were affecting a 
total of 146 genes (some genes were affected in high number). In some instances, large 
deletion events were found (insertion are not identified yet). We then classified these mutations 
into two groups based on the regions of the genomes that were affected by them: structural and 
regulatory mutations (Figure 9). This classification revealed an abundance of mutations that 
affected structural  
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Figure 9 Different mutational events identified in the evolved endpoint population. In panel A, 
all the mutations based on their functions are classified into structural (genes that encode 
functional enzymes) and regulatory gene (regulates important cellular processes) mutation. 
Panel B shows the number of synonymous and non-synonymous mutations observed in Rec- 
and Rec+ populations after ~650 generations. 
genes of the genomes evolved in HD environment, and was higher in Rec+ population (37 vs. 
17, shown by Figure 9(A). Next, we identified the genomic substitutions that were not 
uniformly distributed across treatments and populations (Figure 9(B)). We saw that the 
frequency of the non-synonymous mutations relative to synonymous mutations were higher in 
Rec- than Rec+ (i.e. 74/97 vs. 19/97), and the majority of these mutations were detected in 
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clones that had evolved in stressful conditions. However, the relative abundance of overall 
mutations in Rec+ and Rec- in stressful environments (LD and HD) was higher compared to 
unstressed (ND) environment. In ND environment, we observed very few mutations as has 
previously been observed [48, 49]. 
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Figure 10 Number of deletions and intergenic mutations occurred in the evolved endpoint 
population. Panel A shows number of large deletions (from 100 to 49K bp long) events 
observed in both Rec+ and Rec- populations. Panel B shows the number of intergenic 
mutations observed in Rec- and Rec+ populations after ~650 generations. 
Some earlier studies provided evidence of the genomic basis of adaptation in experimentally 
evolved population, where mutation rates were ranging from 1.07/100 to 4/100 generation [50, 
51]. In the later case, this difference was predicted as a signature of strong selection imposed 
by antibiotic treatment [52]. In line with this, we compared the number of mutations in the 
populations that were evolved with or without antibiotics. We observed a high number of 
mutations in stressed populations suggesting that the selection pressure we used was strong 
enough to produce an antibiotic-mediated benefit among these genotypes. However, the 
difference between Rec+ and Rec- suggests a possibility that natural selection in some 
populations evolved under HD environment could have played role in shaping the spectrum of 
mutations. We found that non-synonymous and synonymous mutations (as mentioned earlier) 
in both Rec+ and Rec- populations were different (Figure 9B). Large deletions and intergenic 
mutations were also different in both Rec+ and Rec- (Figure 10). In line with the above 
explanations, we observed an increased abundance of rpoB mutations both in Rec+ and Rec- 
clones evolved under LD and HD environment (Figure 11). Detailed mutational background is 
given in supplementary Table S1. 
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Figure 11 Major mutations identified in the endpoint populations. The plot shows major SNPs 
found across Rec+ and Rec- genotypes, a majority of them involved in drug resistance. High 
abundance of drug resistance mutations was found in the rpoB gene in both Rec+ and Rec- 
genotypes, responsible for rifampicin resistance. No observed mutations were detected in rpsL 
gene known for streptomycin resistance. Mutations were also detected in the efflux system 
encoding genes such as mdtC, rnd and acrB, which are well known for phenotypic multidrug 
resistance. 
Mutation in rpoB gene encoding RNA-polymerase β-subunit is widely responsible for 
resistance to rifampicin antibiotics [44, 53]. In addition to rpoB mutation, we observed 
mutations in rpoC, rpoD, acrB, ndtc and rnd. It is well known that secondary mutation in rpoC 
and rpoD are associated with adaptation in resistant population by compensating the fitness 
cost associated with resistance mutations [43, 44], whereas mutations in efflux pump system 
including acrB, rnd and ndtc contribute to the high level of phenotypic resistance to multiple 
drugs, including common fluoroquinolones resistance [54-56]. Thus, we speculated that this 
high number of mutations possibly played a role in the adaptive process in populations evolved 
under LD and HD environment. However, both Rec+ and Rec- lineages carried rpoB mutations 
indicating a substantial parallel evolution, which means that natural selection acted upon rpoB 
mutation in LD and HD environment. This genotypic parallelism probably appeared in the 
earlier generations of the population during the course of evolution. This parallel evolution can 
further be supported by looking at the fitness or growth rates of different lineages from 
different generations, as has been documented in many experimentally evolved bacteria, 
116 
 
including evolution of P. aeruginosa under sub-lethal concentration of ciprofloxacin antibiotic 
[50]. Together with this, rpoB and other lineage-specific mutations arose in our evolved 
populations are beneficial. We observed the same mutation in each replicate population line 
suggesting that the majority of parallel evolution was indeed due to the selection of drug 
specific resistance mutations. 
 
To determine the effect of these drug specific resistance mutations in the evolved population, 
we carried out E-test phenotypic assay by which we further determined the MIC by using not 
only the antibiotics we used in our evolution experiment, but also an additional antibiotic 
(ciprofloxacin) as a proxy to determine the putative role of additional mutations associated 
with the efflux system as well as other unknown mutations. We observed an elevated level of 
MIC for ciprofloxacin (Cip) (Figure 8) for the strains evolved under LD and HD environment, 
but no changes were observed in populations evolved under ND environment. This indicates 
possible adaptive evolution attributed to these drug specific genomic mutations or other 
mutations. 
 
Among others, we also observed a mutation in the hsdR regulatory gene. This gene encodes the 
conserved HsdR protein and belongs to type 1 restriction-modification (RM) system. This 
system protects bacterial DNA from restriction (degradation) by modification (methylation) of 
specific sequences that are recognised by restriction enzymes of the RM system [57]. The RM 
system in E. coli protects bacteria from invading foreign DNA such as bacteriophage genomes. 
Inactivation of hsdR mediated type 1 RM systems was also found to be associated with the 
transformation process in S. aureus [58]. In a previous study by Waldron and Lindsay, it was 
reported that the conserved type I RM system was solely responsible for the inability to 
transform S. aureus isolates with E. coli derived plasmid DNA and a premature stop codon in 
the type I restriction gene (hsdR) was identified [59]. Furthermore, disruption of this restriction 
barrier can reduce the degree of virulence in clinical isolates of MRSA lineages CC22, CC30, 
and CC45 [60]. Although we observed a synonymous substitution in this gene in one of the 
Rec- strains, this mutation might have entailed profound evolutionary implications for 
adaptation in that particular environment by elevated resistance to many antibiotics without 
altering this restriction modification system. 
 
Overall, we identified a low number of functional mutations in the Rec+ populations. For the 
low mutations rate, we further searched for the putative known mutator lineages in the evolved 
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populations because mutator phenotypes increase the mutation rate through error prone DNA 
replications in presence of antimicrobial stress [61, 62]. Although we did not observe any 
putative mutation in the Rec+ population for the SOS inducer, Rec- constituted majority of the 
mutations including mutation in nusG gene encodes transcription elongation factors. Some 
earlier studies reported that transcription anti-termination gene nusA as well as rifampicin 
resistant rpoB mutation are required for stress-induced mutagenesis in E. coli [63, 64]. 
Rifampicin resistance mutation affects the cellular anti-termination system involved in the 
synthesis of stable RNA by interacting with nusG, and also acts as a possible compensatory 
mutation in P. aeruginosa genes such as gyrA, gyrB and nfxB under ciprofloxacin antibiotic 
pressure [50]. Therefore, Rec- populations indicate mutator phenotypes in our experiment. 
However, based on the mutations we observed, we did not determine the mutation rate 
differences in each population from Rec+ and Rec- group. It is evident that stress induces both 
competence and SOS-pathway in bacteria [45]. In order to distinguish mutator strains from 
non-mutators and infer the role of competence and non-competence in the adaptive process, we 
first categorised all the populations by giving a rank based on the highest number of mutations 
(nucleotide substitutions) occurred in a single genome, where strain with highest mutation is 
categorised as Rank1 (>5 mutation plus a putative gene responsible for stressed-associated 
mutagenesis) to Rank3 (<3 mutation with no putative SOS-associated gene). According to this, 
all the Rec+ populations belonged to Rank3. In the Rec- populations, mutation in the nusG 
gene (functions in transcription anti-termination) was found in one strain with other mutations 
including mutation in rpoB gene. In some other Rec- strains, mutations were detected in some 
other genes including murB (peptidoglycan biosynthesis, stressed and recombination 
inhibition) and rimM (16S rRNA-processing protein RimM; essential for efficient processing 
of 16S rRNA and for the SOS response). Taken together, this rank based classification suggest 
that Rec- populations were more genetically diverse compared to Rec+ which helped them 
adapt in the HD environment, probably by inducing SOS systems in some of the strains, for 
example interactions between rpoB and nusG genes. By contrast, in Rec+ strains, we observed 
less broad patterns of genetic diversity where rpoB mutation was predominant (rpoB mutations 
8/12 strains); however, we did not observe any evidence for antibiotics mediated genetic 
divergence in Rec+ population suggesting no recombination via natural transformation. 
  
Intergenic mutation between two functional genes could be an indication of possible 
recombination event such that population acquiring non-synonymous intergenic mutations can 
be acquired with other mutations in functional genes by recombination, and this can be tracked 
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by targeted sequencing as has been shown by one recent study in A. baylyi. [30]. We did not 
sequence our populations from different time points, but intergenic mutations in the endpoint 
populations could provide some evidence of recombination. We identified 25 intergenic 
mutations, and most of these mutations were detected in Rec- population (19/25). This result 
suggests that Rec- population could be mutator phenotypes. One previous study reported 
intergenic mutation mostly occurred in mutator phenotypes [50]. In the present study, we 
identified intergenic mutations between glcB and ATPase, and between fimU (encoding the 
type 4 fimbrial biogenesis protein FimU, which modulates virulence in many different 
bacteria) and ispH (encoding IspH and functioning in the MEP pathway). Overall, this high 
number of intergenic mutation indicates that some of these mutations were possibly driven by 
selection. However, we only detected 6 intergenic mutations in Rec+ populations, of which 2 
were found in populations that evolved under ND treatment, three in LD environment and a 
single intergenic mutation in the HD environment. Therefore, this low number of intergenic 
mutations in Rec+ populations suggests that these mutations were not driven by recombination. 
 
We further focused specifically on the genes that were affected by non-synonymous 
substitutions, because non-synonymous mutations cause functional effect on the gene level. 
We detected 64 non-synonymous changes in protein coding genes where Rec+ populations 
bore 25 substitutions (ND = 4, LD = 8, HD = 13), and Rec- population bore 41 substitutions 
(ND = 3, LD = 11, HD = 27). Furthermore, we identified two clones from Rec- bore a 
substitution that caused a stop codon in the mdtc gene. This mdtc belongs to heteromultimeric 
RND superfamily of transporter, which is well reported for multidrug resistance including 
resistance to β−lactams, novobiocin, and many more [65].  
 
Genome reduction by large deletions has been reported to be an efficient means of adaptive 
processes in many different environments, including during adaptation of P. aeruginosa to 
cystic fibrosis patients [66]. We also observed many such reductive events through various 
deletions; among these, most notable were 15 large deletions (we considered these large when 
they exceeded 100bp). We only found 3 such deletion events in two of the Rec- populations, 
whereas the Rec+ populations harboured most of these deletions. The largest deletion event 
was ~49kb, observed in three replicate population of AB3_Rec+ and two AB4_Rec+. 
Interestingly, all these deletion events were detected in Rec+ populations that evolved in the 
HD environment. This represents a strong signature of parallel evolution, as has also been 
observed in Methylobacterium extorquens [67]. The large deletion mainly involved many 
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functional domains of the genome including comF, integrase, and many unknown hypothetical 
proteins in our evolved strains. These large deletions of crucial genes together with other 
deletions possibly contributed to the accelerated adaptation under HD treatment. Thus, this 
large deletion could be an effective mean of sustaining multiple drug pressure and involves a 
significant genome size reduction. Based on these results, these large deletion events in Rec+ 
population probably open up a new path towards a limited niche leading to further genome 
changes to cope up with upcoming perturbation. 
 
Based on the above genetic and phenotypic results, our data show that Rec+ population under 
LD environment adapted better through reduction of mutation fixations and also the mutator 
phenotypes. However, Rec+ population under HD environment faces larger deletions of 
important regulatory genomic portions which encompasses competence associated genes as 
well as other important accessory and essential gene pools suggest that this reduced genetic 
architecture overcome competences by generation of effective population size through genome 
reduction, or possibly deletions may have epistatically induced fitness by producing deletion 
vs. mutation, or deletion vs. deletion interactions, perhaps because these were exploited among 
these strains as less costly but efficient strategies for optimal adaptation under strong selection 
pressure.  
Discussion 
Recombination via natural transformation is argued to be an important adaptive evolutionary 
process in many bacterial species, ranging from soil dwelling bacteria to important clinical 
pathogens [68-73]. Specifically, this adaptive process enables bacteria to evolve multiple drug 
resistance as well as enrich many pathogenic bacteria with novel modes of virulence 
mechanisms [71, 74]. However, this adaptive benefit of recombination via natural 
transformation in the evolution of de novo multidrug resistance is not well studied in 
experimental bacterial population under two-drug environment with varying concentrations. In 
previous work, the role of transformation was assessed by employing either naturally 
competent or non-competent bacterial populations already harboured antibiotic resistance 
genes, where the effect of competence was investigated by employing only a specific drug 
targeting bacterial important cellular processes whose disruption created heterogeneous 
population, and thus facilitated transformation process, or the effect of recombination was not 
investigated at genomic level [13, 29, 49]. Therefore, the actual benefit of recombination was 
not fully understood in all those studies. Here, we employed an experimental approach 
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consisting of both naturally competent Rec+ and non-competent Rec- A. baylyi, and 
systemically investigated how a fully susceptible bacterial population exposed to two-drug 
combinations evolves multiple drug resistance via mutation, selection and – potentially – 
natural transformation. To the best of our knowledge, this is the first time that the impact of 
recombination via natural transformation in the evolution of de novo multidrug resistance has 
been assessed. 
We found that the strength of selection pressure we used affected the benefit of recombination 
via natural transformation. In particular, in the LD environment, the Rec+ population evolved 
higher fitness compared to the Rec- counterparts (Figure 5 & 6). This LD environment 
decreased bacterial growth significantly (p-value = <0.0001) before we started the evolution 
experiment (Figure S2). Therefore, we speculated that the greater fitness under this stress was 
the consequence of recombination. On the contrary, in the HD environment, there was no 
fitness difference between Rec+ and Rec- populations. This HD treatment also caused a 
significant growth disadvantage (p-value = <0.0001) in the ancestral genotypes (Figure S2). 
 
Therefore, we predicted that selection of de novo resistance mutations occurred during serial 
transfer over one hundred days in these selection regimes, irrespective of Rec+ and Rec-. Our 
phenotypic data based on the fold MIC change (Figure 8) revealed that adaptation to both 
drugs that we used in LD and HD treatments was strong enough to produce a selection-based 
benefit in all the population, irrespective of competence or non-competence, as we observed a 
varying degree of adaptation to rifampicin. On the other hand, for streptomycin resistance, we 
did only observe mild selection after ~650 generations. Moreover, we did not detect any known 
mutations such as in rpsL and rrs genes that are commonly associated with streptomycin 
resistance. However, in two cases, we observed a mutation in gidB (16S rRNA 
methyltransferase GidB; SAM-dependent methyltransferase; glucose-inhibited division protein 
B; methylates the N7 position of guanosine in position 527 of 16S rRNA). This gene has been 
reported to be associated with low-level of resistance to streptomycin; in one report a gidB 
mutation was found together with an rpoB mutation in M. tuberculosis [75, 76]. We considered 
some plausible alternative explanations for low number of mutations or no known 
streptomycin resistance mutations spread in our evolved populations such that: either known 
resistance mutations had not yet arisen, or other unknown mutations were selected for in these 
populations. Alternatively, for the streptomycin resistance, mutants were present but they were 
only slowly increasing in number and eventually lost from the population (Figure 6; table S1) 
due to limited benefits at the streptomycin concentrations they faced after ~650 generations. Or 
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no resistance or low resistance to streptomycin could be due to adaptive resistance to 
streptomycin either by mutation in efflux pumps system [77]. Furthermore, based on our 
previous mutation-screening assay (data not shown here) by plating appropriate dilution of 
bacterial cultures (plate streptomycin concentration was 10 fold higher than the MIC) indicated 
a lower mutation frequency for streptomycin compared to rifampicin supports this idea.  This 
has probably affected to follow the benefit of recombination via natural transformation, and 
thus the benefit of recombination in HD environment is counterpoised by the observed 
untraceable differences in relative competitive fitness (DS) (Figure 2) among Rec+ and Rec- 
population after ~650 generations. 
  
Another possibility is that the fitness costs induced by sub-MIC could be low for both LD- and 
HD-evolved population when tested in the absence of drug pressure compared to the initial 
ancestral strains (Figure 1). This could be due the fact that only particular but strong resistant 
clones, for example, it could be rpoB mutation, competed weakly against susceptible clones 
(which were not killed yet but their growth was arrested by adaptive genes involved in growth 
bi-stability [78]) at these sub-MIC drug combinations (here we consider situation in both LD 
and HD). This weak competition (low cost resistance, less than 20%, in absence of drug) 
between resistance and arrested clones may be associated with or perhaps delayed the 
emergence of new strong resistant genotypes to another drug (in this case, streptomycin 
resistant genotypes). Or the newly emerged resistant clones could have carried resistance 
mutations imposing very high costs, and thus those clones were lost from the population. 
Overall, if this prediction was correct, the competition between low cost and high cost resistant 
clones would prevent clonal interference (assumed in the traditional Fisher-Muller model) 
through the loss of costly mutants from the Rec+ populations, which would result in no 
recombination but other mechanism to adapt better in the HD environment for both Rec+ and 
Rec- population. One recent study reported the evolution of low-cost but strong resistance at 
sub-MIC of streptomycin in S. coelicolor while concurrently escaping the cost associated with 
this phenotype [79]. But in our case of a two-dug HD environment, we did not observe any 
significant fitness costs in the evolved strains, perhaps because there were other mechanisms 
that alleviate the cost of resistance. We expected such other mechanisms because the HD 
treatment would increase the overall mutation rates in the populations through mutagenic 
effects, including SOS-response or other yet unidentified genomic mutations – as has been 
observed in response to kanamycin, streptomycin and ciprofloxacin [80-82]. Therefore, we 
aimed at determining whether this drug pressure accelerate mutations frequency by inducing 
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natural transformation through the SOS-system. Because previous studies indicate that 
antibiotics targeting DNA-replication system induce SOS system or induce competence, which 
has no repressor of the SOS-system, leading to the hypothesis that DNA-damage inducing 
competence provide genomic plasticity and stress resistance [45]. In our evolution experiment, 
we evolved the populations under static streptomycin and rifampicin antibiotics in combination 
that target two different important cellular pathways. Therefore, our observed indistinguishable 
fitness characteristics between Rec+ and Rec- population could be due to other complex 
mechanisms, and thus we further pursued to investigate fitness at the population level. 
However, we also observed increased MIC to ciprofloxacin, which is a different antibiotic than 
what we had not used in our evolution experiment. This suggests that sub-MIC concentrations 
of some particular classes of antibiotics can give rise to multidrug resistance evolution with 
elevated MIC to a new class of drug (Figure 9). 
  
We obtained the whole genome sequences of clones from the evolved endpoint populations, 
and compared them with clones from the ancestral populations to determine the impact of 
recombination via natural transformation in the evolution of multidrug resistance at the 
genomic level. We expected that under sub-lethal concentrations of rifampicin and 
streptomycin, the populations would be enriched with drug specific resistance mutations at 
first, for example, mutations in rpsL and rpoB genes, and that these two drug specific 
resistance mutations compete against each other. Thus, recombination via natural 
transformations will reduce these competitions (clonal interference) by bringing these 
competing mutations into a single genome, which will in turn results in multidrug resistance. 
Our whole genome sequences revealed that both Rec+ and Rec- were enriched with different 
mutations that were evolved under LD and HD treatment environments. We only observed an 
abundance of rpoB mutations both in Rec+ and Rec- populations across LD and HD 
treatments. These rpoB mutations confer resistance to rifampicin in many bacteria. In a few 
cases, we only found gidB mutation, which is conditionally responsible for the low level of 
streptomycin resistance (Table SI). In some instances, Rec+ population evolved under LD and 
HD environments often carried additional mutations, and most notably, in two cases, we 
observed that population carrying rpoB mutation also carried rpoC and rpoD. Mutations in 
rpoD are responsible for increased resistance or compensate the cost of resistance in S. typhi, 
whereas rpoC mutations are responsible for high-level resistance to cefuroxime (CEF). 
Furthermore, we observed some mutations including a mutation in nusG gene in Rec- 
population, which was previously reported to be associated with stress induced by rifampicin 
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and streptomycin. This mutation also contributes to the elevated level of resistance to 
ciprofloxacin. From phenotypic MIC data, we observed an elevated level of resistance (8-fold) 
to ciprofloxacin but low-level resistance to rifampicin (3 fold) and streptomycin (2-fold) in 
these strains (Figure 9). The remaining non–synonymous changes that occurred in many genes 
– irrespective of competent and non-competent populations – were previously reported to 
confer resistance to multiple drugs in many clinical bacterial isolates, including M. 
tuberculosis, E. coli, A. baumanii, P. aeruginosa and other important pathogens. [54, 55, 83-
88]. However, we did not observe any such mutations in the Rec+ populations, providing no 
support for the possibility that accelerated competitive fitness under HD environment was 
driven by recombination. 
 
Genome reduction by inducing many deletion mutations was previously reported as an active 
means of adaptive process in many bacteria [89, 90]. We also observed such genome 
reductions via deletions mutations, most notably larger deletions were detected in Rec+ 
population from the HD environment (Figure 9A). In some instances, these were involved in 
the deletions of many regulatory proteins as well as transformation related proteins; therefore, 
we expected that deletion mutations could be a strategy of creating an increased growth 
competitive ability in this stressful environment by counterbalancing the costly transformation 
process. However, these deletion events cannot explain the contribution of recombination in 
the adaptive potential (i.e. whether deletion was accelerated by recombination process) under 
stressed environment for at least two reasons: 1) homogenous competitive fitness between 
Rec+ and Rec- evolved under LD and HD; 2) deletions were also observed in the LD and ND 
environments. 
 
After one hundred days of the evolution under sub-lethal concentrations of rifampicin and 
streptomycin combinations, our phenotypic data revealed no significant differences in fitness 
gain between recombination proficient and deficient populations. Whole genome sequencing 
data also revealed a low number of substitution mutations in the evolved endpoint populations. 
Togther these results disqualify the possible effect of recombination in the adaptive process 
under multidrug environments. Although most of the mutations that we found here have many 
different effects on a variety of genes and on their functions, strikingly these genomic changes 
in the majority of our evolved populations (table S1) under these selection regimes were 
previously shown to be associated with resistance to multiple antimicrobial compounds 
through targeted and off-targeted mechanisms [91, 92]. This has been reflected in the elevated 
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level of ciprofloxacin resistance (Figure 11). Finally, we observed no significant evidence that 
recombination by natural transformation facilitates adaptation to multiple antibiotics, 
presumably because the limited number of mutations that were spreading simultaneously 
prevented clonal interference.  
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Supplementary materials 
 
 
Figure S1 Plot shows disk diffusion test assay between genotype vs. transfer (indicated by 0 for 
ancestral and 100 for the evolved endpoint population). Each bar from the evolved endpoint 
populations represents the mean of the six population replicates of each genotype from 
three different plates. Each of these six populations was measured with three independent 
measurements. SEM = ±1   
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Figure S2 Growth rates for the ancestral genotypes. Each bar represents the mean of more than 
3 independent measurements under three different treatment environments. Error bar was 
calculated using 1 standard error from the mean. ANOVA: F-test ratio = 56.5423; DF = 2; p-
value = <0.0001*). 
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Figure S3: Box plot of growth rates for the Rec+ and Rec- populations at different time points. 
The horizontal line in each box plot represents the mean, and the black circles present the 
outliers. ND: no drug; LD: low drug; HD: high drug  
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Table S1 List of mutations observed in the endpoint populations previously reported for 
antibiotic resistance.  
Population RecType AA change 
Nucleotide 
 change Gene Antibiotic resistance 
ADP1Rec+4 Rec+ Ala ->Val C -> T catB Chloramphenicol 
ADP1Rec+4 Rec+ Asp->Tyr G -> T rpoB Rifampicin 
ADP1Rec+4 Rec+ Gly->Ser G -> A rpoB Rifampicin 
ADP1Rec+4 Rec+ Glu->Arg A->G rpoB Rifampicin 
ADP1Rec+4 Rec+ Glu->His A->C rpoB Rifampicin 
ADP1Rec+4 Rec+ Arg->His G -> A cycA Cycloserine 
ADP1Rec+3 Rec+ Ser->Leu C->T rpoB Rifampicin 
ADP1Rec+3 Rec+ Arg->His G->A rpoD Rifampicin 
ADP1Rec+3 Rec+ Asp->Glu T->G rpoB Rifampicin 
ADP1Rec+3 Rec+ Leu->Pro G -> A rpoC Cephalosporine 
ADP1Rec+3 Rec+ Ser->Arg A->C catB Chloramphenicol 
ADP1Rec+3 Rec+ Gly->Asp G->A acrB Mar 
ADP1Rec-132 Rec- Iso->Thr T->C rpoB Rifampicin 
ADP1Rec-132 Rec- Ser->Leu C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Gly->Asp G -> A gidB Streptomycin 
ADP1Rec-132 Rec- Arg->Cys C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Arg->Cys C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Pro->Leu C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Glu->Lys) G -> A ppsA Pyrazinamide 
ADP1Rec-132 Rec- Pro->Ser C -> T salA Antibiotic resistance 
ADP1Rec-132 Rec- Glu->Lys C -> T mdtc Mar 
ADP1Rec-132 Rec- Met -> Arg T -> G fstK 
Ampicillin, cefoxitin, 
and piperacillin 
ADP1Rec-132 Rec- Met->Val A -> G rpoB Rifampicin 
ADP1Rec-132 Rec- Iso->Val A -> G ABC Antibiotic resistance 
ADP1Rec-132 Rec- Pro->Ser C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Pro->Ser C -> T salA 
Lincosamides, 
Streptogramin 
ADP1Rec-132 Rec- Val->Ala T -> C ppsA Pyrazinamide 
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ADP1Rec-132 Rec- Ser->Leu C -> T rpoB Rifampicin 
ADP1Rec-132 Rec- Leu->Leu G -> A gidB Streptomycin 
Reference for these resistance genes has been provided in the result sections.  In this study, we 
tested resistance to rifampicin, streptomycin and ciprofloxacin. RecType indicates Rec+ and 
Rec- population; Mar (multiple antibiotic resistances) = Tetracycline, Ampicillin, Puromycin, 
Nalidixic acid, Rifampicin, Chloramphenicol, and Ciprofloxacin. 
 
Table S2 List of different intergenic mutations. Different intergenic mutations arose in the 
evolved populations. RecType indicates recombination proficient/deficient, population evolved 
under different treatment environments indicated by EvolEnv, whereas Rec+ and Rec- 
indicating recombination efficient and deficient evolved genotypes, RepPlate for replicate 
plates. 
Strain RecType EvolEnv RepPlate Change SNP Type 
ADP1Rec+4 Rec+ HD P2 C -> T SNP (transition) 
ADP1Rec+4 Rec+ LD P1 C->A SNP (transition) 
ADP1Rec+4 Rec+ LD P2 C->A SNP (transition) 
ADP1Rec+4 Rec+ ND P1 G -> T SNP (transition) 
ADP1Rec+4 Rec+ ND P2 G -> T SNP (transition) 
ADP1Rec+3 Rec+ LD P3 C->T SNP (transition) 
ADP1Rec-131 Rec- HD P2 C->T SNP (transition) 
ADP1Rec-131 Rec- HD P3 T -> C SNP (transition) 
ADP1Rec-131 Rec- LD P1 T -> C SNP (transversion) 
ADP1Rec-131 Rec- LD P2 G -> A SNP (transition) 
ADP1Rec-131 Rec- LD P3 T -> C SNP (transition) 
ADP1Rec-131 Rec- ND P1 T -> C SNP (transition) 
ADP1Rec-131 Rec- ND P2 G->A SNP (transition) 
ADP1Rec-131 Rec- ND P2 A -> C SNP (transversion) 
ADP1Rec-131 Rec- HD P2 A -> G SNP (transition) 
ADP1Rec-131 Rec- HD P2 C -> T SNP (transition) 
ADP1Rec-131 Rec- HD P2 A -> G SNP (transition) 
ADP1Rec-131 Rec- HD P2 C -> T SNP (transition) 
ADP1Rec-131 Rec- HD P2 C -> T SNP (transition) 
ADP1Rec-131 Rec- HD P2 G -> A SNP (transition) 
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ADP1Rec-131 Rec- HD P2 T -> A SNP (transversion) 
ADP1Rec-131 Rec- HD P2 T -> C SNP (transition) 
ADP1Rec-131 Rec- HD P2 T -> C SNP (transition) 
ADP1Rec-131 Rec- HD P2 T -> C SNP (transition) 
ADP1Rec-131 Rec- HD P3 T -> C SNP (transition) 
 
Table S3 List of primers used in amplifying targeted rpoB allele sequences. 
Gene name Primer sequence 
rpoB 1 (forward) TTCGATTCAGGTCGACTCGT 
rpoB 1 (reverse) CAGGCGTTCTGGAACAAGAT 
rpoB 2 (forward) TGGATCAAAACAACCCATTG 
rpoB 2 (reverse) ATCGCCACGACCCACTTTAT 
 
 
Table S4 PCR master mix preparation per reaction 
Reagents Amount [uL/reaction tube] 
PCR buffer 10x 2.5 
MgCl2 25 mM 2.5 
dNTP 10mM 0.5 
TaqGold 5U /µL 0.1 
Primer mix (conc. 0.5µM) (F+R)  1.5 
Sigma H2O 17.9 
Template DNA 5 
Tolal volume  30 
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Table S5 Temperature profile for the PCR for amplifying rpoB allele sequences 
PCR program:      
Step Temperature Time 
1 (hold) 95°C 6 minutes 
2 (denaturation) 94°C 45 seconds 
3 (annealing) 58°C 45 seconds 
4 (elongation) 72°C 2 minutes 
5 (repetition) Step 2 to 4 for 35 cycles   
6 (final elongation) 72°C 10 minutes 
 
 
Table S6: Parameter estimates of the fixed effect test using populations from different time 
points. 
Source Nparm DF Sum of Squares F Ratio Prob > F 
Genotype    1 1 0.00000146 0.2210 0.6385 
Transfer    4 4 0.00051062 19.3081 <.0001* 
Treatment    2 2 0.00000389 0.2945 0.7450 
Genotype*Transfer    4 4 0.00002968 1.1222 0.3451 
Genotype*Treatment    2 2 0.00000622 0.4704 0.6250 
Transfer*Treatment    8 8 0.00009798 1.8524 0.0652 
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Chapter 4: Compensatory evolution of the costs of single versus 
multidrug resistance in Acinetobacter baylyi 
Summary 
The phenomenon of drug resistance is pervasive in pathogen populations whenever they face 
any selective pressure exerted by antibiotics. Often, resistant bacteria suffer fitness costs once 
the drug usage is discontinued. However, this deleterious effect of resistant mutations can be 
ameliorated by compensatory mutations (CM), thus preventing the rapid elimination of the 
resistant bacteria from the population. Although this mechanism of compensation has been 
extensively studied in bacterial populations resistant to only a single drug, adaptation to the 
costs associated with multiple drug resistance mutations remains unexplored. We therefore 
tested the mechanism of compensation in multidrug resistant bacteria by employing an 
evolution experiment. We constructed a set of genotypes comprising a completely susceptible 
genotype, a streptomycin resistant genotype carrying the K43T mutation at rpsL locus, a 
rifampicin resistant genotype carrying the P573L mutation at rpoB locus, and a doubly 
resistant genotype carrying both of these mutations. Sixteen populations from each of these 
genotypes were subjected to daily serial transfer for ~325 generations. To follow the dynamics 
of fitness compensation and track the mutational spectrum, the resultant endpoint populations 
with their ancestral counterparts were phenotyped and their genomes sequenced. Our 
phenotypic results show that the deleterious effects of resistance mutations can be compensated 
for by a varying degree of fitness improvement. Specifically, we found that adaptation to the 
cost of resistance in a set of multidrug resistant populations was higher compared to the subset 
of single resistant populations. The MIC data also suggest that fitness was improved without 
altering their resistance level. Moreover, this greater fitness improvement was influenced by 
some of the fittest lineages following a bimodal fitness distribution. Our whole genome 
sequencing data revealed that both costly rifampicin resistant and costly double resistant 
lineages adapted by compensatory mutations in RNA polymerase core enzyme. We also 
observed minor fitness compensation to the low cost streptomycin resistant mutation where we 
detected no evidence of putative compensatory mutations but parallel secondary mutations in 
hypothetical genes. However, we observed a different parallel adaptive evolution in double 
resistant genotype, which harboured an unexpected additional deleterious mutation. 
Surprisingly, half of the lineages originating from this double resistant genotype was better 
compensated through reversion mutation in the same nucleotide position of the same genetic 
locus, which were also accompanied by distinct compensatory mutations in the RNA 
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polymerase core enzyme, and those mutations were not shared by any rifampicin resistant 
genotypes. Our data suggest that adaptation to the cost of multidrug resistance is independent 
of the genetic background of mutations that appeared in single resistant genotypes. 
Furthermore, our study indicates how selection at other locations in the genome can influence 
the dynamics of resistance alleles in multidrug resistant clinical populations.  
Introduction 
The majority of mutations – even synonymous mutation [1, 2] and mutations in intergenic 
regions [3, 4] – have been found to be associated with organism’s fitness in an unfavourable 
way. Some of these deleterious mutations may disappear from the population or revert back to 
the original wild type state, but in some cases such deleterious effect is reduced by so called 
second-site compensatory/suppressor mutations (CMs) at the same or a different locus in the 
genome. By definition, CMs are deleterious or at best neutral when on their own but beneficial 
when co-occurring with the original deleterious mutation, thus representing a form of sign-
epistasis (see also Chapter 2). This poorly understood biological phenomenon has important 
implications, not only for the evolutionary consequences of mutations, but also for the genetic 
complexity of adaptation. In instances of resistance evolution such as bacterial resistance to 
antibiotics, pesticide resistance and resistance of HIV-1 to antiretroviral therapy, this 
phenomenon has contributed an adaptive advantage to pathogen populations [1]. In order to 
gain a better understanding of the biological relevance of CMs in the organism’s fitness – both 
in terms of evolutionary significances of mutation and also for the genetic consequences of 
adaptation – both theoretical and empirical studies have been conducted. For example, theories 
suggest that the CMs appear in the population to mask the deleterious effect of another 
mutation or they arise independently as deleterious mutations in the same population but are 
neutral when they combine with other mutations [2, 3]. In evolutionary biology and genetics, 
the role of CMs have further been assessed under a variety of contexts including the evolution 
of sex, the structure of fitness landscapes and epistasis, mutational load, the extinction of 
populations, and the mechanism of suppressions in determining various regulatory or 
functional interactions between protein or RNAs [4-9]. 
 
It is well known that bacteria can evolve resistance to antibiotics by acquiring drug specific 
new genomic mutations or by acquiring horizontally transferred genetic material carrying 
resistance determinants [10-12]. During acquisition of resistance mutations, these genetic 
changes often involve deleterious effects as they weaken or interfere with important cellular 
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functions including cell wall synthesis, regulation of DNA supercoiling, transcription and 
protein synthesis, or undergo many other metabolic disruptions. Not surprisingly, these 
interruptions of essential cellular functions by antibiotic resistance mutations are often 
associated with fitness costs. This means that the resultant resistant bacterial population 
experiences decreased fitness in the absence of drugs, reflected in, for example, decreased 
survival, reduced growth rate, reduced transmission, and/or reduced virulence in pathogenic 
bacteria [13-15]. The cost associated with this resistance mutation has been empirically studied 
both in vitro and in vivo in many bacterial pathogens in many different settings [9, 16-22]. 
These studies have provided evidence that when the drug-selective pressure is removed, the 
resistance mutations become a disadvantage for the organisms with reduced fitness compared 
to the parental susceptible ones. This means that the resistant subpopulation may go extinct 
because of their low fitness compared to their susceptible counterparts.  
 
In some cases the fitness cost of this genomic single mutation conferring resistance to a 
particular drug in bacteria can be alleviated temporarily by increasing the activity of the 
mutated enzymes. However, compensation may also arise on a permanent basis by additional 
point mutations throuh which the focal mutated-target-proteins become more active, or 
strengthen the flow of this protein through biochemical pathways [5].  Alternatively, it has 
been shown that drug resistance mutations can incur high levels of fitness cost by increasing 
the degree of catalytic activity of the target antibiotics, and this high affinity biochemical-
specificity-associated fitness cost is compensated by additional point mutations in the same 
gene through the thermodynamic activity of that mutated enzyme [23, 24]. One earlier study by 
Schrag and Perrot [25] provided direct evidence of the mechanism of compensation by 
evolving streptomycin resistant E. coli populations in the absence of streptomycin. This study 
found that resistance was stably maintained by evolving a second-site compensatory mutation 
that reduced the fitness cost by 6%. Subsequently, many other observations have been made by 
studying both clinical and laboratory populations, including in Staphylococcus aureus, 
Salmonella typhimurium, M. tuberculosis and P. fluorescens [26-28]. 
 
In all previous studies, the genetic and molecular mechanisms of compensation were 
investigated only for single chromosomal resistance mutations. Nevertheless, it is important to 
also ascertain the role of additional mutations that have been frequently associated with 
multiple drug resistance, but to date this has not been investigated systematically. From a 
clinical perspective, compensation is of special interest since resistant organisms may still 
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maintain their resistance while adapting genetically to its costs, resulting in the stabilization of 
resistant organisms in patients. Thus, it may make it difficult to eradicate the pathogen 
population from infection sites. At the same time, there is a possibility that some fraction of 
resistant populations may acquire additional mutations or compensatory mutations, which may 
perhaps carry higher fitness costs during the course of compensation (Figure 1). One empirical 
study reported that epistatic interactions drive the acquisition of multiple drug resistance and 
also compensate the cost of initial resistance mutation by evolving the second mutation [29]. 
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Figure 1 Genetics of compensation to the cost of resistance. Horizontal axis shows genotypes 
and vertical axis represents fitness. Here, ‘S’ indicates a susceptible locus, ‘R’ indicates a 
resistant locus, ‘C’ indicates compensatory locus. Strain carrying ‘SSS’ indicates a susceptible 
genotype with higher fitness in absence of antibiotics, where the first two ‘S’ indicating drug 
resistant loci that can acquire two distinct resistant mutations, and with the third ‘S’ indicating 
a locus that acquire a compensatory mutation (indicated by green circle). Two single resistant 
genotypes can be achieved by acquiring a single drug specific resistant mutation indicated by 
circle with ‘RSS’. Here, for the simplicity I only consider the first locus, but another single 
resistant genotype conferring resistance to a new drug can be selected for by another point 
mutation in the second locus. The green ‘RSS’ genotype can also be achieved by negligible or 
low cost resistance mutations, whereas red ‘RSS’ resistant genotype has lower fitness because 
of a costly resistant point mutation. For the double resistant genotype indicated by red ‘RRS’ 
fitness is greatly reduced because of the two distinct costly resistant mutations. The solid arrow 
indicates the known mechanism of compensation for a single resistant mutation. The 
mechanism is unknown in terms of fitness and mutational spectrum for multidrug resistant 
bacteria indicated by broken arrow – here two plausible outcomes can be expected: the double 
mutant may acquire a fitness compensatory mutation (i.e., this mutation could be similar to the 
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single drug or a distinct new compensatory mutation) or may acquire a deleterious mutation 
that can further exacerbate the cost of resistance. 
Since this work concerns the possible differences between compensation of single vs. 
multidrug resistance, both in terms of fitness and the spectrum of mutations, we investigated 
the adaptive role of compensatory mutations by employing a set of genotypes comprising a 
completely susceptible genotype, two single drug resistant genotypes, and a multidrug resistant 
bacteria derived from those two singly resistant genotypes through an evolution experiment for 
~325 generations. We then followed the dynamics of fitness compensation and the mutational 
spectrum of these evolved populations by characterizing them both at the phenotypic (growth 
rate, competitive fitness, MIC-assay) and genomic level (whole genome sequencing). We 
attempted to identify de novo mutations that accumulated in these genotypes during the course 
of evolution to uncover the mutational spectrum as well as to what extent these mutations are 
involved in the dynamics of fitness compensations in both single vs. double resistant genotypes 
Thus, we will be able to determine whether evolutionary adaptation to the cost of multiple drug 
resistance by compensatory mutations generates substantial genetic variations which differ 
from compensation to the cost of single-drug resistant mutations. This should shed light on our 
understanding of new evolutionary processes that may also be present in multidrug resistant 
bacteria of clinical origin. 
Materials and methods 
Genetic background of strains and growth conditions  
To construct mutant genotypes, a completely susceptible, tryptophan auxotroph A. baylyi 
ADP1 strain containing a cyan fluorescence marker (trpE27 ACIAD0921::ecfp) was used. 
Before initiating the experiments, these strains were preserved in 15% glycerol (v/v) and stored 
in -80° freezer. 
Genotypes constructions 
To construct rifampicin and streptomycin resistant mutants, the ancestral sensitive strain was 
streaked on LB agar plate and incubated at 30°C overnight. From this plate, an overnight 
culture was initiated from a single clone in 20mL LB broth in a 50mL tube at 30° C with 
constant shaking at 180 r.p.m. Mutant screening for a single drug was carried out by plating 
this overnight culture on LB agar plates supplemented with appropriate antibiotics. 
Specifically, 100uL of overnight culture was inoculated on LB agar plates supplemented with 
either 10ug/mL of rifampicin or 10ug/mL of streptomycin antibiotics and incubated at 30°C for 
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a maximum of 48 hours. The concentrations we used were 10-fold and 5-fold higher than the 
MIC of rifampicin (1ug/mL) and streptomycin (2ug/mL), respectively. After a maximum of 48 
hours of incubation, individual mutants were isolated from both the rifampicin and 
streptomycin supplemented plates and overnight cultures with these individual clones were 
established in LB broth supplemented with the respective antibiotics and concentrations. 
Individual mutants were then frozen in 15% (v/v) glycerol at -80°C for further assays. 
  
Sanger sequencing was employed to sequence the targeted genomic locations of the individual 
mutants. We sequenced two regions of the rpoB gene (rpoBI primer pair which covered 
nucleotides 1–1342, including resistance cluster I, and rpoBII primer pair which covered a 
second region spanning nucleotides 1240–2226, including resistance cluster II) [30-32] to 
detect the mutation responsible for rifampicin resistance (Rif). These primers pairs were 
designed based on an extensive literature search to detect the common regions covering the 
occurrence of common rifampicin resistance pathway conferred by mutation in the rpoB gene 
[31]. Similarly, to detect the streptomycin resistance (Stp) mutation, two pairs of primers were 
constructed targeting rrs and a single pair of primers for the rpsL gene, because most of the 
mutations conferring resistance to streptomycin appear in these two genetic loci [27, 32]. 
Detailed primer information can be found in the supplementary Table S1. DNA extraction was 
carried out from these individual resistant clones using Promega genomic DNA extraction kits 
(Promega, California), followed by PCR amplification of rpoB, rpsL and rrs gene fragments. 
Detailed PCR protocols can be found in supplementary Tables S2 and S3. Sanger sequencing 
was carried out on these amplified PCR gene products at the Australian Genome Research 
Facility, and mutations were determined by using CodonCode Aligner version 5.0 
(CodonCode, Deadham, MA). 
  
In the following step, we constructed a double resistant genotype (resistant to both rifampicin 
and streptomycin) by a natural transformation assay according to de Vries and Wackernagel 
[33] with slight modification. In short, individual competent cells of rifampicin and 
streptomycin resistant mutant strains obtained earlier were prepared by adding 1mL overnight 
culture into 100 mL of LB broth in Erlenmeyer flask for a period of 6-8 hours growth at 30°C 
with constant shaking at 180rpm, followed by centrifugation at 8500rpm for 2 minutes and 
collection of pellets. In the next step, approximately 300uL LB broth supplemented with 
glycerol (20% v/v) was used to re-suspend the pellets by pipette tips very gently. This 
suspension of pellet contained competent cells and was stored in a -80°C freezer. The 
143 
 
following day, transformation of competent cells with genomic DNA (obtained from 
rifampicin and streptomycin mutants as the donor strain in either way) was carried out by 
taking 20mL of LB broth supplemented with MgCI2 (0.25mM) and CaCI2 (0.25mM) in 
300mL Erlenmeyer flasks. After adding DNA, the flask containing both competent cells and 
DNA was placed on the shaker (at 30°C with 170 rpm as shaker conditions) for aeration for a 
period of 90 minutes. This allowed competent cells to take up DNA from their surroundings. 
After appropriate aeration, the cultures were centrifuged at 6000g for 5 minutes and the pellet 
re-suspended by adding 300uL fresh LB and gently mixing the pellet with pipette tips. From 
this tube, 100 uL of culture was streaked on an LB agar plate supplemented with both 
antibiotics, for example, plates were supplemented with 4 ug/uL rifampicin and 20 ug/uL 
streptomycin in combination. The cultures were then diluted and 100 L of these cultures was 
plated and left for adequate time to dry (maximum of 5 minutes). After this, all the plates were 
incubated for a maximum of 40 hours at 30°C, visible individual colonies were picked and 
overnight cultures were setup in LB broth supplemented with 4ug/uL rifampicin and 20ug/uL 
streptomycin in combination. Cultures of these double resistant mutants (StprRifr) were frozen 
in 15% (v/v) glycerol at -80°C. Sanger sequencing was carried out on this StprRifr strain to 
confirm the location of the mutations in rpoB and rpsL genetic loci. 
Measuring cost of resistance 
To determine the cost of resistance, we measured the growth rate of the Rifr, Stpr, and StprRifr 
mutants in 96-well plates in 180uL LB broth where optical density (OD600) was estimated in 
triplicate by using a Tekan Synergy HT plate reader (BioTek., Synergy, USA). Each strain 
taken from the -80°C freezer was grown on an LB agar plate followed by transfer of a single 
colony into 20mL LB broth for overnight growth at 30°C with continuous shaking at 180rpm 
for a period of 18 hours. Then 5uL of this overnight culture was transferred into a 96-well 
microplate where each well contained 175uL of LB broth (without any antibiotics). The 
spectrometer was run for 12 hours, which gave 145 reads in total with a five-minute read 
interval. Specifications for the run protocol for the spectrometer were: set point temperature 
30°C, wavelength 600nm, continuous shaking at medium speed. 
Evolution experiment 
A single colony of each mutant strain of A. baylyi – a rifampicin resistant genotype (Rifr), a 
streptomycin resistant genotype (Stpr) and a double mutant genotype (RifrStpr), and the 
ancestral genotype AB3 (SS) – were grown independently overnight in LB media in absence of 
any antibiotics. Sixteen lineages were founded from each of these four progenitor strains by 
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adding 10uL overnight culture in 990uL of LB medium without antibiotics. All sixteen 
lineages per genotype were grown in 24-well plates on an orbital shaker (280 rpm) at 30°C for 
24 hours, and these growth conditions were maintained throughout the experiment. After 24 
hours, 10uL of each population was serially passaged to 990uL of fresh LB medium and 
propagated for another 24 hours. In this way, fifty serial transfers were made which resulted in 
approximately 325 generations of bacterial growth. Samples were stored and frozen at 8 
different time points at -80°C in 15% (v/v) glycerol solution.  
Growth rate measurement 
Since our aim was to determine the fitness trajectories of all lineages founded from a single 
colony of each of the four initial genotypes, growth rates for the evolved populations at 
different time points were first measured by spectrometry (SynergyTM HT microplate reader, 
BioTek, USA). In doing so, for each linage, 5uL of mixed culture from 24 hours culture 
contained in 24-well plate were directly transferred into 175 uL of LB broth containing 96-well 
plates of different generations at different time (day) points (0, 7, 14, 21, 28, 35, 42, 50). For 
each lineage, we measured this growth rate in duplicates by using two plate readers. We also 
measured the growth rates of all of our evolved endpoint populations and the initial population 
from time 0 (day 1) by taking individual clones; for example, we measured growth rates for all 
sixteen population lineages  derived from each of the four different initial genotypes. In this 
case, we first streaked individual lineages of mixed samples from the frozen stock on fresh LB 
agar plates from a -80°C freezer, and then a single colony was picked and further grown 
overnight in LB medium without adding any antibiotics at 30°C with 180 r.p.m on an orbital 
shaker. From this overnight culture, the growth rate of each clone was measured by obtaining 
the growth curve (OD600) in LB broth without adding any antibiotics. The individual clones 
were also stored in a -80°C freezer in 15% glycerol (v/v) for further analysis. The statistical 
software R version 3.3.0 was used for estimating the maximum exponential growth rate from 
the OD data. Here, raw OD values were normalized to a blank well and Log-transformed 
before analysis. Then the steepest slope over a 32 data point range, corresponding to growth 
over 160 minutes, was determined.  
Antibiotic susceptibility assay by E-test 
To characterize the antibiotic susceptibility profile of the ancestral and evolved endpoint 
populations, we carried out E-test assays. Individual clones were streaked on Mueller-Hinton 
(MH-II; Becton, Dickinson, and company, N.J, U.S.A) plates from frozen stock, and incubated 
for 18 hours. Suspensions of the organisms were prepared by picking the appropriate number 
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of colonies and suspending in 1.5 ml of saline under aseptic conditions, and the turbidity was 
adjusted by measuring the optical density (OD600) of this bacterial saline suspension by 
spectrometry (SynergyΤΜ HT microplate reader, BioTek, USA). Turbidity of this bacterial saline 
suspension was adjusted to that of a 0.06 to 1.0 McFarland standard. A total of approximately 
0.1ml of the 1.0 McFarland and suspension was plated on a MH-II agar plate by using a sterile 
cotton swab. In doing this, the sterile cotton swab was dipped into the adjusted suspension, and 
rotated several times and pressed firmly on the inside wall of the tube above the fluid level to 
remove the excessive inoculum from the swab. Then the MH-II agar plate was inoculated by 
streaking the cotton swab over the whole sterile agar surface.  This procedure was repeated at 
least two more times by rotating the plate approximately 60° each time to ensure an appropriate 
distribution of inoculum on the whole surface of the plate. In the final step, the rim of the MH-
II plate was swabbed at least twice. Then the lid of the plate was kept open for approximately 5 
minutes to allow for any excess surface moisture to be absorbed before applying the E-test 
strip. After adequate drying, a maximum of three E-strips (rifampicin, streptomycin and 
ciprofloxacin) were placed in one plate. The antibiotic strips were placed by maintaining a 
minimal distance between two antibiotics in order to avoid any potential drug interactions (i.e. 
antagonism, synergism, inhibition or induction) that may give rise to distortion of inhibition 
zones. All plates were inverted with the lid side up and placed inside a plastic bag and 
incubated at 30°C for 18 hours. MICs were read from the test strip where the elliptical zone of 
inhibition intersected with the MIC scale on the strip. Although there are no specific 
susceptibility breakpoints set by either the EUCAST (European Committee for Antimicrobial 
Susceptibility Testing) nor the CLSI (Clinical and Laboratory Standards Institute, USA) for the 
tested antimicrobial stripes for the strain (A. baylyi) used in this study, we also carried out E-
tests on E. coli strain ATCC 25552 as a control to better interpret the MIC of our experimental 
strains. 
Fitness estimation by competition experiment 
For the competition assay, a kanamycin resistant A. baylyi ADP1 strain (trpE27 
ACIAD0921::ecfp ACIAD3309::nptIII) was used as a reference marker strain [30]. Pairwise 
competition experiments for each of the evolved clones from the end point (~325 generations) 
populations and the clones from ancestral genotypes were carried out in the same culture 
conditions used to propagate the evolving populations. Specifically, each of the evolved clones, 
ancestral clones and the marker strain were taken from the freezer, plated on LB agar plates 
and incubated overnight at 30°C. Then, a single colony was transferred into 1mL of LB broth 
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in 24-well plates. These cultures were then incubated for 24 hours on an orbital shaker at 30°C 
with continuous shaking at 250 rpm, representing one complete growth cycle as has been done 
for the actual evolution experiment. Then, to start with the actual competition assay, equal 
densities of tested clone and reference marker clone were mixed in 990uL LB broth without 
antibiotics (i.e. 5uL of competitor and 5uL of reference culture was added into a well 
containing 990 uL of LB broth which represents the conditions of the actual evolution 
experiment). Individual samples (10uL) were taken immediately after mixing from the 
individual wells of 24-well plate into 990uL PBS containing 2mL tubes, returning the 24-well 
plate to the incubator, followed by dilution and plating of 100 uL on LB agar plates 
supplemented with or without kanamycin (at least 3 replicate plates per dilution per plate type). 
The rationale of this sampling at the beginning of the competition experiment was to determine 
the number of cells of both evolved clone and reference clone, then calculate the number of 
cells after 24 hours of competition, which gives an indication of the competitive ability of the 
evolved and reference strain. Thus, similarly, samples were taken after 24 hours, and serially 
diluted and plated on LB agar supplemented with or without kanamycin antibiotics. All plates 
were incubated for ~16 to 18 hours at 30°C, and subsequently colony forming units (CFUs) 
were counted visually. Then the relative fitness of the ancestral and evolved strains was 
determined according to Travisano et al. [34]. 
Genome sequencing 
Based on initial growth rates, we selected eight replicate lineages from each of the sixteen 
evolved end-point resistant genotypes for whole genome sequencing. We also selected a 
completely susceptible and three different initial resistant genotypes (i.e. rifampicin resistant 
genotype, streptomycin resistant genotype and a double resistant genotype harbouring both 
rifampicin and streptomycin resistance mutations) for whole genome sequencing. All these 
populations were also assessed with competitive fitness assays. Initially, individual clones were 
inoculated on LB agar plates from the cryotube followed by overnight incubation at 30°C. A 
single colony was then inoculated in 10mL LB broth and incubated overnight at 30°C on an 
orbital shaker (180 rpm). Then DNA extractions from pure culture of the individual clones 
were performed using PureLink® Genomic DNA Kits (Invitrogen). After extraction, DNA 
quantification was carried out using a spectrometer based microplate reader on Take3 plate 
(SynergyTM HT, Bio Tek, USA). Then samples were diluted in TRIS buffer to 8-10 ng/uL and 
stored at -20°C. Libraries were prepared using a Nextera XT kit (Illumina, San Diego, CA, 
USA) according to manufacturer’s instructions but with slight modifications. Overall, library 
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preparation comprises five different modules. In short, module 1 involves standardization of 
gDNA concentrations across samples. In module 2, input DNA is tagged and fragmented by 
the Nextera XT transposome. The Nextera XT transposome simultaneously fragments the input 
DNA and adds adapter sequences to the ends, allowing amplification by PCR in subsequent 
steps. In module 3, tagmented DNA is amplified via a limited-cycle PCR program. In module 
4, PCR-amplified DNA fragments library is subject to purify using AMPure XP beads to 
remove short library fragments from the samples. In the final module, each library is 
normalized which ensures that equal library representation has been achieved in pooled 
sample. In doing so, we run our purified samples further on the Shimadzu bioanlyzer for the 
selection of expected fragment lengths between 300 and 800bp. Then we pooled the library and 
further purified with AMPure XP beads followed by Pippin-Prep size selection (250-800 bps). 
Finally, the pooled library was sequenced using 300bp paired-end reads on the Illumina MiSeq 
platform.  
Analysis of sequencing data 
The reads including both forward and reverse reads generated from Illumina MiSeq were first 
quality trimmed and paired into consensus sequences, and then aligned with our original 
wildtype A. baylyi which we had previously assembled against the reference genome of A. 
baylyi, from the NCBI GenBank database (Accession NC_005966) [30]. All these steps were 
carried out using the program Geneious version 9.1.4 (Biomatters, Inc.). We used the ‘Find 
variations/SNPs’ tool implemented in Geneious to identify SNPs and indels with a minimum 
sequencing coverage of 5 and a variant frequency of at least 95% (see Table S2 for different 
parameters used in bioinformatics analysis). Unique mutations were identified by direct 
comparison of the ancestral strains with the evolved resistant strains. We also classified other 
spontaneous mutations that could potentially emerge in the populations propagated in medium 
without supplementing any antibiotics during the course of the evolution experiment [35] for 
example, we speculated that some mutations will emerge in the populations to adapt to LB 
medium only. A subset of SNPs identified in different locations of the genome will be further 
verified by Sanger sequencing of polymerase chain reaction (PCR) amplicons as has been done 
in chapter 3.  
Statistical analysis 
Various statistical methods were employed at the population level for data analysis. We first 
employed an analysis of variance (ANOVA) to compare growth rate of the ancestral genotypes 
with evolved endpoint populations with the genetic background and replicate lines as fixed 
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factor. Differences in growth rates among genotypes were compared between ancestral and 
evolved lines, and were measured using an ANOVA model where genetic background and 
transfer were taken as fixed factors and replicate lines were used as random factor. We also 
employed a similar model for the relative comparison of finesses for evolved population 
between transfer 50 (T50) representing about ~325 generations of evolved populations, and 
transfer 0 (T0) representing the ancestral populations. We used least square (LS) means 
contrasts in the factorial ANOVA model. Similar analysis was employed for both competitive 
fitness and e-Test MIC assay for the ancestral and evolved populations. All statistical analyses 
were carried out using JMP version 12 (SAS Institute Inc., Cary, NC, 1989-2007). 
Results 
Determining mutants genotypes 
From a susceptible ancestral genotype, we obtained a streptomycin resistant and a rifampicin 
resistant genotype through mutant screening. Sanger sequencing indicated a K43T substitution 
at the rpsL locus to be responsible for resistance to streptomycin (MIC >128 ug/mL) and a 
P573L mutation at the rpoB locus responsible for rifampicin resistance (MIC >32 ug/mL). We 
constructed a double resistant genotype carrying both of these mutations through natural 
transformation. The presence of both mutations was confirmed by Sanger sequencing and the 
strain was indeed found to be resistant to both streptomycin and rifampicin (MIC for 
rifampicin: >32ug/mL; MIC for streptomycin: >128ug/mL). This double resistant genotype 
forms the main focus of this study.  
 
Costs of resistance 
Growth rate and competitive fitness assays revealed that significant fitness costs are associated 
with the two single and the double resistant genotype (Figure 2). Fitness costs in growth rate 
were significantly higher in the double resistant genotype (p < 0.0001) compared to single 
resistant genotypes, and the cost associated with the rifampicin genotype was higher than that 
of the streptomycin genotype (p < 0.0001), and the streptomycin resistant genotype was also 
significantly different from the ancestral wild-type genotype (Table1).  
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Figure 2 Fitness cost among ancestral resistant genotypes. Results are based on growth rate are 
shown panel (a) in box plot. Here, green lines indicate the lower and upper quartile with an 
open circle represents an outlier. In panel (b), fitness cost is shown in negative competitive 
ability among three different resistant genotypes. Filled circle represent the mean negative 
competitive fitness connected. Error bar represents ±1 standard error from the mean. 
Table 1 ANOVA with mean growth rate vs. strain. Ordered differences report for comparisons 
for all pairs using Tukey-Kramer HSD test. Positive difference in a pair indicates significantly 
fitter genotype. 
Genotype -Genotype Differences SE of Diff. Lower CL Upper CL p-value 
Susc StpRRifR 0.0067385 0.000286 0.0061752 0.0073019 <0.0001* 
Susc RifR 0.0047685 0.0001811 0.0044119 0.0051252 <0.0001* 
StpR StpRRifR 0.004050 0.0002995 0.003460 0.0046399 <0.0001* 
Susc StpR 0.0026886 0.0001774 0.0023391 0.0030380 <0.0001* 
StpR RifR 0.002080 0.0002017 0.0016826 0.0024773 <0.0001* 
RifR StpRRifR 0.001970 0.0003017 0.0013758 0.0025643 <0.0001* 
 
Similarly, significant fitness cost in competitive ability was also found in all the resistant 
strains, where streptomycin and rifampicin mutant genotypes were significantly fitter than the 
double resistant genotype. However, no significant difference was between streptomycin and 
rifampicin resistant genotypes (see Table 2 for parameter estimates). 
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Table 2 LS means differences in competitive fitness cost between different genotypes. 
Comparisons for all three pairs using Tukey HSD. Positive difference in a pair indicates 
significantly fitter genotype. 
Genotype -Genotype Differnece Std Err Di Lower CL Upper CL p-value 
Stp StpRif 1.924304 0.3337942 1.06300 2.785603 <0.0001* 
Rif StpRif 1.120122 0.2977052 0.35194 1.888300 0.0046 
Stp Rif 0.0804182 0.3142568 -0.00670 1.615068 0.0521 
 
Growth rate trajectories over time 
We measured the growth rates of mixed populations for all sixty-four replicate populations 
evolving from the four different genotypes at eight different time points during the course of 
the evolution experiment. First, we observed that the mean growth rate trajectories for all 
different genotypes were stably maintained throughout the evolution experiments except fir all 
lines that originated from rifampicin and the double resistant genotype. Overall, mean fitness 
varied most in double resistant genotypes, and two distinct groups are apparent: one group 
comprising seven lineages exhibited markedly increased growth rates whereas the other nine 
lineages did not. Rifampicin resistant genotypes also showed varying degrees of fitness 
compensation. For the rest of the genotypes, no apparent trajectories were classifiable, except 
for one lineage (L13) from the streptomycin genotype, which showed a series of adaptive 
walks but this lineage converged with others in the late phase of the evolution experiment 
(Figure 3). 
 
Figure 3 Growth rate trajectories over time. The x-axis shows different sampling time points in 
day, which also corresponds to generation time. Mean growth rates over different time points 
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for all 16 mixed populations (indicated by L1-L16) evolved from each of the ancestral 
genotypes. 
Further, we investigated whether the dynamics of fitness for all the genotypes over different 
sampling points imply any statistical significance by employing a linear mixed effect model. 
We find that all the genotypes were significantly different from each other (p = <0.0001*), and 
also they significantly differ during the course of evolution (p = <0.0025*). All statistical 
parameter estimates are given in Table 3.  
 
 
Table 3 Results of a general mixed effect model. Table shows the result on the dynamics of 
fitness for different genotype and transfer. 
Source No. parm DF SSs F-ratio p-value 
Genotype 3 3 0.00045397 196.9585 <0.0001* 
Transfer 7 7 0.00002989 5.5577 <0.0001* 
Gen*Tra 21 21 00.00003450 2.1385 <0.002* 
 
The level of adaptation was further assessed by comparing growth rates of the evolved strains 
(i.e. after transfer 50, corresponding to ~325 generations) with their corresponding ancestral 
strains. We observed significant fitness differences between the T0 and T50 lineages originated 
from the double resistant genotype (StpRRifR) (ANOVA: F1, 30 = 4.3250, p = 0.0462). 
However, no significant differences were observed for the rifampicin and streptomycin 
resistant lineages (F1, 30 = 3.6629, p = 0.0652 and F1, 30 = 1.2779, p = 0.2672).  
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Figure 4 Histogram of minimum replication times. Histogram of replication time after ~325 
generation representing distribution of fitness improvement in populations (founded on each of 
the resistant genotypes) in the absence of drug. Replication time for each of the ancestral 
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resistant genotypes is indicated by dashed vertical line. Numbers indicated above the bars 
represent the number of evolved lines. 
In addition to this, we determined the distribution of minimum replication times for all 
different genotypes derived from endpoint population. We observed a higher number of double 
resistant lineages with improved fitness (10/16) than single mutant genotypes (Figure 4).  
Growth compensation as a measure of mean competitive ability 
Fitness compensation for each of the resistant genotypes from endpoint populations was further 
assessed among a subset of lineages by carrying out a head-to-head competition assays. 
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Figure 5 Mean selection rate (competitive fitness) vs. transfer (generation) of a subset of 
evolved resistant genotypes after ~325 generation. For each resistant genotype, competitive 
fitness was measured over a subset of 8 different endpoint populations at transfer 50 (8 
populations per genotype were selected based on earlier growth rate trajectories). For example, 
8 total populations for each resistant endpoint populations were tested for competitive fitness; 
At least 5 replicate measurements were made on each population and the resultant fitnesses 
(selection rates) were averaged, and finally grand completive fitness was calculated from these 
8 populations. Competitive fitness for each ancestral genotype was carried out for at least 5 
replicate measurements including the original wild type ancestor genotype. Error bar = ±1 
SEM. 
The mean relative improvement of fitness compensation was higher in rifampicin and double 
mutant genotypes than their ancestral resistant counterparts indicated by transfer 0 (Figure 5). 
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Further, pairwise mean comparisons using Student's t-tests among these genotypes revealed 
that the double resistant genotypes were significantly different from single resistant genotypes. 
This test also revealed significant differences between the two of singly resistant genotypes 
(see parameter estimates in Table 4). 
 
 
 
 
 
Table 4 LS means differences. Comparison of each pair using Student's t-test. 
Genotype -(Genotype) Differences SE of Diffe. Lower CL Upper CL p-value 
StpR StpRRifR 1.410458 0.1886498 1.037186 1.783731 <0.0001* 
RifR StpRRifR 1.010824 0.2009188 0.613228 1.40842 <0.0001* 
StpR RifR 0.399634 0.1998093 0.004238 0.79503 0.04760 
 
MIC-determination as a means of tracking the evolvability  
 
The stability of the resistance profile was determined with the end point populations. This was 
done because the change in MIC in absence of drug pressure may be linked to adaptation in a 
number of ways: a decrease in MIC to a particular drug could indicate reversion of resistance, 
whereas an increase in MIC may indicate acquisition of compensatory mutations that at the 
same time are also new resistance mutation. More specifically, if the fitness improvement 
occurs through reversion, it can be expected that antibiotic resistance level will be reduced to 
the level of wild-type ancestor strain. Alternatively, fitness improvement can be effected 
through compensatory mutations without altering or even increasing the MIC. Thus, the MIC 
of rifampicin and streptomycin was determined using E-test for all genotypes previously 
assessed with the competitive fitness assay.  
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Figure 6 Stability of the antibiotic-resistant phenotype in the subsets of resistance populations 
after ~325 generations. MICs of ancestral rifampicin resistant population (Rif) was 32 mg/mL, 
ancestral streptomycin resistant genotype (Stp) was 128 mg/mL, and ancestral double mutant 
genotype (StpRRifR) was 32 mg/mL for rifampicin and 128 for streptomycin (this is based on 
the maximum E-stripe concentration for each antibiotic). 
This MIC profile among different resistant genotypes (Figure 6) revealed that most lineages 
did not exhibit any change in MIC, and that there was no an incident of reversion. For 
streptomycin resistant genotypes, marginal increases in MIC to rifampicin were observed 
without shifting the level of resistance to the original streptomycin antibiotic. For the 
rifampicin resistant genotype, in most of the cases, we observed no apparent changes in MIC to 
streptomycin, except in one case where resistance to streptomycin was increased by more than 
2.5 fold. This higher MIC to streptomycin in this lineage could be the result of either 
acquisition of new drug specific resistance mutation (i.e. mutation in rpsL or rrs gene) or this 
lineage could have acquired adaptive resistance through phenotypic heterogeneity. In one 
evolved lineage of rifampicin resistant genotype, we observed a two-fold reduction in MIC of 
rifampicin antibiotics; and this could be due to either the original resistance mutation was 
swapped by a newly arising but weaker mutation or by other mutation during the course of 
evolution. Interestingly, all double resistant populations kept their MIC level unchanged, 
indicating that double mutant genotypes improved their average fitness through other 
mechanisms. 
Genomic basis of compensation 
We further explored the genomic basis of compensatory adaptations by carrying out whole 
genome sequencing on the evolved populations. Our objective was to investigate the actual 
mechanism of compensation at the genomic level after ~325 generations to primary resistance 
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mutations carried by both single and double resistant genotypes. We attempted to identify de 
novo mutations that accumulated in these genotypes during the course of evolution to uncover: 
1) how pervasive these adaptive mutations are, and where they appear in the genome, 2) to 
what extent compensatory mutations are influenced by already existing drug specific resistance 
mutations, 3) which adaptive routes are more accessible, for example, adaptation to the cost of 
single vs. double resistance mutation, 4) to what extent de novo gene disruption can affect the 
evolvability in both single and double resistant genotypes, 5) to determine what genetic 
changes further exacerbate the cost of resistance (this is of particular importance for infection 
control), 6) to determine the mutations that improve fitness to an optimal level (for example, by 
rare mutation suggested by Fisher geometric model), 7) to determine mutations that are 
associated with pleotropic effects, for example, a genotype with a newly arisen mutation in a 
costly background is further away from the fitness peak, 8) or whether newly arising mutations 
that can both compensate and give rise to resistance to a new drug through epistatic 
interactions between resistance and compensatory mutations [29, 36], 9) whether compensation 
achieved by inactivation of other genes, for example through truncation or premature 
termination in the costly genome. Thus, we will be able to determine whether evolutionary 
adaptation to the cost of multiple drug resistance by compensatory mutations generates any 
substantial genetic variations, which differ from compensation to the cost of single drug 
resistant mutations. Therefore, we sequenced clones from eight independently evolved lines 
from each of the three evolved resistant genotypes, all of which we previously assessed for 
growth rate, competitive fitness, and antimicrobial susceptibility. Additionally, we sequenced 
the three ancestral resistant genotypes to compare the genomic changes underlying 
compensatory adaptations. 
Whole genome sequencing investigation on the ancestral genotypes 
Whole genome sequencing of ancestral origin has revealed an additional mutation in a less 
characterised cyoA locus in a double resistant genotype. This mutation unexpectedly occurred 
during construction of this genotype through natural transformation and this mutation also 
produced significant fitness cost (ANOVA: F-test: 319.87; DF: 2; p-value = <0.001). Although 
we did not construct any genotypes with identical cyoA mutation alone or in combination with 
other resistance mutations to determine the actual effect on bacterial physiology we assume 
that this additional mutation may also cause additional fitness cost through epistatic interaction 
(Figure S1). However, it has been reported that disruption in cyoA can give adaptive resistance 
to multiple antibiotics [37, 38]. We included this double resistant genotypes in our evolution 
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experiment and evolved for ~325 generations along with other three different genotypes since 
natural populations always undergo simultaneous acquisition of genetic determinants along 
with resistant elements from their exogenous sources via recombination. Therefore, we 
assumed that such additional deleterious mutations might occur in both natural populations as 
well as in the laboratory populations but the true role of such additional mutations were 
unexplored in absence of whole genomic information. 
 
Whole genome sequencing investigation on the evolved endpoint populations 
Whole genome sequencing detected 27 secondary mutations in each subset of the evolved 
endpoint populations founded on three different genotypes during the course of evolution 
(Table 5). Among these, we identified seven different secondary mutations in five of the eight 
different StpR evolved populations. However, none of these mutations occurred in putative 
compensatory loci such as rpsL, rpsD, rpsE, and rrs (detailed information on this mutation can 
be found in supplementary table S4). Three out of those five StpR evolved lineages each 
carried a single point mutation; two lineages each carried two different mutations. One lineage 
carried a secondary mutation in gene encoding FSR protein, which greatly benefitted growth 
improvement (by ~6%). Minor growth improvement (~2%) was also observed in a single 
lineage carrying an intergenic mutation between a transcriptional regulatory protein and citrate 
transporter protein. We also identified 4 different secondary mutations in three different genes 
of unknown function encoding hypothetical proteins (HPs). We observed these 4 different 
mutation in three different lineages. Two lineages (C and E) harboured the identical 
substitution mutation in the same genetic location suggesting parallel evolution. Lineage C 
improved its fitness cost by ~3%, which was accompanied by an additional point mutation 
(synonymous) in a gene encoding an ABC-transporter protein. 
 
 Protein/locus affected 
Genotype FSR Int ABC HP RNAP S4 HRP TCS Lrp CyoA Lon 
RifR 0/8 0/8 0/8 0/8 6/8 0/8 1/8 1/8 1/8 0/8 0/8 
StpR 1/8 1/8 1/8 4/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 
RifRStpR 0/8 0/8 0/8 1/8 3/8 1/8 0/8 1/8 0/8 4/8 1/8 
FSR-follic siderophore receptor protein; Int-intergenic mutation; ABC- abc tranporter protein; 
RNAP-RNA-polymerase; S4-ribosomal subunit protein 4; TCS-two component sensory 
kinase; Lrp- Leucine responsive protein; Lon – Lon protease 
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Mutations in these hypothetical loci suggest that all these mutations are alone not sufficient to 
improve the fitness burden, but the cost reduction is accelerated by a mutation in another 
genetic locus through an epistatic interaction. However, lineage E carried two secondary 
mutations (one non-synonymous and another one synonymous mutation) in a hypothetical gene 
that caused about 5% increase in fitness cost, and another lineage (line F) carried a single 
mutation in a hypothetical gene that caused about 1.4% increased fitness cost. However, three 
lineages (3/8) did not carry any secondary mutations where fitness was improved by ~2% 
among two of these lineages (lineage G and H), but the cost was further increased in one 
lineage (lineage D). The MIC of streptomycin was unchanged in all the evolved lineages, but 
interestingly increased resistance to rifampicin was observed among all these replicate 
populations evolved from streptomycin resistance genotypes (Figure 6) suggesting that less 
sensitive resistant genotypes (i.e. streptomycin resistance mutation with low fitness cost) 
helped these populations develop resistance to a new antibiotic (i.e. rifampicin) by avoiding 
both extreme beneficial or deleterious secondary mutations in the absence of selection 
pressure. 
 
In seven out of eight RifR evolved populations, we identified a total of nine secondary 
mutations, of which six are intragenic mutations in rpoB (the same locus that carries the 
primary mutation conferring resistance to rifampicin), and four extragenic mutations 
(secondary mutations in loci other than the primary resistance locus). In one lineage we did not 
identify any secondary mutation. Among these six secondary mutations found in rpoB, four 
were newly arisen putative compensatory mutations of which two lineages carried the same 
mutation (lineage A and B), and thus suggesting a parallel compensatory evolution in this 
resistance locus. Surprisingly, in one lineage (lineage D), the primary resistance mutation 
(rpoBP571L) was replaced by another mutation (rpoBL571H). This lineage experienced 
greater fitness improvement (by more than 23%) than any other rifampicin resistant evolved 
lineages. In this clone, we also observed a reduced MIC to rifampicin (Figure 6) suggesting 
that this mutation represents an incomplete reversion mutation at the phenotypic level. This 
lineage also carried an additional truncation mutation (Q->Stop) in a gene encoding a 
multifunctional two-component sensory (TCS) kinase. A similar truncation mutation such as a 
premature stop codon in glutamine amino acid (Q->Stop) was also observed in a gene 
encoding two-component sensory kinase (lineage E) whose fitness cost was further intensified 
by more than 5% (detailed information for the observed mutation can be found in 
supplementary Table S5). In lineage H, a new extragenic secondary mutation was also 
158 
 
observed in lrp gene encoding a global regulatory protein (leucine responsive protein) where 
fitness was improved by 2%. 
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Figure 7 Observed secondary mutations in different resistance lineages after ~325 generations 
in absence of drug pressure. Empty bar represents no secondary mutations observed after ~325 
generations for particular lineages. 
Disruption in this gene has been associated with reduced virulence in E. coli [39] suggesting a 
putative new mechanism of compensatory adaptation to the cost of rifampicin resistance. 
Overall, all the secondary mutations observed in the evolved RifR populations were sufficient 
to ameliorate the fitness cost incurred by rpoB P571L rifampicin resistance mutation (fitness 
cost improvement ranging from 3 to 23 %), these secondary mutations observed in rifampicin 
resistance evolved lineages are thus regarded as putative compensatory mutations. Such 
intragenic compensation has previously been identified in experimental bacterial population 
[17]. No other known secondary mutations (i.e. putative compensatory mutations in rpoA and 
rpoC) were observed in any of the eight evolved Rifr lineages (Table S5). 
 
Following the evolution experiment, the double resistant lineages had acquired 11 different 
secondary mutations distributed in five out of eight lineages (Figure 9). Among these, three 
lineages of each carried a single intragenic secondary mutation where a putative compensatory 
mutation appeared in the same rpoB locus. Four lineages (B, C, E, F) carried a reversion 
mutation in the cyoA gene and, surprisingly, all these four lineages improved their growth rates 
ranging from 5% to 17%. Among these 4 lineages, we also identified a mutation in rpsD gene 
encoding small subunit of ribosome called S4 together with a secondary mutation in rpoB and 
a cyoA reversion mutation, and the highest fitness improvement was observed in this lineage 
(E). 
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Figure 8 Observed mutations and corresponding fitness compensation among RifRStpR double 
resistant evolved lineages. Top panel shows the secondary mutations observed in the evolved 
lineages, and the bottom panel shows relative fitness compensation [% relative growth rate]. 
All the green bars and red bars represent positive and negative fitness respectively. Lineage G 
(indicated by the red bar) compensated cost compared to other three (A, D and H) by 
harbouring a secondary mutation in lon the gene. 
However, one lineage (F) improved fitness by 5% without harbouring any secondary mutations 
in  rpoB or rpsL locus suggesting that the greater fitness compensation in this lineage was 
mediated by cyoA reversion together with a secondary mutation in gene encoding TCS kinase 
(Figure 8). Interestingly, all the rpoB mutations found in the double resistance genotypes were 
distinct, and none of them were found to be common in any lineages initialised with the RifR 
resistant genotype (Figure 9). 
  
0kb 4kb 2kb 
P->L T->A 
N->K 
P->H 
S->A 
N->T 
D->A 
A->S 
 
Figure 9 A map of rpoB gene showing the distribution of secondary mutations observed in the 
populations evolved from both RifR and RifRStpR after ~325 generations. The amino acid 
change highlighted in red is the primary rifampicin resistance mutation. Green and blue colour 
indicates the secondary mutations observed in the RifR and RifRStpR population, respectively. 
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By contrast, in four lineages (A, D, G and H), we did not identify any secondary mutation in 
rpoB, rpsD or cyoA, and there was no compensation of the cost of resistance among these three 
lineages. However, we observed a secondary mutation in a gene encoding Lon protease in one 
lineage (G). This lineage experienced improved fitness compared to other three lineages (A, D, 
and H) suggesting a putative compensatory mutation. Spontaneous mutation in the lon gene 
has been found to be associated with tetracycline or chloramphenicol resistant E. coli [40]. 
However, in a recent study, it has been shown that mutations in lon genes confer low level of 
multidrug resistance via the activation of efflux pump systems [41]. For example, mutated Lon 
protease stabilizes MarA and SoxA transcriptional activators and induces the AcrAB-TolC 
efflux-pump, which in turn confers multidrug resistance. However, the co-occurrence of this 
mutation along with other resistance mutations may suggest that this mutation may be involved 
in simultaneously improving fitness as well as conferring strong resistance to other drugs 
through epistatic interaction.   
Discussion 
The frequency of resistant bacteria and their subsequent adaptation in the absence of 
antimicrobial compounds are associated with the amount of antibiotics used, the cost of 
resistance mutations (i.e., reduced competitive ability compared to the susceptible 
counterparts), and the ability of resistant genotypes to compensate this cost [14, 36-39]. This 
phenomenon of compensation in bacterial populations has been well characterised by 
employing both in vivo and in vitro experiments in many studies [17, 18, 40-42]. It is assumed 
that compensatory adaptation to the cost of resistance is critical to these evolutionary dynamics 
because it can slow or prevent the extinction of resistant genotypes in the absence of selection 
pressure. More specifically, the mechanism of compensation is thought to depend on many 
factors such as mutation in a particular genetic background, the degree of cost associated with 
the resistance mutation as well as adaptation to the infected hosts [13, 14, 22, 42]. In previous 
studies [16-18, 43, 44], the mechanism of compensation was mostly investigated by employing 
a bacterial population resistant to a single drug. For example, the mechanism of compensation 
was studied in strains carrying known rifampicin (rpoB resistance) and streptomycin (rpsL 
resistance) mutations. However, no comparative studies at the genomic level have been 
conducted to uncover the genetics of compensation in strains carrying multiple drug resistance 
mutations. 
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In this study, whole genome sequencing of a double resistant genotype of ancestral origin 
revealed an additional mutation in the cyoA gene (which encodes cytochrome bo terminal 
oxidase A associated with respiratory chain system) with other two distinct drug-specific 
resistance mutations in the rpoB and rpsL loci. This mutation in cyoA locus unexpectedly 
occurred during construction of this genotype by natural transformation assay. The mutation 
may have arisen for a number of reasons, for example: 1) natural transformation requires 
competent cells which are more vulnerable to the environmental perturbation, 2) natural 
transformation itself a costly metabolic process which involves many genes to take up the 
foreign DNA pieces into cytoplasm, and 3) this process also requires sets of other genes in the 
final step of homologous recombination. In our case, the additional cost of this transformation 
process incurred by a costly rpoB mutation may have given rise to this additional mutation. 
This mutant has previously been found to be associated with reduced rates of cellular 
respiration [45]. Recent studies also suggested that altered cellular respiration could be the 
result of the altered translation process, or translation inhibition may have other non-metabolic 
effects on the cell which in turn could give rise to decreased susceptibility to bactericidal 
antibiotics, as has recently been shown by a study carried out with mutant cyoA harbouring E. 
coli, which conferred high a level of resistance against bactericidal antibiotics such as 
norfloxacin, ampicillin, and gentamicin [37, 38]. Therefore, motivated by these findings, we 
also assume that this additional cyoA mutation was responsible for reduced growth rate through 
epistatic interaction, and also may have given rise to high-level resistance to other bactericidal 
antibiotics in our study organism that we have not tested in our yet. In addition to this, 
additional mutations in other genetic loci may occur in both single and multidrug resistant 
bacterial population of laboratory and natural origin. This additional mutation may have 
profound effects on the rate of bacterial adaptation in the absence of drug pressure, especially 
in cases where resistance to multiple drugs conferred by mutations at multiple loci. One recent 
study [44] has opined the importance of general beneficial mutations in overcoming the fitness 
cost of the compensatory mutation. This study has suggested to include antibiotic-resistant 
mutants that carry other types of resistance mutations and assess compensatory adaptation in 
those genotypes evolved from experimental evolution, since the mechanism of antibiotic 
resistance is diverse and many other parts of the genome are also affected by antibiotics, for 
example resistant genotypes may enriched with other beneficial or deleterious mutations in the 
genome. 
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One of the main findings in our study is that 50% of evolved multidrug resistant lineages (4/8 
lineages) carried reversion mutations in the cyoA gene, suggesting parallel evolution [46, 47]. 
Thus, the cyoA gene in these populations under strong positive selection also played a central 
role in the adaptive process.  Surprisingly, three of these lineages (B, C, E) experienced higher 
fitness compensation and also harboured a secondary mutation in the rpoB locus, but one 
lineage (F) was less fit because this lineage evolved with a mutation in a gene encoding TCS 
kinase protein with no secondary mutation in the rpoB locus. This result suggests that all the 
rpoB secondary mutations that occurred in these populations were indeed involved in the 
compensatory adaptation. Most notably one lineage (E) that experienced greater fitness 
improvement (17.5%) harboured a secondary mutation in the rpsD gene. Mutations in the rpsD 
gene are well known for fitness compensation of rpsL mutations conferring resistance to 
streptomycin [48]. It is also worth mentioning that rpsD mutations are associated with fitness 
compensation of streptomycin resistance mutations in the rpsL gene, but in the absence of rpsL 
mutations rpsD mutations alone can confer resistance to streptomycin [43]. Thus, these results 
suggest that, even in presence of an additional mutation in the cyoA locus, both rpoB and rpsD 
are indeed common loci, where most of the secondary mutations involved in fitness 
compensation for rifampicin and streptomycin resistant genotypes occurred. In one case, we 
have also found a minor fitness compensation induced by a secondary mutation in a gene 
encoding two-component sensory kinase (TCS). This result suggests that adaptation to the cost 
of multiple resistance mutations can also be achieved by acquiring secondary mutation in off-
targeted region (different from commonly found compensatory regions, such as rpoB and 
rpoD) of the genome. However, we have not observed any fitness compensation among four 
other lineages owing to the fact that none of these lineages harboured any secondary mutations 
like what we have observed in four different fitness-compensatory double resistant lineages. 
Interestingly, in one lineage, we have observed that fitness cost was further exacerbated by a 
mutation in the lon gene previously reported to be associated with low level of multidrug 
resistance [41, 49-51]. Competitive fitness estimate for all the double resistant genotypes also 
revealed that all the lineages harbouring secondary mutations together with cyoA reversion 
greatly improved fitness cost after ~325 generation. Together with this, our results suggest that 
fitness compensation among multidrug resistant population is caused mainly by secondary 
mutations commonly occurring at compensatory loci (targeted regions such as rpoB and rpsL) 
and also follow a parallel evolutionary trajectory (i.e. reversion mutation) for costly mutations 
in other loci in the same genome. Furthermore, our results suggest that in the absence of 
compensation multidrug resistant populations can intensify their fitness cost further by 
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acquiring additional drug resistance mutations in other locations of the genome. Reversion in 
the cyoA locus may also suggest that some genomic loci may accidentally acquire deleterious 
mutations, which can then revert back to the original state at high rate owing to the cost 
associated with it.   
 
We have observed seven different secondary mutations in five of the eight different StpR 
evolved populations, but none of them were found in the expected rpsD or rpsE loci [16, 48]. 
Most of the observed secondary mutations in StpR resistant evolved lineages were either 
neutral or deleterious given that some mutations were either involved in negligible fitness 
compensation or were found to be associated with further increase in fitness cost. This could be 
due to the fact that mutation conferring resistance to streptomycin antibiotic incurred low 
fitness cost in absence of drug pressure; thus this low cost resistance mutation has given rise to 
secondary mutations in less-known genetic loci which are involved in minor fitness 
compensation or slight increases in fitness cost, as has been found in earlier studies [52]. 
Among these, in two lineages, we have observed identical transversion mutation in genes 
encoding hypothetical proteins, which were not involved in significant fitness compensation. 
This observation, though found in a limited number of lineages, may also suggest parallel 
evolution in uncharacterised hypothetical genes of strains carrying streptomycin resistance 
mutation in rpsL locus. Among these, only a single lineage carried a secondary mutation in a 
gene encoding ferric siderophore receptor protein greatly benefitted from growth improvement 
(by ~6%).  However, one lineage that carried a secondary mutation in a hypothetical gene 
improved its fitness by about 3%, which was accompanied by an additional point mutation 
(synonymous) in a gene encoding the ABC-transporter protein. Mutations in these hypothetical 
loci suggest that all these mutations are alone not sufficient to improve the fitness burden, but 
the cost reduction could be accelerated by a mutation in other genetic locus through an epistatic 
interaction [16, 53]. The MIC of streptomycin was unchanged in all the evolved lineages, but 
interestingly increased resistance to rifampicin was observed among all these replicate 
populations evolved from streptomycin resistance genotypes (Figure 6) suggesting that less 
sensitive resistant genotypes (i.e. a streptomycin resistance mutation with low fitness cost) 
helped these populations develop resistance to a new antibiotic (i.e. rifampicin) by avoiding 
both extremely beneficial or deleterious secondary mutations in the absence of selection 
pressure. However, none of these secondary mutations were commonly detected in any of the 
double resistant genotypes. This could be explained by the fact that selection for the low-cost 
resistance mutation (conferred by streptomycin resistance mutation) in the double resistant 
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background is less effective since the selection of compensatory adaptation for the costly 
rifampicin resistant mutation in rpoB locus in the genome is stronger. 
 
We observed secondary mutations in six different RifR resistant evolved lineages, whereas no 
secondary mutation was observed for two lineages. Interestingly, two of these lineages have 
evolved with an identical secondary mutation in the rpoB gene suggesting parallel evolution 
and thus this mutation was fixed in these populations by positive selection. Interestingly, this 
mutation has also helped these lineages recover maximum fitness. We have also identified 
identical transition mutations in two other lineages but in two different loci; in one lineage this 
mutation was accompanied by a secondary mutation in the rpoB gene and improved fitness, 
whereas this transition mutation was found in another locus but not accompanied by other 
secondary mutations and fitness cost was further accelerated in this lineage. These results 
support the proposition that this secondary mutation in rpoB locus is indeed a fitness 
compensatory mutation which can improve fitness to a greater extent in presence of a transition 
mutation in other loci, but fitness is deteriorated further by a secondary transition mutation in 
the absence of a secondary mutation in the rpoB locus. In addition to this, our results support 
the notion that owing to the costly resistance mutation, rifampicin resistant genotypes evolved 
with more compensatory mutations rather than other beneficial mutation. 
 
Furthermore, we were interested to see whether the secondary mutations that occurred in RifR 
lineages were also observed in the RifRStpR lineages. Therefore, we mapped the location of all 
rpoB secondary mutations (Figure 9). The map shows that none of these mutations were 
commonly shared by any RifR and RifRStpR evolved populations suggesting that the genetic 
basis of compensation of multidrug resistant bacteria is independent of the genetic 
backgrounds associated with the single drug resistant bacteria. In three other lineages of 
RifRStpR, fitness costs were further magnified where no secondary mutations were observed. 
In all these double mutant lineages, the MIC to both rifampicin and streptomycin remained 
unchanged. 
 
Our experimental evolution experiment using single and double resistant genotypes with an 
additional mutation has revealed the genetic basis of adaptation to the cost of resistance. In 
most cases, we have observed minor improvements in fitness due to off-targeted beneficial 
mutations, and this has constrained the compensatory evolution which is thought to occur in 
the same protein or pathway where antibiotic resistance mutations also arise [1, 54] . In our 
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case, we have observed pathway-specific secondary mutations, which improved highest fitness 
among genotypes belonging to both rifampicin resistant genotype and the double resistant 
genotype, highlighting the dependency of compensatory adaptation on costly resistance 
mutation. 
 
In conclusion, our data supports the empirical observation that genetic basis of compensation 
in both single and double resistant genotype depends on both intragenic and extragenic 
mutations. In double resistant genotypes, this compensation is independent of the genetic 
background of mutations occurred in single resistant genotypes. Furthermore, we have 
identified some regions in the rpoB locus from costly RifR and RifRStpR lineages where most 
of the secondary mutations were observed. Overall, the results we have presented here further 
increase our understanding of the adaptive molecular evolution, and partially explain the 
increasing clinical problem of multidrug resistant bacteria. 
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Supplementary materials 
Table S 4 List of primers used in amplifying target genes. 
 
Table S5 PCR master mix preparation per reaction 
Gene name Primer sequence 
rpoB 1 (forward) TTCGATTCAGGTCGACTCGT 
rpoB 1 (reverse) CAGGCGTTCTGGAACAAGAT 
rpoB 2 (forward) TGGATCAAAACAACCCATTG 
rpoB 2 (reverse) ATCGCCACGACCCACTTTAT 
rrs 1 (forward) GGCAGGCTTAACACATGCAA 
rrs 1 (reverse) CTACGCATTTCACCGCTACA 
rrs 1 (forward) CTGGAGGAATACCGATGGCG 
rrs 1 (reverse) TAACCGCCCTCTTTGCAGTT 
rpsL (forward) ATGGCAACAACAAATCAGTT 
rpsL (reverse) TTATTTCTTAGGACGTTTAG 
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Reagents Amount [uL/reaction tube] 
PCR buffer 10x 2.5 
MgCl2 25 mM 2.5 
dNTP 10mM 0.5 
TaqGold 5U /µL 0.1 
Primer mix (conc. 0.5µM) (F+R)  1.5 
Sigma H2O 17.9 
Template DNA 5 
Tolal volume  30 
 
Table S6 Setup for PCR program 
PCR program:      
Step Temperature Time 
1 (hold) 95°C 6 minutes 
2 (denaturation) 94°C 45 seconds 
3 (annealing) 58°C 45 seconds 
4 (elongation) 72°C 2 minutes 
5 (repetition) Step 2 to 4 for 35 cycles   
6 (final elongation) 72°C 10 minutes 
 
 
Table S7 Observed mutations in the evolved streptomycin resistant lineages. 
Original 
lineage 
Technical 
lineage 
Position Amino Acid 
Change 
Protein Effect Mutaion history 
3 A 732,196 V -> M Substitution FSR 
3 A 865,048 K -> T Substitution Original rpsL 
resistance mutation 
5 B 2,755,427 Intergenic Intergenic Int (between Trp and 
CitN) 
5 B 865,048 K -> T Substitution Original rpsL 
resistance mutation 
6 C 865,048 K -> T Substitution Original rpsL 
resistance mutation 
6 C 943,763 I -> R Substitution HP 
6 C 1,487,504 L -> L Synonymous ABC transporter 
7 D 865,048 K -> T Substitution Original rpsL 
resistance mutation 
8 E 943,763 I -> R Substitution HP 
8 E 865,048 K -> T Substitution Original rpsL 
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resistance 
mutation 
8 E 2,747,986 T-> T Synonymous HP 
9 F 865,048 K -> T Substitution Original rpsL 
resistance mutation 
9 F 294,112 M -> T Substitution HP 
10 G 865,048 K -> T Substitution Original rpsL 
resistance mutation 
11 H 865,048 K -> T Substitution Original rpsL 
resistance mutation 
 
 
 
 
 
 
Table S8 Observed mutation in the evolved rifampicin resistant lineages. 
Lineage Technical 
lineage 
Position Amino acid 
change 
Protein ffect Mutation history 
1 A 304,167 P -> L Substitution rpoB, original mutaion 
1 A 302,864 T -> A Substitution rpoB, compensatory 
2 B 302,864 T -> A Substitution rpoB, compensatory 
2 B 304,167 P -> L Substitution rpoB, original mutaion 
3 C 304,167 P -> L Substitution rpoB, original mutaion 
3 C 304,608 D -> A Substitution rpoB, compensatory 
4 D 304,167 P -> H Substitution New mutation in rpoB 
4 D 931,154 Q -> Stop Truncation hemagglutinin/hemolysin-related protein 
5 E 304,167 P -> L Substitution rpoB, original mutaion 
5 E 3,392,952 Q -> Stop Truncation Two component sensor kinase  
8 F 304,167 P -> L Substitution rpoB, original mutaion 
8 F 304,196 S -> A Substitution rpoB, compensatory 
10 G 304,167 P -> L Substitution rpoB, original mutaion 
15 H 115,202 Y -> C Substitution Lrp 
15 H 304,167 P -> L Substitution rpoB original mutation  
172 
 
 
 
 
 
 
 
 
 
Table S9 Observed mutation in the evolved double resistant evolved lineages 
Lineage Technical 
lineage 
Position Amino 
acid 
change 
Type of mutaion Mutation history 
1 A 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
1 A 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
1 A 2,391,960 S -> P Nonsynonymous Original cyoA mutation 
2 B 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
2 B 304,466 A -> S Nonsynonymous Compensatory 
2 B 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
2 B 2,392,267 S -> L Nonsynonymous Compensatory 
4 C 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
4 C 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
6 D 302,860 N -> K Nonsynonymous Compensatory 
6 D 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
6 D 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
9 E 304,029 N -> T Nonsynonymous Compensatory 
9 E 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
9 E 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
9 E 3,123,145 S -> F Nonsynonymous Compensatory 
10 F 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
10 F 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
10 F 3,392,837 S -> R Nonsynonymous Compensatory 
11 G 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
11 G 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
11 G 1,102,100 G -> D Nonsynonymous Compensatory 
11 G 2,391,960 S -> P Nonsynonymous Original cyoA mutation 
16 H 304,167 P -> L Nonsynonymous rpoB original resistance mutation 
16 H 865,048 K -> T Nonsynonymous Original rpsL resistance mutation 
16 H 2,391,960 S -> P Nonsynonymous Original cyoA mutation 
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Figure S5 Fitness of double resistant genotype. Plot shows two different double mutant 
genotypes (StpRRifR) with a star indicating an additional mutation in cyoA harboured by one 
double resistant (StpRRifR) genotype. locus and a completely susceptible genotype. Error bar =  
±1 S.E.M. Susc: completely susceptible genotype; StpRRifR: double mutant genotype 
harbouring both K43T in rpsL gene and P571L mutation in rpoB gene. 
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Chapter 5: General discussion 
Multidrug therapy has been regarded as an effective treatment strategy over traditional 
monotherapy because of the rapid evolution of resistant pathogen against single drug. For 
example, combination therapy produces effective therapeutic response by producing 
synergistic interactions with different cellular targets of the pathogen simultaneously [1].  
Therefore, drug combination yet regarded as a standard-of-care treatment. One prominent 
example of such treatment protocol widely being used is against M. tuberculosis. In recent 
days this therapy is also extensively being prescribed against many other important clinical 
pathogens, such as Gram negative bacilli [2]. However, the widespread prevalence of bacterial 
resistance to multiple antibiotics has restricted our current therapeutic arsenal to a greater 
extent. This is due to the fact that multidrug resistance remains a poorly understood biological 
phenomenon. Therefore, evolution of de novo resistance and subsequent adaptation to multiple 
drugs present both practical and theoretical challenges for proposing successful therapeutic 
interventions and control of such problematic infectious organisms. 
  
Many earlier studies have drawn different conclusions concerning factors contributing to the 
rate of resistance evolution under varying contexts, including the molecular characteristics of 
the resistance mutations, the fitness effects of drug resistance mutations in the presence and 
absence of drug induced selective pressure, and how these factors impact the evolutionary 
trajectories of the resistant population [3-7]. However, it is not fully understood how de novo 
multidrug resistance evolution takes place in an environment enriched with drug combinations. 
In relation to this, we remain largely ignorant of many factors, for example to what extent two-
drug pharmacodynamics, drug-drug interaction, cross-resistance, epistasis, recombination and 
compensatory mutations contribute to the emergence, spread and adaptation of de novo 
multidrug resistance in bacteria. These factors are important in predicting and preventing future 
multidrug resistance evolution [8]; therefore these factors deserve to be assessed by taking 
proper experimental approaches. This PhD thesis attempted to expand our understanding 
further by investigating these factors involving the de novo multidrug resistance evolution and 
subsequent adaptation under laboratory conditions. 
 
In chapter 2, fitness landscapes comprising both susceptible and resistant genotypes were 
characterised under two-drug antimicrobial therapy to understand the evolutionary dynamics of 
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mutations at multiple loci conferring resistance to multiple drugs. Specifically, motivated by a 
recent theoretical work [9], I investigated to what extent two-drug pharmacodynamics, drug-
drug interaction, and cross-resistance are associated with epistasis – an important property of 
the pharmacodynamic fitness landscapes and a determinant of the evolution of antibiotic 
resistance [10, 11]. Epistasis can occur between genes [12], within a single gene encoding a 
single resistance protein [13, 14], or between chromosomal gene and plasmid [15]. Many 
studies have identified a pervasive epistasis in bacterial adaptive evolution of multidrug 
resistance under diverse conditions. For example, in two studies positive epistasis between 
resistance mutations was reported in the cost of resistance [16, 17]. 
  
Here, our results show mostly weak or no epistasis between different sets of resistance 
conferring mutations in absence or presence of varying concentrations of two-drug 
combinations. In all but except one cases (i.e., epistasis between kanamycin-rifampicin and 
kanamycin-streptomycin resistance mutation) diminished fitness for all double resistant 
genotype was apparent in absence of drug pressure. These slower growth rates in absence of 
drug pressure were mostly due to the fitness cost incurred by drug specific resistant mutations 
occurred in the chromosomes, which has given rise to non-epistatic fitness landscapes. 
Although the genetic context is different, such non-epistatic fitness landscape was previously 
reported in E. coli [18], but at the same time our result in absence of drug pressure differs from 
earlier empirical studies where positive epistasis was pervasive [17, 19]. Therefore, from our 
data it is apparent that in order to have an epistatic effect on the fitness landscape, genetic 
background or mutational history with degree of fitness cost incurred by different resistance 
conferring mutations is important component. We observed negative epistasis between 
rifampicin and streptomycin resistance mutation when the concentration of rifampicin was 
higher and combined with streptomycin antibiotics. This could be explained by the fact that the 
high cost rifampicin resistance mutation requires higher concentration of rifampicin antibiotic 
in order to release its high fitness cost. However, it is also important to mention here that an 
additional point mutation (i.e. mutation in cyoA gene we identified by whole genome 
sequencing) was present in this genotype; cyoA was previously reported to be involved in 
bacterial intrinsic physiological constraint [20-22] and also incurred additional fitness cost. We 
speculate that without this additional mutation, the fitness landscape comprising this genotype 
might also be less or non-epistatic. Therefore, we suspect that this type of deleterious mutation 
may be also have occurred and confounded previous studies where epistasis was measured 
without conducting whole genome sequencing [16, 17, 23, 24]. 
176 
 
 
We further investigated the occurrence of cross-resistance and its association with epistasis. 
Theoretical observation suggests that epistasis can emerge when cross-resistance is pervasive. 
For example, in presence of cross-resistance (i.e., when both drugs confer resistance to each 
other with the same degree) positive epistasis will ensue when two resistance mutations jointly 
increase the MIC of both drugs but negative epistasis will follow when combined effect of both 
mutations only entails slightly increase or does not increase in MIC compared to individual 
mutational effect [51]. Multidrug resistance through cross-resistance has already been reported 
in many clinical situations. For example, bacteria harbouring a single point mutation or a 
resistance enzyme capable of neutralizing many different antibiotics, including NDM-1 (New-
Delhi Metallo-β-lactamase carried by the plasmid) producing K. pneumoniae capable of 
hydrolysing many other different antibiotics [25], or altered efflux–pump mediated cross-
resistance has also been found to be associated with resistance to multiple drugs in many 
bacterial species, including P. aeruginosa and many other Gram negative bacilli [26, 27]. We 
also observed cross-resistance in single resistant genotype; for example streptomycin resistant 
genotype can grow slowly in presence of high concentration of rifampicin or kanamycin. The 
observed cross-resistance between streptomycin and kanamycin would be due to the fact that 
both antibiotics belong to the same chemical class and also target the same cellular process. 
Therefore, only a single resistance gene can provide accelerated growth advantage. Our result 
is also well aligned with a previous systematic study, which also identified cross-resistance 
between these two drugs [28]. However, in another case we observed that the same resistant 
genotype exhibited cross-resistance when exposed to rifampicin antibiotics and this finding 
differ by previous study [28]. One plausible explanation is such that both antibiotics target the 
same flow of the cellular process of protein synthesis, involving bacterial transcription and 
translation inhibition. This means that a genotype with an altered protein synthesis machinery 
may be capable of conferring resistance to other antibiotics when the target of both antibiotics 
are belonging to a fundamental cellular process. Therefore, our study highlights the need for 
more detailed studies for further understanding of cross-resistance, which might be helpful in 
designing effective treatment strategies in many clinical situations, especially in the case of 
drug cycling. 
 
Theoretical and empirical studies suggest that synergistic and antagonistic drug interaction 
leading to positive and negative epistasis can also accelerate or slow down the evolution of 
multidrug resistance, respectively [9, 29]. We observed a varying degree of synergistic drug 
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interaction between kanamycin and rifampicin. This result indicates a good concordance with 
previous studies [17, 29], but differs from the expected epistasis [9], where we observed no 
epistasis. This result signifies the fact that evolution of multidrug resistance can be accelerated 
by synergistic drug interaction with non-epistatic fitness landscapes. 
Although our fitness landscapes were largely non-epistatic, we further explored how the 
mutant selection window (MSW) was affected by different genotypes in the presence of 
multidrug environment. Previous studies have reported that the MSW can vary or remain static 
under two-drug antimicrobial environment [30, 31]. In our case, we observed extended MSWs 
ranging from minimal selective concentration (MSC) to the minimum inhibitory concentration 
(MIC). This wider MSW is implicated with resistance emergence such that some drug 
concentrations allowed wild-type susceptible bacteria to grow at very low concentrations of 
kanamycin and rifampicin combination. This clearly suggests that selection of resistance, 
multidrug resistance in particular, may occur at the MSC concentration of this drug pair. 
Similar observations was made by an earlier study in experimental bacterial population in 
presence of a single drug [32]. Wider MSW was observed for the kanamycin-streptomycin 
antibiotic combination, but a narrower MSW was observed for the rifampicin and streptomycin 
drug pair followed a traditional MSW. Overall, our results suggest that selection of resistance 
against multiple drugs may also occur at sub-MIC combination of two-drugs and/or in a 
situation when there is a cross-resistance imparted by a singly resistant genotype. The result we 
have presented here also supports the concept of minimal selective concentration (MSC) as has 
been suggested by an earlier study [32]. Overall, the results we have presented here may 
enhance our understanding of the multidrug resistance evolution under variety of drug 
environments. Our results together with previous study [33] suggest that resistance selection 
occurs at very low antibiotic concentration. Therefore, our study warrants the need for the 
revision of the traditional concept of mutant selection window, especially in the case of 
evolution of multidrug resistance.  
Our results may be constrained by some factors such that we use only growth rate as the proxy 
for fitness, but we have not measured kill rates, which may be associated with epistasis beyond 
the MIC. Besides this, additional fitness components such as carrying capacity and growth rate 
at lag phase were not assessed which are also determinants of the maintenance of resistance. In 
one previous study, it has been shown that rifampicin resistant genotypes were beneficial with 
respect to growth rate but deleterious with respect to their carrying capacity despite their 
competitive superiority [20]. Our results also highlight the importance of studying epistasis 
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between multiple resistance mutations in various organisms to explore the pattern of epistasis 
across species belonging to both Gram positive and Gram negative, since previous studies, 
including ours were predominantly carried out in a limited number of bacterial systems of 
Gram negative origin. 
In chapter 3, an experimental evolution experiment was employed where replicate populations 
of both naturally competent (Rec+) and non-competent (Rec-) A. baylyi was propagated by 
daily serial transfer in presence of two antibiotics used in combinations for ~650 generation. 
Following, evolved populations were systemically investigated to understand how a fully 
susceptible bacterial population gives rise to multiple drug resistance by recombination via 
natural transformation under sub-lethal concentration of rifampicin and streptomycin 
combination. While our phenotypic observation revealed a minor effect of adaptive potential of 
recombination via natural transformation under low selection pressure, but indistinguishable 
fitness between Rec+ and Rec- populations invalidated the benefit of recombination. We 
hypothesized that such uniform fitness between Rec+ and Rec- populations might be due to 
static selection pressure maintained throughout the serial transfer, which only affected 
selectively important regulatory genes of both Rec+ and Rec- populations such that resistance 
mutations arose and selected during the early phase of evolution and this has resulted in 
elevated fitness improvement irrespective of genetic competence. This idea was supported by 
one previous study, which reports selection of resistance at very low MIC [32]. In our study, 
this prediction was supported by the fold-MIC changes in antimicrobial susceptibility, which 
revealed that adaptation to both drugs that we used for the low and high drug treatments was 
strong enough to produce selection based benefit for all the populations, irrespective of 
competence or non-competence. Taken together, these results further suggest that under 
antibiotic combination, adaptation did occur, and it was primarily driven by (1) selection of 
resistance mutations against drug pairs that we applied, and (2) limited genetic diversity in the 
evolving population in response to these selection pressures. 
 
It is assumed that recombination via natural transformation can accelerate bacterial adaptation 
with higher mutation rates or by decreasing mutational loads [34]. The mechanistic basis of 
high mutational load in the population is accomplished by bringing beneficial mutations (i.e., 
here different drug resistance mutations) from separate cells into a single genetic background. 
This phenomenon is called Fisher and Muller effect), this would increase the fixation rate of 
the recombinant cells [35]. Conversely it was suggested that competence could reduce the 
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fixation rate of the recombinant cells and eliminate them from the experimental population 
given that deleterious mutations would be naturally selected and integrated into a single 
genome alone or in combination by epistatic interaction, or the new mutations arising in the 
recipient strain would be replaced or corrected by wild type allele in the population. In the 
latter case, recombination event would be undetectable [36]. In our case, under antibiotic 
combination, we anticipated that Rec+ populations would potentially alter mutation fixation 
rate by bringing drug specific resistant mutations from separate cells into a single genetic 
background and increase the fixation rate of the recombinant cells conferring resistance to 
multiple drugs. However, after one hundred days of evolution our genome data revealed a 
lower abundance of substitution mutations compared to previous naturally transformable 
opportunistic pathogen S. pneumoniae [36], H. pylori [37], Haemophilus influenza [38], and P. 
aeruginosa [39]. Even in the presence of such low number of mutations, Rec- populations were 
enriched with high number of mutations. Large deletions and intergenic mutations were also 
different in both Rec+ and Rec- population. One plausible explanation for the high number of 
mutations in Rec- would be due to the disruption of competence associated genes, and this has 
likely help them acquire more mutations than Rec+ populations. On the contrary, Rec+ 
populations were enriched with high number of intergenic and deletion mutations than Rec- 
populations. Together these results also suggest that some of these mutations were naturally 
selected irrespective of recombination efficient and deficient populations, as has been the case 
in P. aeruginosa [52].  
 
Mutation in rpoB locus was predominantly observed in both Rec+ and Rec- populations. 
Mutation in rpoB gene encoding RNA-polymerase β-subunit is widely responsible for 
resistance to rifampicin antibiotics [46, 55]. This high abundance of rpoB mutation correlates 
with elevated fitness gain during early phase of evolution – irrespective of Rec+ and Rec- 
populations. These results also support that rpoB mutation was fixed by natural selection at the 
early phase of evolution, and also suggest that the frequency of rifampicin resistance is higher 
than the streptomycin resistance. In addition to the rpoB mutation, we observed mutations in 
other genetic loci as has been found in clinically significant bacterial pathogens. Among these, 
some mutations have been found to be associated with fitness compensation of rifampicin 
resistance mutation  [45, 46], while others contribute to the high level phenotypic resistance to 
multiple drugs, including common fluoroquinolone resistance [56-58]. Thus, we suggest that 
this high number of mutations in the populations evolved under stressful environments 
possibly played an adaptive process. Furthermore, high number of rpoB mutation indicates a 
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substantial parallel evolution, which means that natural selection acted upon this mutation in 
antibiotics induced selective environments. Genotypic parallelism has been documented in 
many experimentally evolved bacterial populations, including evolution of P. aeruginosa 
under ciprofloxacin antibiotic drug pressure [52]. Similar rpoB mutation in each replicate 
population line suggesting that the majority of parallel evolution was indeed due to the 
selection of drug specific resistance mutations. 
We further attempted to determine to what extent low number of genomic mutations that we 
have observed is associated with the evolution and maintenance of natural transformation 
under sub-lethal concentration of rifampicin and streptomycin antimicrobials. Therefore, we 
explored transformation frequency (data not presented here) among Rec+ ancestral genotype of 
A. baylyi in identical selective environments, as has been used for the evolution experiment. 
Our result on the low frequency of tranformants cells in the populations across all three 
environments suggesting that the selective environment that we have used is independent of 
transformation frequency. Additionally, low number of transformants may also reflect the fact 
that different pathways involving DNA recombination process basically corrected the altered 
DNA strand, which occurs during taking up DNA under sub-lethal selection environments. 
Thus, we observed a low number of mutations or we were unable to detect the benefit of 
natural transformations in the endpoint populations. Such diminished transformation efficiency 
in A. baylyi was previously reported under variety of environments [40, 41]. In general, the 
genomic changes that we have identified were previously shown to potentiate resistance to 
multiple other antimicrobial compounds through targeted and off-targeted mechanisms [42, 
43]. This has been reflected by the elevated level ciprofloxacin resistance after ~650 
generations. High substitution rates were previously thought to be involved in simultaneous 
fixation of several mutations in presence of an antibiotic environment [44], our results here 
suggest that several drug specific resistance mutations can be fixed under sub-lethal 
combination of two drugs even in presence of low substitution rates. Overall, we observed no 
significant evidence that recombination by natural transformation facilitates adaptation to 
multiple antibiotics, presumably because the limited number of mutations that were spreading 
in the populations prevented clonal interference. 
 
Under antibiotics induced selective environments, bacteria evolve resistance to particular 
antibiotics by acquiring drug specific genomic mutations (as has been shown in chapter 2 and 
3) or by horizontally transferred genetic material carrying resistance determinants [27, 45, 46]. 
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These mutational alterations or acquisition of new genomic determinants weaken or interfere 
with bacterial important physiological functions. And not surprisingly these interruptions are 
often associated with fitness cost, which has resulted in decreased survival, reduced growth 
rate, reduced transmission, and/or reduced virulence in pathogenic bacteria [3, 4, 47]. In 
absence of antibiotics, some of these resistance mutations disappear from the population or 
revert back to the original wild type state, or in some cases the deleterious effect of resistance 
mutations is reduced by so called second-site compensatory/suppressor mutations (CMs) at the 
same or different locus in the genome [48]. CMs are thought to be deleterious when they 
appear alone but beneficial when co-occurring with the original deleterious mutation thus 
representing a form of sign-epistasis. This is yet a poorly understood biological phenomenon, 
and has important implications not only for the evolutionary consequences of mutations but 
also for the genetic complexity of adaptation in many biological systems, including bacterial 
resistance to antibiotics [48]. The study conducted by Schrag and Perrot [49] provided direct 
evidence of the mechanism of compensation by evolving streptomycin resistant E. coli 
population in the absence of streptomycin which found 6% of fitness improvement by evolving 
second-site compensatory mutation. Since then, many other observations have been made by 
studying both clinical and laboratory populations, including in Salmonella typhimurium [50], 
M. tuberculosis [51], Pseudomonas species [52-54] and many more. In the mentioned studies, 
mechanisms of compensation were investigated only for single chromosomal resistance 
mutations. However, the mechanism of compensation of the additional mutations that have 
been frequently associated with multiple drug resistance is not explored properly. From a 
clinical viewpoint understanding of compensatory adaptation in multidrug resistant populations 
is crucial since resistant pathogens can stabilize inside patients by simultaneous adaptation to 
the cost followed by conservation of the resistance phenotype to the drugs. This particular 
scenario probably makes treatment very difficult to eradicate the pathogen from the patients by 
traditional antimicrobial therapy.  
 
In chapter 4, we investigated this adaptive role of compensatory mutations by employing an 
experimental evolution experiment to explore the potential phenotypic and genomic basis of 
compensatory adaptation in resistant genotypes of both single and multidrug resistance origin. 
Specifically, we intended to explore some of the yet unknown questions in terms of the 
dynamics of mutational spectra, effect of additional deleterious mutations on compensation, or 
other genetic changes that arise during adaptive evolution. Uncovering these factors is 
important to determine whether evolutionary adaptation to the cost of multiple drug resistance 
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mutations generate any substantial genetic variations which differ from compensation to the 
cost of single drug resistance mutation. 
 
Although the genetic locations of the evolved mutations were different, whole genome 
sequence data revealed an abundance of pathway specific secondary mutation, namely in rpoB 
locus in both rifampicin resistant genotype and the doubly resistant genotype suggesting a 
putative compensatory mutation. Secondary mutations in other non-specific loci, intergenic 
locations or truncation mutations in both single and double resistant genotypes also provided 
genetic basis of compensation since none of these mutations were detected in the susceptible 
genotype. Surprisingly whole genome sequencing revealed an identical reversion mutation in 
cyoA locus, which was an additional mutation harboured by multidrug resistance populations. 
This additional mutation also contributes to the elevated fitness compensation when coupled 
with putative compensatory or small effect beneficial mutation in costly resistance locus. This 
finding suggests, in terms of clinical relevance, that natural populations constantly facing 
different environmental perturbations inside the body host may acquire deleterious mutation. 
Therefore, the rate of compensation by reversion in these populations is high compared to the 
traditional laboratory reversion rate. We suspect that such additional mutation may have 
occurred in previous studies [50, 55-63] where mechanism of compensation was studied for a 
single drug resistance mutation with unexploited genomic information. Therefore, the true 
biological role of compensatory mutations in those studies may have been misrepresentative. 
However, this additional mutation may have profound effects on the rate of bacterial adaptation 
in absence of drug pressure, especially in the case where resistance to multiple drugs conferred 
by mutation at multiple loci in clinical populations. Another relevance for the inclusion of this 
genotype is that this mutation may have occurred during recombination process; therefore it is 
also possible that this type of mutations may frequently appear in dynamic host environment 
where bacteria frequently acquire resistant determinants by horizontal gene transfer. 
 
In this study, putative compensatory mutations were not identified for the less costly 
streptomycin resistant genotype but were present in the costly rifampicin resistant genotype. 
Such trend also was apparent in double resistant genotype. Two important plausible reasons 
can be drawn: 1) rpoB acts as a global regulator for other genes and thus affect many different 
important cellular pathways. Therefore, any alteration in this global regulator entails significant 
fitness burden, 2) the simplest explanation for the absence of compensatory mutations to 
streptomycin mutation is presumably owing to the low fitness cost, or rpsL gene is more 
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restrictive because of the high fidelity translation process, thus only minor fitness cost 
conferring single mutation is accessible for streptomycin resistance but cannot accommodate 
more mutations in any ribosomal proteins but can improve fitness by acquiring small step 
secondary mutations in other loci, 3) similar explanation could be drawn for the double 
resistant genotype where we observe compensatory mutation in the rpoB locus, except one 
where rpsD compensatory mutation was also observed. This is due to the fact that rpsL 
mutation can cause streptomycin dependency, which means that streptomycin resistant 
genotype can grow better in presence of elevated concentration of streptomycin antibiotic, and 
secondary mutation in rpsD can release the streptomycin dependency and also can compensate 
for the fitness cost. Overall, we did not find any overlap across the three mutant backgrounds 
suggesting that genetic basis of compensation is independent of genetic background between 
single and multidrug resistant bacteria. 
 
In conclusion, determining evolutionary routes towards antibiotic resistance is essential, and 
this will extend the successful use of antibiotics in real clinical situation.  Among many factors, 
evolution of resistance can be predicted once we know about factors such as the mutation 
supply rate, the degree and level of resistance conferred by different resistance mechanisms, 
the fitness (i.e., growth rate and death rate) of the resistant bacteria in presence and absence of 
antibiotics, and the strength of selective pressures [3, 5, 64, 65]. Additionally, other factors 
such as epistatic interactions, compensatory evolution, co-selection of drug resistances, and 
population bottlenecks with clonal interference can strongly impact the resistance evolution 
[8]. Determining all these factors is challenging owing to the lack of quantitative data. 
However, this PhD thesis attempted to explore some of these factors involving the evolution of 
antibiotic resistance, multidrug resistance in particular. For example, our findings suggest that 
the sub-MIC antibiotic concentrations thought to be generated in certain body compartment 
during combination therapy may potentiate the evolution of de novo multidrug resistance, as 
has previously been reported for different single drugs [66, 67]. Another important aspect of 
this current study is the occurrence of cross-resistance [28]. We suggest that a wider MSW can 
also occur in presence of cross-resistance. Overall, our results underlies the importance of 
choosing the right drug during cyclic treatment, as well as using optimal treatment dosing 
regimes during combination therapy that exclude the prolonged exposure of sub-MIC level of 
antibiotics. In future more extension of our works would be necessary to pinpoint different 
factors implicating the evolution of de novo multidrug resistance in bacteria. 
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